U.S. patent number 9,303,040 [Application Number 12/307,526] was granted by the patent office on 2016-04-05 for substituted piperazines as akt inhibitors.
This patent grant is currently assigned to ARRAY BIOPHARMA INC.. The grantee listed for this patent is Josef R. Bencsik, James F. Blake, Nicholas C. Kallan, Ian S. Mitchell, Keith Lee Spencer, Dengming Xiao, Rui Xu. Invention is credited to Josef R. Bencsik, James F. Blake, Nicholas C. Kallan, Ian S. Mitchell, Keith Lee Spencer, Dengming Xiao, Rui Xu.
United States Patent |
9,303,040 |
Mitchell , et al. |
April 5, 2016 |
**Please see images for:
( Certificate of Correction ) ** |
Substituted piperazines as AKT inhibitors
Abstract
The present invention provides compounds, including resolved
enantiomers, diastereomers, solvates and pharmaceutically
acceptable salts thereof, comprising the Formula: ##STR00001## Also
provided are methods of using the compounds of this invention as
AKT protein kinase inhibitors and for the treatment of
hyperproliferative diseases such as cancer.
Inventors: |
Mitchell; Ian S. (Lafayette,
CO), Blake; James F. (Longmont, CO), Xu; Rui
(Longmont, CO), Kallan; Nicholas C. (Boulder, CO), Xiao;
Dengming (Longmont, CO), Spencer; Keith Lee (Lyons,
CO), Bencsik; Josef R. (Longmont, CO) |
Applicant: |
Name |
City |
State |
Country |
Type |
Mitchell; Ian S.
Blake; James F.
Xu; Rui
Kallan; Nicholas C.
Xiao; Dengming
Spencer; Keith Lee
Bencsik; Josef R. |
Lafayette
Longmont
Longmont
Boulder
Longmont
Lyons
Longmont |
CO
CO
CO
CO
CO
CO
CO |
US
US
US
US
US
US
US |
|
|
Assignee: |
ARRAY BIOPHARMA INC. (Boulder,
CO)
|
Family
ID: |
38631534 |
Appl.
No.: |
12/307,526 |
Filed: |
July 5, 2007 |
PCT
Filed: |
July 05, 2007 |
PCT No.: |
PCT/US2007/072884 |
371(c)(1),(2),(4) Date: |
December 30, 2009 |
PCT
Pub. No.: |
WO2008/006039 |
PCT
Pub. Date: |
January 10, 2008 |
Prior Publication Data
|
|
|
|
Document
Identifier |
Publication Date |
|
US 20120329808 A1 |
Dec 27, 2012 |
|
Related U.S. Patent Documents
|
|
|
|
|
|
|
Application
Number |
Filing Date |
Patent Number |
Issue Date |
|
|
60818952 |
Jul 6, 2006 |
|
|
|
|
Current U.S.
Class: |
1/1 |
Current CPC
Class: |
A61P
9/00 (20180101); A61P 35/00 (20180101); A61P
9/10 (20180101); A61P 15/02 (20180101); A61P
25/28 (20180101); A61P 43/00 (20180101); A61P
15/00 (20180101); A61P 29/00 (20180101); A61P
17/00 (20180101); C07D 495/04 (20130101) |
Current International
Class: |
A61K
31/496 (20060101); C07D 495/04 (20060101); C07D
409/02 (20060101) |
Field of
Search: |
;544/253,376
;514/256,252.16 ;546/210 ;548/518 |
References Cited
[Referenced By]
U.S. Patent Documents
Foreign Patent Documents
|
|
|
|
|
|
|
194161 |
|
Sep 1986 |
|
EP |
|
WO 95/03286 |
|
Feb 1995 |
|
WO |
|
WO 98/43960 |
|
Oct 1998 |
|
WO |
|
WO 99/01421 |
|
Jan 1999 |
|
WO |
|
WO 99/01426 |
|
Jan 1999 |
|
WO |
|
WO 00/40235 |
|
Jul 2000 |
|
WO |
|
WO 00/40237 |
|
Jul 2000 |
|
WO |
|
WO 00/41505 |
|
Jul 2000 |
|
WO |
|
WO 00/41994 |
|
Jul 2000 |
|
WO |
|
WO 00/42002 |
|
Jul 2000 |
|
WO |
|
WO 00/42003 |
|
Jul 2000 |
|
WO |
|
WO 00/42022 |
|
Jul 2000 |
|
WO |
|
WO 00/42029 |
|
Jul 2000 |
|
WO |
|
WO 00/68201 |
|
Nov 2000 |
|
WO |
|
WO 01/05390 |
|
Jan 2001 |
|
WO |
|
WO 01/05391 |
|
Jan 2001 |
|
WO |
|
WO 01/05392 |
|
Jan 2001 |
|
WO |
|
WO 01/05393 |
|
Jan 2001 |
|
WO |
|
WO 01/68619 |
|
Sep 2001 |
|
WO |
|
WO 02/06213 |
|
Jan 2002 |
|
WO |
|
WO 02/18319 |
|
Mar 2002 |
|
WO |
|
WO 02/44166 |
|
Jun 2002 |
|
WO |
|
WO 02/083139 |
|
Oct 2002 |
|
WO |
|
WO 03/022214 |
|
Mar 2003 |
|
WO |
|
WO 03/064397 |
|
Aug 2003 |
|
WO |
|
WO 03/077855 |
|
Sep 2003 |
|
WO |
|
WO 03/077914 |
|
Sep 2003 |
|
WO |
|
WO 03/086279 |
|
Oct 2003 |
|
WO |
|
WO 03/086394 |
|
Oct 2003 |
|
WO |
|
WO 03/086403 |
|
Oct 2003 |
|
WO |
|
WO 03/086404 |
|
Oct 2003 |
|
WO |
|
WO 03/094918 |
|
Nov 2003 |
|
WO |
|
WO 2004/041162 |
|
May 2004 |
|
WO |
|
WO 2004/096130 |
|
Nov 2004 |
|
WO |
|
WO 2005/014558 |
|
Feb 2005 |
|
WO |
|
WO 2005/117909 |
|
Dec 2005 |
|
WO |
|
WO 2006/027346 |
|
Mar 2006 |
|
WO |
|
WO 2006/046023 |
|
May 2006 |
|
WO |
|
WO 2006/071819 |
|
Jul 2006 |
|
WO |
|
WO 2006/090261 |
|
Aug 2006 |
|
WO |
|
WO 2006/136830 |
|
Dec 2006 |
|
WO |
|
WO 2007/042298 |
|
Apr 2007 |
|
WO |
|
WO 2007/077961 |
|
Jul 2007 |
|
WO |
|
WO 2007/125320 |
|
Nov 2007 |
|
WO |
|
WO 2008/003697 |
|
Jan 2008 |
|
WO |
|
WO 2008/003958 |
|
Jan 2008 |
|
WO |
|
WO 2008/003978 |
|
Jan 2008 |
|
WO |
|
WO 2008/005511 |
|
Jan 2008 |
|
WO |
|
WO 2008/005964 |
|
Jan 2008 |
|
WO |
|
WO 2008/006032 |
|
Jan 2008 |
|
WO |
|
WO 2008/006039 |
|
Jan 2008 |
|
WO |
|
WO 2008/006040 |
|
Jan 2008 |
|
WO |
|
WO 2008/012635 |
|
Jan 2008 |
|
WO |
|
Other References
Wang, et al., Experimental and Therapeutic Medicine 7: 1265-1270,
2014. cited by examiner .
Walsh, Circulation. 2006;113:2032-2034. cited by examiner .
Pal, et al., Acta Pharmacologica Sinica (2012) 33: 1441-1458. cited
by examiner .
Jordan, V. C. Nature Reviews: Drug Discovery, 2, 2003, 205. cited
by examiner .
Hackam, et al. JAMA, 296(14), 2006, 1731-1732. cited by examiner
.
Database accession No. 147:166330 abstract, Database CAPLUS,
Chemical Abstracts Service, Columbus Ohio, US, Retrieved from STN
accession No. 2007:711051, 2007, 1 page. cited by applicant .
D'Souza et al., "(R)--(+)--3-Amino-2-phenylpropanoic Acid: a
Revised Absolute Configureation based on an Enantioselective
Synthesis and an X-Ray Crystal Structure of the Salt with
(1S)--(+)--Camphor-10-sulfonic Acid", J. Chem. Soc. Perkins Trans.
1, 2 pages, (1995). cited by applicant .
Li, Qun "Expert Opinion: Recent Progress in the Discovery of Akt
Inhibitors as Anticancer Agents", Informa Healthcare, 2007, 17(9),
pp. 1077-1130. cited by applicant .
Ohno, S., et al., "Synthesis and Hypoglycemic Activity of
7,8-Dihydro-6H-thiopyrano[3,2-d]pyrimidine Derivatives and Related
Compounds", Chem. Pharm. Bull., 1986, 34(10), 4150-4165. cited by
applicant .
Patent Cooperation Treaty, "International Search Report and Written
Opinion of the International Searching Authority",
PCT/US2007/072884, Nov. 14, 2007, 15 pages. cited by applicant
.
Ross, L., et al., "Potential Anticancer Agents. XVIII. Synthesis of
Substituted 4,5-Trimethylenepyrimidines", J. Am. Chem. Soc., 1959,
81, 3108-3113. cited by applicant .
Thomas, S. A., "Identification of a novel 3,5-disubstituted
pyridine as a potent, selective, and orally active inhibitor of
Akt1 kinase", Bioorg. Med. Chem. Lett., 2006, 16, 3740-3744. cited
by applicant .
Truong, T. N., "Office Action for U.S. Appl. No. 10/993,173",
United States Patent and Trademark Office, Aug. 6, 2008, 8 pages.
cited by applicant .
Truong, T. N., "Office Action for U.S. Appl. No. 10/993,173",
United States Patent and Trademark Office, May 26, 2009, 8 pages.
cited by applicant .
"European Office Action for Application No. 07799326.9", European
Patent Office, Nov. 26, 2009, 3 pages. cited by applicant .
Vippagunta, S.R., (Adv. Drug. Delivery Rev., 2001, 48, pp. 3-26).
cited by applicant .
Zhao, Z., et al., "Discovery of 2,3,5-trisubstituted pyridine
derivatives as potent Akt1 and Akt2 dual inhibitors", Bioorg. Med.
Chem. Lett., 2005, 15, 905-909. cited by applicant .
Zhu, G., "Discovery and SAR of oxindole-pyridine-based protein
kinase B/Akt inhibitors for treating cancers", Bioorg. Med. Chem.
Lett., 2006, 16, 3424-3429. cited by applicant.
|
Primary Examiner: Willis; Douglas M
Attorney, Agent or Firm: Viksnins Harris & Padys
PLLP
Parent Case Text
PRIORITY OF INVENTION
This application claims priority to U.S. Provisional Application
No. 60/818,952 that was filed on 6 Jul. 2006, which is hereby
incorporated herein by reference in its entirety.
Claims
What is claimed is:
1. A compound of the Formula: ##STR00134## and enantiomers and
salts thereof, wherein: X is S, SO or SO.sub.2; R.sup.1 is H, Me,
Et, CF.sub.3, CHF.sub.2 or CH.sub.2F; R.sup.2 is H or Me; R.sup.5
is H, Me, Et, or CF.sub.3; A is ##STR00135## wherein G is phenyl
optionally substituted independently with one to four R.sup.9
groups; R.sup.6 and R.sup.7 are independently H, (C.sub.3-C.sub.6
cycloalkyl)-(CH.sub.2), (C.sub.3-C.sub.6
cycloalkyl)-(CH.sub.2CH.sub.2), V--(CH.sub.2).sub.0-1 wherein V is
a 5-6 membered heteroaryl, W--(CH.sub.2).sub.1-2 wherein W is
phenyl optionally substituted with F, Cl, Br, I, OMe, CF.sub.3 or
Me, C.sub.3-C.sub.6-cycloalkyl,
hydroxy-(C.sub.3-C.sub.6-cycloalkyl),
fluoro-(C.sub.3-C.sub.6-cycloalkyl), CH(CH.sub.3)CH(OH)phenyl, 4-6
membered heterocycle optionally substituted with F, OH,
cyclopropylmethyl, C.sub.1-C.sub.3 alkyl or
C(.dbd.O)(C.sub.1-C.sub.3 alkyl), or C.sub.1-C.sub.6-alkyl
optionally substituted with one or more groups independently
selected from OH, O(C.sub.1-C.sub.6-alkyl), CN, F, NH.sub.2,
NH(C.sub.1-C.sub.6-alkyl), N(C.sub.1-C.sub.6-alkyl).sub.2,
tetrahydropyranyl, tetrahydrofuranyl, morpholinyl, oxetanyl,
piperidinyl, and pyrrolidinyl, or R.sup.6 and R.sup.7 together with
the nitrogen to which they are attached form a 3-6 membered
heterocyclic ring optionally substituted with one or more groups
independently selected from OH, halogen, oxo, CF.sub.3,
CH.sub.2CF.sub.3, and (C.sub.1-C.sub.3)alkyl; R.sup.a and R.sup.b
are H, or R.sup.a is H, and R.sup.b and R.sup.6 together with the
atoms to which they are attached form a 5-6 membered heterocyclic
ring having one or two ring nitrogen atoms; R.sup.c and R.sup.d are
H or Me, or R.sup.c and R.sup.d together with the atom to which
they are attached form a cyclopropyl ring; R.sup.8 is H, Me, or OH,
or R.sup.8 and R.sup.6 together with the atoms to which they are
attached form a 5-6 membered heterocyclic ring having one or two
ring nitrogen atoms; each R.sup.9 is independently halogen,
C.sub.1-C.sub.6-alkyl, C.sub.3-C.sub.6-cycloalkyl,
O--(C.sub.1-C.sub.6-alkyl), CF.sub.3, OCF.sub.3,
S(C.sub.1-C.sub.6-alkyl), CN, OCH.sub.2-phenyl, NH.sub.2,
NH--(C.sub.1-C.sub.6-alkyl), N--(C.sub.1-C.sub.6-alkyl).sub.2,
piperidine, pyrrolidine, CH.sub.2F, CHF.sub.2, OCH.sub.2F,
OCHF.sub.2, OH, SO.sub.2(C.sub.1-C.sub.6-alkyl), C(O)NH.sub.2,
C(O)NH(C.sub.1-C.sub.6-alkyl), and
C(O)N(C.sub.1-C.sub.6-alkyl).sub.2; and m, n and p are
independently 0 or 1.
2. The compound of claim 1, having the Formula: ##STR00136## and
enantiomers and salts thereof, wherein: R.sup.1 is H, Me, Et,
CF.sub.3, CHF.sub.2 or CH.sub.2F; R.sup.2 is H or Me; R.sup.5 is H,
Me, Et, or CF.sub.3; A is ##STR00137## wherein G is phenyl
optionally substituted independently with one to four R.sup.9
groups; R.sup.6 and R.sup.7 are independently H, (C.sub.3-C.sub.6
cycloalkyl)-(CH.sub.2), (C.sub.3-C.sub.6
cycloalkyl)-(CH.sub.2CH.sub.2), V--(CH.sub.2).sub.0-1 wherein V is
a 5-6 membered heteroaryl, W--(CH.sub.2).sub.1-2 wherein W is
phenyl optionally substituted with F, CI or Me,
C.sub.3-C.sub.6-cycloalkyl, hydroxy-(C.sub.3-C.sub.6-cycloalkyl),
fluoro-(C.sub.3-C.sub.6-cycloalkyl), CH(CH.sub.3)CH(OH)phenyl, or
C.sub.1-C.sub.6-alkyl optionally substituted with one or more
groups independently selected from OH, O(C.sub.1-C.sub.6-alkyl),
CN, F, NH.sub.2, NH(C.sub.1-C.sub.6-alkyl),
N(C.sub.1-C.sub.6-alkyl).sub.2, piperidinyl, and pyrrolidinyl, or
R.sup.6 and R.sup.7 together with the nitrogen to which they are
attached form a 4-6 membered heterocyclic ring optionally
substituted with one or more groups independently selected from OH,
halogen, oxo, CF.sub.3, CH.sub.2CF.sub.6, and
(C.sub.1-C.sub.3)alkyl; R.sup.a and R.sup.b are H, or R.sup.a is H,
and R.sup.b and R.sup.6 together with the atoms to which they are
attached form a 5-6 membered heterocyclic ring having one or two
ring nitrogen atoms; R.sup.c and R.sup.d are H or Me, or R.sup.c
and R.sup.d together with the atom to which they are attached form
a cyclopropyl ring; R.sup.8 is H, Me, or OH, or R.sup.8 and R.sup.6
together with the atoms to which they are attached form a 5-6
membered heterocyclic ring having one or two ring nitrogen atoms;
each R.sup.9 is independently halogen, C.sub.1-C.sub.6-alkyl,
C.sub.3-C.sub.6-cycloalkyl, O--(C.sub.1-C.sub.6-alkyl), CF.sub.3,
OCF.sub.3, S(C.sub.1-C.sub.6-alkyl), CN, OCH.sub.2-phenyl,
NH.sub.2, NH--(C.sub.1-C.sub.6-alkyl),
N--(C.sub.1-C.sub.6-alkyl).sub.2, piperidine, pyrrolidine,
CH.sub.2F, CHF.sub.2, OCH.sub.2F, OCHF.sub.2, OH,
SO.sub.2(C.sub.1-C.sub.6-alkyl), C(O)NH.sub.2,
C(O)NH(C.sub.1-C.sub.6-alkyl), and
C(O)N(C.sub.1-C.sub.6-alkyl).sub.2; and m, n and p are
independently 0 or 1.
3. The compound of claim 1, wherein R.sup.2 is H.
4. The compound of claim 3, wherein R.sup.5 is H or (S)-methyl.
5. The compound of claim 4, wherein G is phenyl, 2-chlorophenyl,
3-chlorophenyl, 4-chlorophenyl, 4-fluorophenyl, 4-bromophenyl,
4-methylphenyl, 4-ethylphenyl, 4-isopropylphenyl,
4-trifluoromethylphenyl, 4-cyanophenyl, 4-methoxyphenyl,
4-ethoxyphenyl, 4-thiomethylphenyl, 4-trifluoromethoxyphenyl,
4-cyclopropylphenyl, 4-chloro-3-fluorophenyl, 3,4-difluorophenyl,
4-bromo-3-fluorophenyl, 3-fluoro-4-methylphenyl,
3-fluoro-4-methoxyphenyl, 3-fluoro-4-trifluoromethylphenyl,
4-cyano-3-fluorophenyl, 3,4-dichlorophenyl, 2,4-dichlorophenyl,
2,4-difluorophenyl, 2-chloro-4-fluorophenyl,
2-fluoro-4-chlorophenyl, 3,5-dichlorophenyl, 3,5-difluorophenyl,
3-chloro-5-fluorophenyl, 3-chloro-4-fluorophenyl,
3-bromo-4-fluorophenyl, 3,5-difluoro-4-chlorophenyl,
2,3-difluoro-4-chlorophenyl, 2,5-difluoro-4-chlorophenyl,
3,5-difluoro-4-bromophenyl, 2,3-difluoro-4-bromophenyl,
2,5-difluoro-4-bromophenyl or 4-(OCH.sub.2Ph)-phenyl.
6. The compound of claim 5, wherein m is 0, n is 1 and p is 0, such
that A is represented by the formula: ##STR00138##
7. The compound of claim 6, wherein R.sup.8 is H.
8. The compound of claim 7, wherein R.sup.c and R.sup.d are H.
9. The compound of claim 7, wherein R.sup.c and R.sup.d together
with the atom to which they are attached form a cyclopropyl
ring.
10. The compound of claim 7, wherein R.sup.6 and R.sup.7 are
independently H, methyl, ethyl, isopropyl, isobutyl, tert-butyl,
3-pentyl, CH(isopropyl).sub.2, CH.sub.2CH.sub.2OH,
CH.sub.2CH.sub.2CH.sub.2OH, CH(CH.sub.2CH.sub.2OH).sub.2,
CH.sub.2CH.sub.2OMe, CH(CH.sub.2CH.sub.2OMe).sub.2,
CH.sub.2CH.sub.2CH.sub.2OMe, CH.sub.2CN, CH.sub.2-cyclopropyl,
CH.sub.2-cyclobutyl, cyclopentyl, cyclohexyl, CH.sub.2-phenyl,
CH.sub.2-(pyrid-2-yl), CH.sub.2-(pyrid-3-yl),
CH.sub.2-(pyrid-4-yl), 4-hydroxycyclohex-1-yl, or
CH(CH.sub.3)CH(OH)phenyl.
11. The compound of claim 7, wherein R.sup.6 and R.sup.7 together
with the nitrogen to which they are attached form a pyrrolidinyl,
piperidinyl, azetidinyl, morpholinyl or piperazinyl ring, wherein
said pyrrolidinyl, piperidinyl, azetidinyl, morpholinyl and
piperazinyl rings are optionally substituted with one or two groups
independently selected from OH, F methyl, CH.sub.2CF.sub.3, and
oxo.
12. The compound of claim 6, wherein A is selected from:
##STR00139## ##STR00140## ##STR00141##
13. The compound of claim 5, wherein m is 1, n is 1 and p is 0,
such that A is represented by the formula: ##STR00142##
14. The compound of claim 13, wherein A is selected from:
##STR00143## ##STR00144##
15. The compound of claim 13, wherein R.sup.8 is H.
16. The compound of claim 13 or 15, wherein R.sup.c and R.sup.d
together with the atom to which they are attached form a
cyclopropyl ring.
17. The compound of claim 13 or 15, wherein R.sup.c and R.sup.d are
H.
18. The compound of claim 17, wherein R.sup.6 and R.sup.7 are
independently H, methyl, ethyl, propyl, isopropyl,
CH.sub.2-cyclopropyl, or CH.sub.2-cyclobutyl, or R.sup.6 and
R.sup.7 together with nitrogen form a pyrrolidinyl, piperidinyl, or
azetidinyl ring, or R.sup.6 and R.sup.8 together with the atoms to
which they are attached form a piperidinyl or pyrrolidinyl
ring.
19. The compound of claim 5, wherein m is 0, n is 1 and p is 1,
such that A is represented by the formula: ##STR00145##
20. The compound of claim 19, wherein R.sup.8 is H.
21. The compound of claim 20, wherein R.sup.c and R.sup.d together
with the atom to which they are attached form a cyclopropyl
ring.
22. The compound of claim 20, wherein R.sup.c and R.sup.d are
H.
23. The compound of claim 22, wherein R.sup.6 and R.sup.7 are
independently H, methyl, ethyl, propyl, isopropyl, t-butyl,
CH.sub.2-cyclopropyl, or CH.sub.2-cyclobutyl.
24. The compound of claim 19, wherein A is selected from the
structures: ##STR00146##
25. The compound of claim 19, wherein A is selected from
##STR00147##
26. The compound of claim 5, wherein m is 0, n is 0 and p is 1,
such that A is represented by the formula: ##STR00148##
27. The compound of claim 26 wherein A is selected from:
##STR00149##
28. The compound of claim 26, wherein R.sup.8 is H.
29. The compound of claim 28, wherein R.sup.6 and R.sup.7 are H or
Me.
30. The compound of claim 1, wherein NR.sup.6R.sup.7 is the
structure: ##STR00150##
31. The compound of claim 1 having the structure: ##STR00151##
##STR00152## ##STR00153## ##STR00154## ##STR00155## ##STR00156##
##STR00157## ##STR00158## ##STR00159## ##STR00160## ##STR00161## or
a salt thereof.
32. A pharmaceutical composition comprising a compound of claim 1
or an enantiomer or salt thereof and a pharmaceutically acceptable
diluent or carrier.
Description
BACKGROUND OF THE INVENTION
1. Field of the Invention
This invention relates to novel inhibitors of serine/threonine
protein kinases (e.g., AKT and related kinases), pharmaceutical
compositions containing the inhibitors, and methods for preparing
these inhibitors. The inhibitors are useful, for example, for the
treatment of hyperproliferative diseases, such as cancer and
inflammation, in mammals.
2. Description of the State of the Art
Protein kinases (PK) are enzymes that catalyze the phosphorylation
of hydroxy groups on tyrosine, serine and threonine residues of
proteins by transfer of the terminal (gamma) phosphate from ATP.
Through signal transduction pathways, these enzymes modulate cell
growth, differentiation and proliferation, i.e., virtually all
aspects of cell life in one way or another depend on PK activity
(Hardie, G. and Hanks, S. (1995) The Protein Kinase Facts Book. I
and II, Academic Press, San Diego, Calif.). Furthermore, abnormal
PK activity has been related to a host of disorders, ranging from
relatively non-life threatening diseases such as psoriasis to
extremely virulent diseases such as glioblastoma (brain cancer).
Protein kinases are an important target class for therapeutic
modulation (Cohen, P. (2002) Nature Rev. Drug Discovery 1:309).
Significantly, atypical protein phosphorylation and/or expression
is often reported to be one of the causative effects of abnormal
cellular proliferation, metastasis and cell survival in cancer. The
abnormal regulation and/or expression of various kinases, including
Akt, VEGF, ILK, ROCK, p70S6K, Bcl, PKA, PKC, Raf, Src, PDK1, ErbB2,
MEK, IKK, Cdk, EGFR, BAD, CHK1, CHK2 and GSK3 amongst numerous
others, has been specifically implicated in cancer.
Protein kinases include two classes; protein tyrosine kinases (PTK)
and serine-threonine kinases (STK). The Protein Kinase B/Akt
enzymes are a group of serine/threonine kinases that are
overexpressed in a variety of human tumors. One of the
best-characterized targets of the PI3K lipid products is the 57 KD
serine/threonine protein kinase Akt, downstream of PI3K in the
signal transduction pathway (Hemmings, B. A. (1997) Science
275:628; Hay N. (2005) Cancer Cell 8:179-183). Akt is the human
homologue of the protooncogene v-akt of the acutely transforming
retrovirus AKT8. Due to its high sequence homology to protein
kinases A and C, Akt is also called Protein Kinase B (PKB) and
Related to A and C(RAC). Three isoforms of Akt are known to exist,
namely Akt1, Akt2 and Akt3, which exhibit an overall homology of
80% (Staal, S. P. (1987) Proc. Natl. Acad. Sci. 84:5034; Nakatani,
K. (1999) Biochem. Biophys. Res. Commun. 257:906; Li et al (2002)
Current Topics in Med. Chem. 2:939-971; WO 2005/113762). The Akt
isoforms share a common domain organization that consists of a
pleckstrin homology domain at the N-terminus, a kinase catalytic
domain, and a short regulatory region at the C-terminus. In
addition, both Akt2 and Akt3 exhibit splice variants. Upon
recruitment to the cell membrane by PtdInd(3,4,5)P.sub.3, Akt is
phosphorylated (activated) by PDK1 at T308, T309 and T305 for
isoforms Akt1 (PKB.alpha.), Akt2 (PKB.beta.) and Akt3 (PKB.gamma.),
respectively, and at S473, S474 and S472 for isoforms Akt1, Akt2
and Akt3, respectively. Such phosphorylation occurs by an as yet
unknown kinase (putatively named PDK2), although PDK1 (Balendran,
A., (1999) Curr. Biol. 9:393), autophosphorylation (Toker, A.
(2000) J. Biol. Chem. 275:8271) and integrin-linked kinase (ILK)
(Delcommenne, M. (1998) Proc. Natl. Acad. Sci. USA, 95:11211) have
been implicated in this process. Akt activation requires its
phosphorylation on residue Ser 473 in the C-terminal hydrophobic
motif (Brodbeck et al (1999) J. Biol. Chem. 274:9133-9136; Coffer
et al (1991) Eur. J. Biochem. 201:475-481; Alessi et al (1997)
Curr. Biol. 7:261-269). Although monophosphorylation of Akt
activates the kinase, bis(phosphorylation) is required for maximal
kinase activity.
Akt is believed to assert its effect on cancer by suppressing
apoptosis and enhancing both angiogenesis and proliferation (Toker
et al (2006) Cancer Res. 66(8):3963-3966). Akt is overexpressed in
many forms of human cancer including, but not limited to, colon
(Zinda et al (2001) Clin. Cancer Res. 7:2475), ovarian (Cheng et al
(1992) Proc. Natl. Acad. Sci. USA 89:9267), brain (Haas Kogan et al
(1998) Curr. Biol. 8:1195), lung (Brognard et al (2001) Cancer Res.
61:3986), pancreatic (Bellacosa et al (1995) Int. J. Cancer
64:280-285; Cheng et al (1996) Proc. Natl. Acad. Sci.
93:3636-3641), prostate (Graff et al (2000) J. Biol. Chem.
275:24500) and gastric carcinomas (Staal et al (1987) Proc. Natl.
Acad. Sci. USA 84:5034-5037).
The PI3K/Akt/mammalian target of rapamycin (mTOR) pathway has been
explored for targeted small molecule inhibitor therapy (Georgakis,
G. and Younes, A. (2006) Expert Rev. Anticancer Ther. 6(1):131-140;
Granville et al (2006) Clin. Cancer Res. 12(3):679-689). Inhibition
of PI3K/Akt signaling induces apoptosis and inhibits the growth of
tumor cells that have elevated Akt levels (Kim et al (2005) Current
Opinion in Investig. Drugs 6(12):1250-1258; Luo et al (2005)
Molecular Cancer Ther. 4(6):977-986).
The development of kinase inhibitors that target abnormally
regulated pathways and ultimately result in disease is of enormous
ethical and commercial interest to the medical and pharmaceutical
community. A compound that inhibits (1) recruitment of Akt to the
cell membrane, (2) activation by PDK1 or PDK2, (3) substrate
phosphorylation, or (4) one of the downstream targets of Akt could
be a valuable anticancer agent, either as a stand-alone therapy or
in conjunction with other accepted procedures.
United States Patent Application Publication 2005/0130954 discloses
inter alia, a variety of compounds that act as AKT inhibitors. The
compounds are said to be useful in the treatment of
hyperproliferative diseases such as cancer.
SUMMARY OF THE INVENTION
This invention provides novel compounds that inhibit AKT protein
kinases. The compounds of the present invention have utility as
therapeutic agents for diseases and conditions that can be treated
by the inhibition of AKT protein kinases.
The present invention includes compounds having the general Formula
I:
##STR00002## and enantiomers and salts thereof, wherein X, A,
R.sup.1, R.sup.2, and R.sup.5 are as defined below.
An additional aspect of the present invention includes compounds
having the general Formula Ia:
##STR00003## and enantiomers and salts thereof, wherein A, R.sup.1,
R.sup.2, and R.sup.5 are as defined below.
The invention also provides pharmaceutical compositions comprising
a compound of Formula I or Ia, or an enantiomer or pharmaceutically
acceptable salt thereof.
In a further aspect, the present invention provides a method of
treating diseases or medical conditions in a mammal mediated by AKT
protein kinases, comprising administering to said mammal one or
more compounds of Formula I or Ia, or an enantiomer or
pharmaceutically acceptable salt thereof, in an amount effective to
treat or prevent said disorder. AKT protein kinase mediated
conditions that can be treated according to the methods of this
invention include, but are not limited to, inflammatory,
hyperproliferative, cardiovascular, neurodegenerative,
gynecological, and dermatological diseases and disorders.
In a further aspect, the present invention provides a method of
inhibiting the production of AKT protein kinases in a mammal, which
comprises administering to said mammal a compound of Formula I or
Ia, or an enantiomer or pharmaceutically acceptable salt thereof in
an amount effective to inhibit production of an AKT protein
kinase.
In a further aspect, the present invention provides methods of
inhibiting the activity of AKT protein kinases, comprising
contacting said kinase with a compound of Formula I or Ia.
The inventive compounds may be used advantageously in combination
with other known therapeutic agents. Accordingly, this invention
also provides pharmaceutical compositions comprising a compound of
Formula I or Ia or an enantiomer or pharmaceutically acceptable
salt thereof, in combination with a second therapeutic agent.
This invention also provides compounds of Formula I or Ia and
enantiomers and pharmaceutically acceptable salts thereof for use
as medicaments in the treatment of AKT protein kinase-mediated
conditions.
An additional aspect of the invention is the use of a compound of
Formula I or Ia, or an enantiomer or pharmaceutically acceptable
salt thereof, for therapy. In one embodiment, the therapy comprises
the treatment of an AKT protein kinase-mediated condition.
This invention further provides kits for the treatment of an AKT
protein kinase-mediated disease or disorder, said kit comprising a
compound of Formula I or Ia, or an enantiomer or pharmaceutically
acceptable salt thereof, a container, and optionally a package
insert or label indicating a treatment. The kits may further
comprise a second compound or formulation comprising a second
pharmaceutical agent useful for treating said disease or
disorder.
This invention further includes methods of preparing, methods of
separating, and methods of purifying of the compounds of this
invention.
Additional advantages and novel features of this invention shall be
set forth in part in the description that follows, and in part will
become apparent to those skilled in the art upon examination of the
following specification, or may be learned by the practice of the
invention. The advantages of the invention may be realized and
attained by means of the instrumentalities, combinations,
compositions, and methods particularly pointed out in the appended
claims.
DETAILED DESCRIPTION OF THE INVENTION
Reference will now be made in detail to certain embodiments of the
invention, examples of which are illustrated in the accompanying
structures and formulas. While the invention will be described in
conjunction with the enumerated embodiments, it will be understood
that they are not intended to limit the invention to those
embodiments. On the contrary, the invention is intended to cover
all alternatives, modifications, and equivalents which may be
included within the scope of the present invention as defined by
the claims. One skilled in the art will recognize many methods and
materials similar or equivalent to those described herein, which
could be used in the practice of the present invention. The present
invention is in no way limited to the methods and materials
described. In the event that one or more of the incorporated
literature and similar materials differs from or contradicts this
application, including but not limited to defined terms, term
usage, described techniques, or the like, this application
controls.
Definitions
The term "alkyl" as used herein refers to a saturated linear or
branched-chain monovalent hydrocarbon radical of one to twelve
carbon atoms, wherein the alkyl radical may be optionally
substituted independently with one or more substituents described
below. Examples of alkyl groups include, but are not limited to,
methyl (Me, --CH.sub.3), ethyl (Et, --CH.sub.2CH.sub.3), 1-propyl
(n-Pr, n-propyl, --CH.sub.2CH.sub.2CH.sub.3), 2-propyl (i-Pr,
i-propyl, --CH(CH.sub.3).sub.2), 1-butyl (n-Bu, n-butyl,
--CH.sub.2CH.sub.2CH.sub.2CH.sub.3), 2-methyl-1-propyl (1-Bu,
i-butyl, --CH.sub.2CH(CH.sub.3).sub.2), 2-butyl (s-Bu, s-butyl,
--CH(CH.sub.3)CH.sub.2CH.sub.3), 2-methyl-2-propyl (t-Bu, t-butyl,
--C(CH.sub.3).sub.3), 2,2-dimethylpropyl
(CH.sub.2C(CH.sub.3).sub.3), 1-pentyl (n-pentyl,
--CH.sub.2CH.sub.2CH.sub.2CH.sub.2CH.sub.3), 2-pentyl
(--CH(CH.sub.3)CH.sub.2CH.sub.2CH.sub.3), 3-pentyl
(--CH(CH.sub.2CH.sub.3).sub.2), 2-methyl-2-butyl
(--C(CH.sub.3).sub.2CH.sub.2CH.sub.3), 3-methyl-2-butyl
(--CH(CH.sub.3)CH(CH.sub.3).sub.2), 3-methyl-1-butyl
(--CH.sub.2CH.sub.2CH(CH.sub.3).sub.2), 2-methyl-1-butyl
(--CH.sub.2CH(CH.sub.3)CH.sub.2CH.sub.3), 1-hexyl
(--CH.sub.2CH.sub.2CH.sub.2CH.sub.2CH.sub.2CH.sub.3), 2-hexyl
(--CH(CH.sub.3)CH.sub.2CH.sub.2CH.sub.2CH.sub.3), 3-hexyl
(--CH(CH.sub.2CH.sub.3)(CH.sub.2CH.sub.2CH.sub.3)),
2-methyl-2-pentyl (--C(CH.sub.3).sub.2CH.sub.2CH.sub.2CH.sub.3),
3-methyl-2-pentyl (--CH(CH.sub.3)CH(CH.sub.3)CH.sub.2CH.sub.3),
4-methyl-2-pentyl (--CH(CH.sub.3)CH.sub.2CH(CH.sub.3).sub.2),
3-methyl-3-pentyl (--C(CH.sub.3)(CH.sub.2CH.sub.3).sub.2),
2-methyl-3-pentyl (--CH(CH.sub.2CH.sub.3)CH(CH.sub.3).sub.2),
2,3-dimethyl-2-butyl (--C(CH.sub.3).sub.2CH(CH.sub.3).sub.2),
3,3-dimethyl-2-butyl (--CH(CH.sub.3)C(CH.sub.3).sub.3, 1-heptyl,
1-octyl, and the like.
The term "alkylene" as used herein refers to a linear or branched
saturated divalent hydrocarbon radical of one to twelve carbon
atoms, wherein the alkylene radical may be optionally substituted
independently with one or more substituents described herein.
Examples include, but are not limited to, methylene, ethylene,
propylene, 2-methylpropylene, pentylene, and the like.
The term "alkenyl" as used herein refers to a linear or
branched-chain monovalent hydrocarbon radical of two to twelve
carbon atoms with at least one site of unsaturation, i.e., a
carbon-carbon, sp.sup.2 double bond, wherein the alkenyl radical
may be optionally substituted independently with one or more
substituents described herein, and includes radicals having "cis"
and "trans" orientations, or alternatively, "E" and "Z"
orientations. Examples include, but are not limited to, ethylenyl
or vinyl (--CH.dbd.CH.sub.2), allyl (--CH.sub.2CH.dbd.CH.sub.2),
1-propenyl, 1-buten-1-yl, 1-buten-2-yl, and the like.
The term "alkynyl" as used herein refers to a linear or branched
monovalent hydrocarbon radical of two to twelve carbon atoms with
at least one site of unsaturation, i.e., a carbon-carbon, sp triple
bond, wherein the alkynyl radical may be optionally substituted
independently with one or more substituents described herein.
Examples include, but are not limited to, ethynyl (--C.ident.CH)
and propynyl (propargyl, --CH.sub.2C.ident.CH).
The terms "cycloalkyl," "carbocycle," "carbocyclyl" and
"carbocyclic ring" as used herein are used interchangeably and
refer to saturated or partially unsaturated cyclic hydrocarbon
radical having from three to twelve carbon atoms. The term
"cycloalkyl" includes monocyclic and polycyclic (e.g., bicyclic and
tricyclic) cycloalkyl structures, wherein the polycyclic structures
optionally include a saturated or partially unsaturated cycloalkyl
ring fused to a saturated, partially unsaturated or aromatic
cycloalkyl or heterocyclic ring. Examples of cycloalkyl groups
include, but are not limited to, cyclopropyl, cyclobutyl,
cyclopentyl, cyclohexyl, cycloheptyl, and the like. Bicyclic
carbocycles include those having 7 to 12 ring atoms arranged, for
example, as a bicyclo[4,5], [5,5], [5,6] or [6,6] system, or as
bridged systems such as bicyclo[2.2.1]heptane,
bicyclo[2.2.2]octane, and bicyclo[3.2.2]nonane. The cycloalkyl may
be optionally substituted independently with one or more
substituents described herein.
"Aryl" as used herein means a monovalent aromatic hydrocarbon
radical of 6-20 carbon atoms derived by the removal of one hydrogen
atom from a single carbon atom of a parent aromatic ring system.
Aryl includes bicyclic radicals comprising an aromatic ring fused
to a saturated, partially unsaturated ring, or aromatic carbocyclic
or heterocyclic ring. Exemplary aryl groups include, but are not
limited to, radicals derived from benzene, naphthalene, anthracene,
biphenyl, indene, indane, 1,2-dihydronaphthalene,
1,2,3,4-tetrahydronaphtalene, and the like. Aryl groups may be
optionally substituted independently with one or more substituents
described herein.
The terms "heterocycle", "heterocyclyl" and "heterocyclic ring" as
used herein are used interchangeably and refer to a saturated or
partially unsaturated carbocyclic radical of 3 to 8 ring atoms in
which at least one ring atom is a heteroatom independently selected
from nitrogen, oxygen and sulfur, the remaining ring atoms being C,
where one or more ring atoms may be optionally substituted
independently with one or more substituents described below. The
radical may be a carbon radical or heteroatom radical. The term
"heterocycle" includes heterocycloalkoxy. "Heterocyclyl" also
includes radicals where heterocycle radicals are fused with a
saturated, partially unsaturated, or aromatic carbocyclic or
heterocyclic ring. Examples of heterocyclic rings include, but are
not limited to, pyrrolidinyl, tetrahydrofuranyl, dihydrofuranyl,
tetrahydrothienyl, tetrahydropyranyl, dihydropyranyl,
tetrahydrothiopyranyl, piperidino, morpholino, thiomorpholino,
thioxanyl, piperazinyl, homopiperazinyl, azetidinyl, oxetanyl,
thietanyl, homopiperidinyl, oxepanyl, thiepanyl, oxazepinyl,
diazepinyl, thiazepinyl, 2-pyrrolinyl, 3-pyrrolinyl, indolinyl,
2H-pyranyl, 4H-pyranyl, dioxanyl, 1,3-dioxolanyl, pyrazolinyl,
dithianyl, dithiolanyl, dihydropyranyl, dihydrothienyl,
dihydrofuranyl, pyrazolidinylimidazolinyl, imidazolidinyl,
3-azabicyco[3.1.0]hexanyl, 3-azabicyclo[4.1.0]heptanyl,
azabicyclo[2.2.2]hexanyl, 3H-indolyl quinolizinyl and N-pyridyl
ureas. Spiro moieties are also included within the scope of this
definition. The heterocycle may be C-attached or N-attached where
such is possible. For instance, a group derived from pyrrole may be
pyrrol-1-yl (N-attached) or pyrrol-3-yl (C-attached). Further, a
group derived from imidazole may be imidazol-1-yl (N-attached) or
imidazol-3-yl (C-attached). Examples of heterocyclic groups wherein
2 ring carbon atoms are substituted with oxo (.dbd.O) moieties are
isoindoline-1,3-dionyl and 1,1-dioxo-thiomorpholinyl. The
heterocycle groups herein are optionally substituted independently
with one or more substituents described herein.
The term "heteroaryl" as used herein refers to a monovalent
aromatic radical of a 5-, 6-, or 7-membered ring and includes fused
ring systems (at least one of which is aromatic) of 5-10 atoms
containing at least one heteroatom independently selected from
nitrogen, oxygen, and sulfur. Examples of heteroaryl groups
include, but are not limited to, pyridinyl, imidazolyl,
imidazopyridinyl, pyrimidinyl, pyrazolyl, triazolyl, pyrazinyl,
tetrazolyl, furyl, thienyl, isoxazolyl, thiazolyl, oxazolyl,
isothiazolyl, pyrrolyl, quinolinyl, isoquinolinyl, indolyl,
benzimidazolyl, benzofuranyl, cinnolinyl, indazolyl, indolizinyl,
phthalazinyl, pyridazinyl, triazinyl, isoindolyl, pteridinyl,
purinyl, oxadiazolyl, triazolyl, thiadiazolyl, thiadiazolyl,
furazanyl, benzofurazanyl, benzothiophenyl, benzothiazolyl,
benzoxazolyl, quinazolinyl, quinoxalinyl, naphthyridinyl, and
furopyridinyl. Spiro moieties are also included within the scope of
this definition. Heteroaryl groups may be optionally substituted
independently with one or more substituents described herein.
By way of example and not limitation, carbon bonded heterocycles
and heteroaryls are bonded at position 2, 3, 4, 5, or 6 of a
pyridine, position 3, 4, 5, or 6 of a pyridazine, position 2, 4, 5,
or 6 of a pyrimidine, position 2, 3, 5, or 6 of a pyrazine,
position 2, 3, 4, or 5 of a furan, tetrahydrofuran, thiofuran,
thiophene, pyrrole or tetrahydropyrrole, position 2, 4, or 5 of an
oxazole, imidazole or thiazole, position 3, 4, or 5 of an
isoxazole, pyrazole, or isothiazole, position 2 or 3 of an
aziridine, position 2, 3, or 4 of an azetidine, position 2, 3, 4,
5, 6, 7, or 8 of a quinoline or position 1, 3, 4, 5, 6, 7, or 8 of
an isoquinoline. Further examples of carbon bonded heterocycles
include 2-pyridyl, 3-pyridyl, 4-pyridyl, 5-pyridyl, 6-pyridyl,
3-pyridazinyl, 4-pyridazinyl, 5-pyridazinyl, 6-pyridazinyl,
2-pyrimidinyl, 4-pyrimidinyl, 5-pyrimidinyl, 6-pyrimidinyl,
2-pyrazinyl, 3-pyrazinyl, 5-pyrazinyl, 6-pyrazinyl, 2-thiazolyl,
4-thiazolyl, or 5-thiazolyl.
By way of example and not limitation, nitrogen bonded heterocycles
and heteroaryls are bonded at position 1 of an aziridine,
azetidine, pyrrole, pyrrolidine, 2-pyrroline, 3-pyrroline,
imidazole, imidazolidine, 2-imidazoline, 3-imidazoline, pyrazole,
pyrazoline, 2-pyrazoline, 3-pyrazoline, piperidine, piperazine,
indole, indoline, 1H-indazole, position 2 of an isoindole, or
isoindoline, position 4 of a morpholine, and position 9 of a
carbazole, or .beta.-carboline. Still more typically, nitrogen
bonded heterocycles include 1-aziridyl, 1-azetedyl, 1-pyrrolyl,
1-imidazolyl, 1-pyrazolyl, and 1-piperidinyl.
The term "halogen" as used herein means fluoro, chloro, bromo or
iodo.
The term "a" as used herein means one or more.
As used herein, the terms "compound of this invention," "compounds
of the present invention" and "compounds of Formula I or Ia"
includes compounds of Formula I or Ia and resolved enantiomers,
resolved diastereomers, racemic mixtures and salts (including
pharmaceutically acceptable salts) thereof.
In general, the various moieties or functional groups of the
compounds of Formula I or Ia may be optionally substituted by one
or more substituents. Examples of substituents suitable for
purposes of this invention include, but are not limited to,
halogen, alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, OR,
NO.sub.2, CN, CO.sub.2R, (C.dbd.O)R, O(C.dbd.O)R, SR, SOR,
SO.sup.2R, aryl, heteroaryl, (C.dbd.O)NR.sup.2R.sup.3,
NR.sup.2R.sup.3, NR(C.dbd.O)R, SO.sub.2NR.sup.2R.sup.3,
PO.sub.3H.sub.2, and SO.sub.3H.sub.2, where R, R.sup.2 and R.sup.3
are alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl or
heteroaryl.
It is to be understood that in instances where two or more radicals
are used in succession to define a substituent attached to a
structure, the first named radical is considered to be terminal and
the last named radical is considered to be attached to the
structure in question. Thus, for example, an arylalkyl radical is
attached to the structure in question by the alkyl group.
AKT Inhibitors
The inventive compounds of Formula I or Ia are useful for
inhibiting AKT protein kinases. The compounds of Formula I or Ia
may also be useful as inhibitors of tyrosine kinases as well as
serine and threonine kinases in addition to AKT. Such compounds
have utility as therapeutic agents for diseases that can be treated
by the inhibition of the AKT protein kinase signaling pathway and
tyrosine and serine/threonine kinase receptor pathways.
In general, the invention includes compounds of the Formula I:
##STR00004## and enantiomers and pharmaceutically acceptable salts
thereof, wherein:
X is S, SO or SO.sub.2;
R.sup.1 is H, Me, Et, CF.sub.3, CHF.sub.2 or CH.sub.2F;
R.sup.2 is H or Me;
R.sup.5 is H, Me, Et, or CF.sub.3;
A is
##STR00005##
G is phenyl optionally substituted independently with one to four
R.sup.9 groups;
R.sup.6 and R.sup.7 are independently H, (C.sub.3-C.sub.6
cycloalkyl)-(CH.sub.2), (C.sub.3-C.sub.6
cycloalkyl)-(CH.sub.2CH.sub.2), V--(CH.sub.2).sub.0-1 wherein V is
a 5-6 membered heteroaryl, W--(CH.sub.2).sub.1-2 wherein W is
phenyl optionally substituted with F, Cl, Br, I, OMe, CF.sub.3 or
Me, C.sub.3-C.sub.6-cycloalkyl,
hydroxy-(C.sub.3-C.sub.6-cycloalkyl),
fluoro-(C.sub.3-C.sub.6-cycloalkyl), CH(CH.sub.3)CH(OH)phenyl, 4-6
membered heterocycle optionally substituted with F, OH,
cyclopropylmethyl, C.sub.1-C.sub.3 alkyl or
C(.dbd.O)(C.sub.1-C.sub.3 alkyl) or C.sub.1-C.sub.6-alkyl
optionally substituted with one or more groups independently
selected from OH, O(C.sub.1-C.sub.6-alkyl), CN, F, NH.sub.2,
NH(C.sub.1-C.sub.6-alkyl), N(C.sub.1-C.sub.6-alkyl).sub.2,
tetrahydropyranyl, tetrahydrofuranyl, morpholinyl, oxetanyl,
piperidinyl, and pyrrolidinyl,
or R.sup.6 and R.sup.7 together with the nitrogen to which they are
attached form a 3-6 membered heterocyclic ring optionally
substituted with one or more groups independently selected from OH,
halogen, oxo, CF.sub.3, CH.sub.2CF.sub.3, and
(C.sub.1-C.sub.3)alkyl;
R.sup.a and R.sup.b are H,
or R.sup.a is H, and R.sup.b and R.sup.6 together with the atoms to
which they are attached form a 5-6 membered heterocyclic ring
having one or two ring nitrogen atoms;
R.sup.c and R.sup.d are H or Me,
or R.sup.c and R.sup.d together with the atom to which they are
attached form a cyclopropyl ring;
R.sup.8 is H, Me, or OH,
or R.sup.8 and R.sup.6 together with the atoms to which they are
attached form a 5-6 membered heterocyclic ring having one or two
ring nitrogen atoms;
each R.sup.9 is independently halogen, C.sub.1-C.sub.6-alkyl,
C.sub.3-C.sub.6-cycloalkyl, O--(C.sub.1-C.sub.6-alkyl), CF.sub.3,
OCF.sub.3, S(C.sub.1-C.sub.6-alkyl), CN, OCH.sub.2-phenyl,
NH.sub.2, NH--(C.sub.1-C.sub.6-alkyl),
N--(C.sub.1-C.sub.6-alkyl).sub.2, piperidine, pyrrolidine,
CH.sub.2F, CHF.sub.2, OCH.sub.2F, OCHF.sub.2, OH,
SO.sub.2(C.sub.1-C.sub.6-alkyl), C(O)NH.sub.2,
C(O)NH(C.sub.1-C.sub.6-alkyl), and
C(O)N(C.sub.1-C.sub.6-alkyl).sub.2; and
m, n and p are independently 0 or 1.
In a further embodiment, the invention includes compounds of the
Formula Ia:
##STR00006## and enantiomers and salts thereof, wherein:
R.sup.1 is H, Me, Et, CF.sub.3, CHF.sub.2 or CH.sub.2F;
R.sup.2 is H or Me;
R.sup.5 is H, Me, Et, or CF.sub.3;
A is
##STR00007##
G is phenyl optionally substituted independently with one to four
R.sup.9 groups;
R.sup.6 and R.sup.7 are independently H, (C.sub.3-C.sub.6
cycloalkyl)-(CH.sub.2), (C.sub.3-C.sub.6
cycloalkyl)-(CH.sub.2CH.sub.2), V--(CH.sub.2).sub.0-1 wherein V is
a 5-6 membered heteroaryl, W--(CH.sub.2).sub.1-2 wherein W is
phenyl optionally substituted with F, Cl or Me,
C.sub.3-C.sub.6-cycloalkyl, hydroxy-(C.sub.3-C.sub.6-cycloalkyl),
fluoro-(C.sub.3-C.sub.6-cycloalkyl), CH(CH.sub.3)CH(OH)phenyl, or
C.sub.1-C.sub.6-alkyl optionally substituted with one or more
groups independently selected from OH, O(C.sub.1-C.sub.6-alkyl),
CN, F, NH.sub.2, NH(C.sub.1-C.sub.6-alkyl),
N(C.sub.1-C.sub.6-alkyl).sub.2, piperidinyl, and pyrrolidinyl,
or R.sup.6 and R.sup.7 together with the nitrogen to which they are
attached form a 3-6 membered heterocyclic ring optionally
substituted with one or more groups independently selected from OH,
halogen, oxo, CF.sub.3, CH.sub.2CF.sub.3, and
(C.sub.1-C.sub.3)alkyl;
R.sup.a and R.sup.b are H,
or R.sup.a is H, and R.sup.b and R.sup.6 together with the atoms to
which they are attached form a 5-6 membered heterocyclic ring
having one or two ring nitrogen atoms;
R.sup.c and R.sup.d are H or Me,
or R.sup.c and R.sup.d together with the atom to which they are
attached form a cyclopropyl ring;
R.sup.8 is H, Me, or OH,
or R.sup.8 and R.sup.6 together with the atoms to which they are
attached form a 5-6 membered heterocyclic ring having one or two
ring nitrogen atoms;
each R.sup.9 is independently halogen, C.sub.1-C.sub.6-alkyl,
C.sub.3-C.sub.6-cycloalkyl, CF.sub.3, OCF.sub.3,
S(C.sub.1-C.sub.6-alkyl), CN, OCH.sub.2-phenyl, NH.sub.2,
NH--(C.sub.1-C.sub.6-alkyl), N--(C.sub.1-C.sub.6-alkyl).sub.2,
piperidine, pyrrolidine, CH.sub.2F, CHF.sub.2, OCH.sub.2F,
OCHF.sub.2, OH, SO.sub.2(C.sub.1-C.sub.6-alkyl), C(O)NH.sub.2,
C(O)NH(C.sub.1-C.sub.6-alkyl), and
C(O)N(C.sub.1-C.sub.6-alkyl).sub.2; and
m, n and p are independently 0 or 1.
In a further embodiment, R.sup.6 and R.sup.7 are independently H,
(C.sub.3-C.sub.6 cycloalkyl)-(CH.sub.2), (C.sub.3-C.sub.6
cycloalkyl)-(CH.sub.2CH.sub.2), V--(CH.sub.2).sub.0-1 wherein V is
a 5-6 membered heteroaryl, W--(CH.sub.2).sub.1-2 wherein W is
phenyl optionally substituted with F, Cl or Me,
C.sub.3-C.sub.6-cycloalkyl, hydroxy-(C.sub.3-C.sub.6-cycloalkyl),
fluoro-(C.sub.3-C.sub.6-cycloalkyl), CH(CH.sub.3)CH(OH)phenyl, or
C.sub.1-C.sub.6-alkyl optionally substituted with one or more
groups independently selected from OH, O(C.sub.1-C.sub.6-alkyl),
CN, F, NH.sub.2, NH(C.sub.1-C.sub.6-alkyl),
N(C.sub.1-C.sub.6-alkyl).sub.2, piperidinyl, and pyrrolidinyl,
or R.sup.6 and R.sup.7 together with the nitrogen to which they are
attached form a 4-6 membered heterocyclic ring optionally
substituted with one or more groups independently selected from OH,
halogen, oxo, CF.sub.3, CH.sub.2CF.sub.3, and
(C.sub.1-C.sub.3)alkyl.
Referring to the G group of Formula I or Ia, examples include
phenyl optionally substituted with one or more R.sup.9 groups
independently selected from F, Cl, Br, CN, methyl, ethyl,
isopropyl, OCH.sub.3, OCH.sub.2CH.sub.3, CF.sub.3, OCF.sub.3,
SCH.sub.3, OCH.sub.2Ph and cyclopropyl. Exemplary embodiments
include, but are not limited to, phenyl, 2-chlorophenyl,
3-chlorophenyl, 4-chlorophenyl, 2-fluorophenyl, 3-fluorophenyl,
4-fluorophenyl, 2-bromophenyl, 3-bromophenyl, 4-bromophenyl,
2-methylphenyl, 3-methylphenyl, 4-methylphenyl, 2-ethylphenyl,
3-ethylphenyl, 4-ethylphenyl, 2-isopropylphenyl, 3-isopropylphenyl,
4-isopropylphenyl, 2-trifluoromethylphenyl,
3-trifluoromethylphenyl, 4-trifluoromethylphenyl, 2-cyanophenyl,
3-cyanophenyl, 4-cyanophenyl, 2-methoxyphenyl, 3-methoxyphenyl,
4-methoxyphenyl, 2-ethoxyphenyl, 3-ethoxyphenyl, 4-ethoxyphenyl,
2-thiomethylphenyl, 3-thiomethylphenyl, 4-thiomethylphenyl,
2-trifluoromethoxyphenyl, 3-trifluoromethoxyphenyl,
4-trifluoromethoxyphenyl, 2-cyclopropylphenyl, 3-cyclopropylphenyl,
4-cyclopropylphenyl, 4-chloro-3-fluorophenyl, 3,4-difluorophenyl,
4-bromo-3-fluorophenyl, 3-fluoro-4-methylphenyl,
3-fluoro-4-methoxyphenyl, 3-fluoro-4-trifluoromethylphenyl,
4-cyano-3-fluorophenyl, 3,4-dichlorophenyl, 2,4-dichlorophenyl,
2,4-difluorophenyl, 2-chloro-4-fluorophenyl,
2-fluoro-4-chlorophenyl, 3,5-dichlorophenyl. 3,5-difluorophenyl,
3-chloro-5-fluorophenyl, 3-chloro-4-fluorophenyl,
3-bromo-4-fluorophenyl, 3,5-difluoro-4-chlorophenyl,
2,3-difluoro-4-chlorophenyl, 2,5-difluoro-4-chlorophenyl,
3,5-difluoro-4-bromophenyl, 2,3-difluoro-4-bromophenyl,
2,5-difluoro-4-bromophenyl and 4-(OCH.sub.2Ph)-phenyl.
Referring to the R.sup.6 and R.sup.7 groups of Formula I or Ia, the
term "(C.sub.3-C.sub.6-cycloalkyl)-(CH.sub.2)" includes
cyclopropyl-CH.sub.2, cyclobutyl-CH.sub.2, cyclopentyl-CH.sub.2,
and cyclohexyl-CH.sub.2.
Referring to the R.sup.6 and R.sup.7 groups of Formula I or Ia, the
term "V--(CH.sub.2).sub.0-1" includes, but is not limited to, the
following structures:
##STR00008##
Referring to the R.sup.6 and R.sup.7 groups of Formula I or Ia, the
term "hydroxy-(C.sub.3-C.sub.6-cycloalkyl)" includes, but is not
limited to, the following structures:
##STR00009##
Referring to the R.sup.6 and R.sup.7 groups of Formula I or Ia, the
phrase "R.sup.6 and R.sup.7 together with the nitrogen to which
they are attached form a 3-6 membered heterocyclic ring optionally
substituted with one or more groups independently selected from OH,
halogen, oxo, CF.sub.3, CH.sub.2CF.sub.3, and
(C.sub.1-C.sub.3)alkyl" includes but is not limited to the
following structures:
##STR00010## ##STR00011##
Referring to the R.sup.6 and R.sup.7 groups of Formula I or Ia, the
phrase "4-6 membered heterocycle optionally substituted with F, OH,
cyclopropylmethyl, C.sub.1-C.sub.3 alkyl or
C(.dbd.O)(C.sub.1-C.sub.3 alkyl)" includes but is not limited to
the following structures:
##STR00012##
Referring to the R.sup.6 and R.sup.7 groups of Formula I or Ia, the
phrase "C.sub.1-C.sub.6-alkyl optionally substituted with one or
more groups independently selected from OH, OMe, and CN" includes,
but is not limited to, CH.sub.2OH, CH.sub.2CH.sub.2OH,
CH.sub.2CH.sub.2CH.sub.2OH, CH.sub.2CH(OH)CH.sub.2,
CH.sub.2CH.sub.2CH(OH)CH.sub.3, CH.sub.2C(OH)(CH.sub.3).sub.2,
CH.sub.2OMe, CH.sub.2CH.sub.2OMe, CH.sub.2CH.sub.2CH.sub.2OMe,
CH.sub.2CH(OMe)CH.sub.2, CH.sub.2CH.sub.2CH(OMe)CH.sub.3,
CH.sub.2C(OMe)(CH.sub.3).sub.2, CH.sub.2CN, CH.sub.2CH.sub.2CN,
CH.sub.2CH.sub.2CH.sub.2CN, CH.sub.2CH(CN)CH.sub.2,
CH.sub.2CH.sub.2CH(CN)CH.sub.3, CH.sub.2C(CN)(CH.sub.3).sub.2, and
the like.
Referring to the R.sup.6 and R.sup.7 groups of Formula I or Ia, in
certain embodiments the term "heteroaryl" refers to a 5-6 membered
heteroaryl having from one to two ring heteroatoms independently
selected from N, O and S.
In certain embodiments of Formula I, X is S. In particular
embodiments, Formula I is Formula Ia:
##STR00013##
In certain embodiments of Formula I, X is SO. In particular
embodiments, Formula I has the structure:
##STR00014##
In certain embodiments of Formula I, X is SO.sub.2. In particular
embodiments, Formula I has the structure:
##STR00015##
In one embodiment of Formula I or Ia, R.sup.1 is methyl, wherein
R.sup.1 is optionally in the (R) or (S) configuration. In another
embodiment of Formula I, R.sup.1 is H.
In another embodiment of Formula I or Ia, R.sup.1 is ethyl, wherein
R.sup.1 is optionally in the (R) or (S) configuration.
In certain embodiments of Formula I or Ia, R.sup.2 is H.
In one embodiment of Formula I or Ia, R.sup.2 is H.
In one embodiment of Formula I or Ia, R.sup.5 is H or methyl. In
another embodiment, R.sup.5 is methyl, wherein R.sup.5 is
optionally in the (S) configuration.
In one embodiment of Formula I or Ia, G is phenyl optionally
substituted with one to three R.sup.9 groups independently selected
from F, Cl, Br, CN, methyl, ethyl, isopropyl, CF.sub.3, OCF.sub.3,
SMe, OMe, and CH.sub.2OPh. Examples include, but are not limited
to, phenyl, 2-chlorophenyl, 3-chlorophenyl, 4-chlorophenyl,
4-fluorophenyl, 4-bromophenyl, 4-methylphenyl, 4-ethylphenyl,
4-isopropylphenyl, 4-trifluoromethylphenyl, 4-cyanophenyl,
4-methoxyphenyl, 4-ethoxyphenyl, 4-thiomethylphenyl,
4-trifluoromethoxyphenyl, 4-cyclopropylphenyl,
4-chloro-3-fluorophenyl, 3,4-difluorophenyl,
4-bromo-3-fluorophenyl, 3-fluoro-4-methylphenyl,
3-fluoro-4-methoxyphenyl, 3-fluoro-4-trifluoromethylphenyl,
4-cyano-3-fluorophenyl, 3,4-dichlorophenyl, 2,4-dichlorophenyl,
2,4-difluorophenyl, 2-chloro-4-fluorophenyl,
2-fluoro-4-chlorophenyl, 3,5-dichlorophenyl. 3,5-difluorophenyl,
3-chloro-5-fluorophenyl, 3-chloro-4-fluorophenyl,
3-bromo-4-fluorophenyl, 3,5-difluoro-4-chlorophenyl,
2,3-difluoro-4-chlorophenyl, 2,5-difluoro-4-chlorophenyl,
3,5-difluoro-4-bromophenyl, 2,3-difluoro-4-bromophenyl,
2,5-difluoro-4-bromophenyl and 4-(CH.sub.2OPh)-phenyl.
In particular embodiments, G is 4-chlorophenyl, 2,4-dichlorophenyl,
4-chloro-3-fluorophenyl, 4-fluorophenyl, 3,4-difluorophenyl,
4-methylphenyl, 4-methoxyphenyl or 4-(CH.sub.2OPh)-phenyl
In certain embodiments, G is a 9 membered heteroaryl. In particular
embodiments, G is an indole.
In particular embodiments, R.sup.6 and R.sup.7 are independently
H.
In particular embodiments, R.sup.6 and R.sup.7 are independently
(C.sub.3-C.sub.6 cycloalkyl)-(CH.sub.2).
In particular embodiments, R.sup.6 and R.sup.7 are independently
(C.sub.3-C.sub.6 cycloalkyl)-(CH.sub.2CH.sub.2).
In particular embodiments, R.sup.6 and R.sup.7 are independently
V--(CH.sub.2).sub.0-1 wherein V is a 5-6 membered heteroaryl.
In particular embodiments, R.sup.6 and R.sup.7 are independently
W--(CH.sub.2).sub.1-2 wherein W is phenyl optionally substituted
with F, Cl, Br, I, OMe, CF.sub.3 or Me. In a further embodiment,
R.sup.6 and R.sup.7 are independently W--(CH.sub.2).sub.1-2 wherein
W is phenyl optionally substituted with F, Cl, or Me.
In particular embodiments, R.sup.6 and R.sup.7 are independently
C.sub.3-C.sub.6-cycloalkyl.
In particular embodiments, R.sup.6 and R.sup.7 are independently
hydroxy-(C.sub.3-C.sub.6-cycloalkyl).
In particular embodiments, R.sup.6 and R.sup.7 are independently
fluoro-(C.sub.3-C.sub.6-cycloalkyl).
In particular embodiments, R.sup.6 and R.sup.7 are independently
CH(CH.sub.3)CH(OH)phenyl.
In particular embodiments, R.sup.6 and R.sup.7 are independently
4-6 membered heterocycle optionally substituted with F, OH,
cyclopropylmethyl, C.sub.1-C.sub.3 alkyl or
C(.dbd.O)(C.sub.1-C.sub.3 alkyl).
In particular embodiments, R.sup.6 and R.sup.7 are independently
C.sub.1-C.sub.6-alkyl optionally substituted with one or more
groups independently selected from OH, O(C.sub.1-C.sub.6-alkyl),
CN, F, NH.sub.2, NH(C.sub.1-C.sub.6-alkyl),
N(C.sub.1-C.sub.6-alkyl).sub.2, tetrahydropyranyl,
tetrahydrofuranyl, morpholinyl, oxetanyl, piperidinyl, and
pyrrolidinyl. In a further embodiment, R.sup.6 and R.sup.7 are
independently C.sub.1-C.sub.6-alkyl optionally substituted with one
or more groups independently selected from OH,
O(C.sub.1-C.sub.6-alkyl), CN, F, NH.sub.2,
NH(C.sub.1-C.sub.6-alkyl), N(C.sub.1-C.sub.6-alkyl).sub.2,
piperidinyl, and pyrrolidinyl.
In particular embodiments, R.sup.6 and R.sup.7 together with the
nitrogen to which they are attached form a 3-6 membered
heterocyclic ring optionally substituted with one or more groups
independently selected from OH, halogen, oxo, CF.sub.3,
CH.sub.2CF.sub.3, and (C.sub.1-C.sub.3)alkyl.
In one embodiment of Formula I or Ia, m is 1, n is 0, p is 0, such
that A is represented by the Formula 1:
##STR00016## wherein G, R.sup.6, R.sup.7, R.sup.8, R.sup.c and
R.sup.d are as defined herein. In certain embodiments, A has the
following configuration:
##STR00017##
In certain embodiments of group A, R.sup.8 is H or OH.
In certain embodiments of the A group having the Formula 1, R.sup.c
and R.sup.d are H. In other embodiments, R.sup.c and R.sup.d
together with the atom to which they are attached form a
cyclopropyl ring.
In certain embodiments of the A group having the Formula 1, R.sup.6
and R.sup.7 are independently H, C.sub.3-C.sub.6-cycloalkyl,
heteroaryl-(CH.sub.2), hydroxy-(C.sub.3-C.sub.6-cycloalkyl), or
(C.sub.1-6)-alkyl optionally substituted with one or more groups
independently selected from OH, OMe, and CN. In particular
embodiments, R.sup.6 and R.sup.7 are independently H, methyl,
ethyl, isopropyl, isobutyl, tert-butyl, 3-pentyl,
CH(isopropyl).sub.2, CH.sub.2CH.sub.2OH,
CH.sub.2CH.sub.2CH.sub.2OH, CH(CH.sub.2CH.sub.2OH).sub.2,
CH.sub.2CH.sub.2OMe, CH(CH.sub.2CH.sub.2OMe).sub.2,
CH.sub.2CH.sub.2CH.sub.2OMe, CH.sub.2CN, CH.sub.2-cyclopropyl,
CH.sub.2-cyclobutyl, CH.sub.2-tBu, cyclopentyl, cyclohexyl,
CH.sub.2-phenyl, CH.sub.2-(pyrid-2-yl), CH.sub.2-(pyrid-3-yl),
CH.sub.2-(pyrid-4-yl), 4-hydroxycyclohex-1-yl, or
CH(CH.sub.3)CH(OH)phenyl.
In particular embodiments of the A group having the Formula 1,
R.sup.6 and R.sup.7 are selected such that NR.sup.6R.sup.7 is
NH.sub.2, NHMe, NHEt, NHPr, NHiPr, NHtBu, NH(CH.sub.2-tBu),
NH(CH.sub.2-cyclopropyl), NH(CH.sub.2-cyclobutyl), NH(cyclopentyl),
NH(CH.sub.2-pyridyl), NH(cyclohexyl), NH(3-pentyl),
NHCH(isopropyl).sub.2, NH(CH.sub.2CH.sub.2OH),
NH(CH.sub.2CH.sub.2CH.sub.2OH), NH(CH.sub.2CH.sub.2OMe),
NH(CH.sub.2CH.sub.2CH.sub.2OMe), NH(CH.sub.2CN), NMe.sub.2, NMeEt,
NMePr, NMe(iPr), NMe(CH.sub.2-cyclopropyl),
NMe(CH.sub.2-cyclobutyl), NMe(CH.sub.2CH.sub.2OH),
NMe(CH.sub.2CH.sub.2CH.sub.2OH), NMe(CH.sub.2CH.sub.2OMe),
NMe(CH.sub.2CH.sub.2CH.sub.2OMe), NEt.sub.2, NEtPr, NEt(iPr),
NEt(CH.sub.2-cyclopropyl), NEt(CH.sub.2-cyclobutyl),
NEt(CH.sub.2CH.sub.2OH), NEt(CH.sub.2CH.sub.2CH.sub.2OH),
##STR00018##
In other embodiments of the A group having the Formula 1, R.sup.6
and R.sup.7 together with the N to which they are attached form a
4-6 membered heterocyclic ring having a ring nitrogen atom and
optionally having a second ring heteroatom selected form N and O,
wherein said heterocyclic ring is optionally substituted with one
or more groups independently selected from OH, halogen, oxo,
CH.sub.2CF.sub.3, and (C.sub.1-C.sub.3)alkyl. For example, in
certain embodiments, R.sup.6 and R.sup.7 together with the N to
which they are attached form a pyrrolidinyl, piperidinyl,
azetidinyl, morpholinyl or piperizinyl ring, wherein said
pyrrolidinyl, piperidinyl, azetidinyl, morpholinyl and piperazinyl
rings are optionally substituted with one or more groups
independently selected from OH, F methyl, CH.sub.2CF.sub.3, and
oxo. In particular embodiments of the A group having the Formula 1,
NR.sup.6R.sup.7 is selected from the structures:
##STR00019##
An additional embodiment of the A group having the Formula 1,
R.sup.6 and R.sup.7 form a 3 membered heterocyclic ring having a
ring nitrogen atom, wherein said heterocyclic ring is optionally
substituted with one or more groups independently selected from OH,
halogen, oxo, CH.sub.2CF.sub.3, and (C.sub.1-C.sub.3)alkyl. In
particular embodiments of the A group having the Formula 1,
NR.sup.6R.sup.7 is selected from the structure:
##STR00020##
In certain embodiments of the A group having the Formula 1, R.sup.6
and R.sup.8 together with the atoms to which they are attached form
a 5-6 membered heterocyclic ring having one or two ring nitrogen
atoms. In other embodiments, R.sup.6 and R.sup.8 together with the
atoms to which they are attached form a pyrrolidinyl or piperidinyl
ring.
In particular embodiments, the A group having the Formula 1 is
selected from the formulas:
##STR00021## ##STR00022## ##STR00023##
In an additional embodiment, the A group having the Formula 1 is
selected from the formulas:
##STR00024##
In certain embodiments, compounds of the present invention are
represented by Formula 1B:
##STR00025## wherein G, R.sup.6 and R.sup.7 are as defined
herein.
In another embodiment of Formula I or Ia, m is 1, n is 1 and p is
0, such that A is represented by the Formula 2:
##STR00026## wherein G, R.sup.6, R.sup.7, R.sup.8, R.sup.c and
R.sup.d are as defined herein. In certain embodiments, the A group
has the following configuration:
##STR00027##
In certain embodiments of the group A having the Formula 2, R.sup.8
is H.
In certain embodiments of the group A having the Formula 2, R.sup.c
and R.sup.d are H. In other embodiments, R.sup.c and R.sup.d are
methyl. In other embodiments, R.sup.c and R.sup.d together with the
atom to which they are attached form a cyclopropyl ring.
In certain embodiments of the group A having the Formula 2, R.sup.6
and R.sup.7 are independently H, methyl, ethyl, propyl, isopropyl,
CH.sub.2-cyclopropyl, or CH.sub.2-cyclobutyl. In certain
embodiments, NR.sup.6R.sup.7 of Formula 2 is NH.sub.2, NHCH.sub.3,
NHEt, NHPr, NH(iPr), NH(CH.sub.2-cyclopropyl),
NH(CH.sub.2-cyclobutyl), NMe.sub.2, NMeEt, NMePr, NMe(iPr),
NEt.sub.2, NEtPr, or NEt(iPr).
In certain embodiments of the group A having the Formula 2, R.sup.6
and R.sup.7 together with N form a 5-6 membered heterocyclic ring
having a ring nitrogen atom and optionally having an additional
ring nitrogen atom. For example, in certain embodiments, R.sup.6
and R.sup.7 together with N form a heterocyclic ring selected from
the structures:
##STR00028##
In other embodiments, R.sup.6 and R.sup.8 together with the atoms
to which they are attached form a piperidinyl or pyrrolidinyl
ring.
Exemplary embodiments of group A of Formula 2 include the
structures:
##STR00029## ##STR00030##
In certain embodiments, compounds of the present invention are
represented by Formula 2B:
##STR00031## wherein G, R.sup.c, R.sup.d, R.sup.6 and R.sup.7 are
as defined herein.
In other embodiments of Formula I or Ia, m is 1, n is 0 and p is 1,
such that group A is represented by the Formula 3:
##STR00032## wherein G, R.sup.6, R.sup.7, R.sup.8, R.sup.a,
R.sup.b, R.sup.c and R.sup.d are as defined herein. In certain
embodiments, group A has the configuration:
##STR00033##
In certain embodiments of the group A of Formula 3, R.sup.8 is
H.
In certain embodiments of the group A of Formula 3, R.sup.c and
R.sup.d are H. In other embodiments, R.sup.c and R.sup.d together
with the atom to which they are attached form a cyclopropyl
ring.
In certain embodiments of the group A of Formula 3, R.sup.6 and
R.sup.7 are independently H, methyl, ethyl, propyl, isopropyl,
t-butyl, CH.sub.2-cyclopropyl, or CH.sub.2-cyclobutyl.
In certain embodiments, NR.sup.6R.sup.7 of Formula 3 is NH.sub.2,
NHMe, NHEt, NHPr, NH(iPr), NHtBu, NH(CH.sub.2-cyclopropyl), or
NH(CH.sub.2-cyclobutyl).
In other embodiments of group A of Formula 3, R.sup.a and R.sup.8
are H, and R.sup.b and R.sup.6 together with the atoms to which
they are attached form a 5 to 6 membered heterocyclic ring wherein
one of the ring atoms is nitrogen. In certain embodiments, R.sup.b
and R.sup.6 together with the atoms to which they are attached form
a pyrrolidinyl ring. In certain embodiments, R.sup.7 is H.
In particular embodiments, group A of Formula 3 is selected from
the structures:
##STR00034##
In certain embodiments, compounds of the present invention are
represented by Formula 3B:
##STR00035## wherein G, R.sup.6 and R.sup.7 are as defined
herein.
In other embodiments of Formula I or Ia, m is 0, n is 0 and p is 1,
such that A is represented by the Formula 4:
##STR00036## wherein G, R.sup.6, R.sup.7, and R.sup.8 are as
defined herein. In certain embodiments, A has the following
configuration:
##STR00037##
In certain embodiments of the group A of Formula 4, R.sup.8 is
H.
In certain embodiments of the group A of Formula 4, R.sup.6 and
R.sup.7 are independently H or Me. In particular embodiments,
NR.sup.6R.sup.7 is NH.sub.2 or NHMe.
In particular embodiments, A is selected from the structures:
##STR00038##
In certain embodiments, compounds of the present invention are
represented by Formula 4B:
##STR00039## wherein G and R.sup.5 are as defined herein.
The compounds of this invention may possess one or more asymmetric
centers; such compounds can therefore be produced as individual
(R)- or (S)-stereoisomers or as mixtures thereof. Unless indicated
otherwise, the description or naming of a particular compound in
the specification and claims is intended to include both individual
enantiomers and diastereomers, and mixtures, racemic or otherwise,
thereof. Accordingly, this invention also includes all such
isomers, including diastereomeric mixtures, pure diastereomers and
pure enantiomers of the compounds of this invention. The term
"enantiomer" refers to two stereoisomers of a compound which are
non-superimposable mirror images of one another. The term
"diastereomer" refers to a pair of optical isomers which are not
mirror images of one another. Diastereomers have different physical
properties, e.g., melting points, boiling points, spectral
properties, and reactivities.
The compounds of the present invention may also exist in different
tautomeric forms, and all such forms are embraced within the scope
of the invention. The term "tautomer" or "tautomeric form" refers
to structural isomers of different energies which are
interconvertible via a low energy barrier. For example, proton
tautomers (also known as prototropic tautomers) include
interconversions via migration of a proton, such as keto-enol and
imine-enamine isomerizations. Valence tautomers include
interconversions by reorganization of some of the bonding
electrons.
In the structures shown herein, where the stereochemistry of any
particular chiral atom is not specified, then all stereoisomers are
contemplated and included as the compounds of the invention. Where
stereochemistry is specified by a solid wedge or dashed line
representing a particular configuration, then that stereoisomer is
so specified and defined.
The compounds of Formula I or Ia include solvates, pharmaceutically
acceptable prodrugs and salts (including pharmaceutically
acceptable salts) of such compounds.
The phrase "pharmaceutically acceptable" indicates that the
substance or composition is compatible chemically and/or
toxicologically with the other ingredients comprising a
formulation, and/or the mammal being treated therewith.
A "solvate" refers to an association or complex of one or more
solvent molecules and a compound of the invention. Examples of
solvents that form solvates include, but are not limited to, water,
isopropanol, ethanol, methanol, DMSO, ethyl acetate, acetic acid,
and ethanolamine. The term "hydrate" can also be used to refer to a
complex wherein the solvent molecule is water.
A "prodrug" is a compound that may be converted under physiological
conditions or by solvolysis to the specified compound or to a salt
of such compound. Prodrugs include compounds wherein an amino acid
residue, or a polypeptide chain of two or more (e.g., two, three or
four) amino acid residues, is covalently joined through an amide or
ester bond to a free amino, hydroxy or carboxylic acid group of a
compound of the present invention. The amino acid residues include
but are not limited to the 20 naturally occurring amino acids
commonly designated by three letter symbols and also includes
phosphoserine, phosphothreonine, phosphotyrosine, 4-hydroxyproline,
hydroxylysine, demosine, isodemosine, gamma-carboxyglutamate,
hippuric acid, octahydroindole-2-carboxylic acid, statine,
1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid, penicillamine,
ornithine, 3-methylhistidine, norvaline, beta-alanine,
gamma-aminobutyric acid, cirtulline, homocysteine, homoserine,
methyl-alanine, para-benzoylphenylalanine, phenylglycine,
propargylglycine, sarcosine, methionine sulfone and
tert-butylglycine.
Additional types of prodrugs are also encompassed. For instance, a
free carboxyl group of a compound of Formula I or Ia can be
derivatized as an amide or alkyl ester. As another example,
compounds of this invention comprising free hydroxy groups may be
derivatized as prodrugs by converting the hydroxy group into a
group such as, but not limited to, a phosphate ester,
hemisuccinate, dimethylaminoacetate, or
phosphoryloxymethyloxycarbonyl group, as outlined in Advanced Drug
Delivery Reviews, 1996, 19, 115. Carbamate prodrugs of hydroxy and
amino groups are also included, as are carbonate prodrugs,
sulfonate esters and sulfate esters of hydroxy groups.
Derivatization of hydroxy groups as (acyloxy)methyl and
(acyloxy)ethyl ethers, wherein the acyl group may be an alkyl ester
optionally substituted with groups including, but not limited to,
ether, amine and carboxylic acid functionalities, or where the acyl
group is an amino acid ester as described above, are also
encompassed. Prodrugs of this type are described in J. Med. Chem.,
1996, 39, 10. More specific examples include replacement of the
hydrogen atom of the alcohol group with a group such as
(C.sub.1-C.sub.6)alkanoyloxymethyl,
1-((C.sub.1-C.sub.6)alkanoyloxy)ethyl,
1-methyl-1-((C.sub.1-C.sub.6)alkanoyloxy)ethyl,
(C.sub.1-C.sub.6)alkoxycarbonyloxymethyl,
N--(C.sub.1-C.sub.6)alkoxycarbonylaminomethyl, succinoyl,
(C.sub.1-C.sub.6)alkanoyl, .alpha.-amino(C.sub.1-C.sub.4)alkanoyl,
arylacyl and .alpha.-aminoacyl, or
.alpha.-aminoacyl-.alpha.-aminoacyl, where each .alpha.-aminoacyl
group is independently selected from the naturally occurring
L-amino acids, P(O)(OH).sub.2,
--P(O)(O(C.sub.1-C.sub.6)alkyl).sub.2 or glycosyl (the radical
resulting from the removal of a hydroxyl group of the hemiacetal
form of a carbohydrate).
Free amines of compounds of Formula I or Ia can also be derivatized
as amides, sulfonamides or phosphonamides. All of these moieties
may incorporate groups including, but not limited to, ether, amine
and carboxylic acid functionalities. For example, a prodrug can be
formed by the replacement of a hydrogen atom in the amine group
with a group such as R-carbonyl, RO-carbonyl, NRR'-carbonyl,
wherein R and R' are each independently (C.sub.1-C.sub.10)alkyl,
(C.sub.3-C.sub.7)cycloalkyl, or benzyl, or R-carbonyl is a natural
.alpha.-aminoacyl or natural .alpha.-aminoacyl-natural
.alpha.-aminoacyl, --C(OH)C(O)OY wherein Y is H,
(C.sub.1-C.sub.6)alkyl or benzyl, --C(OY.sub.0)Y.sub.1 wherein
Y.sub.0 is (C.sub.1-C.sub.4) alkyl and Y.sub.1 is
(C.sub.1-C.sub.6)alkyl, carboxy(C.sub.1-C.sub.6)alkyl,
amino(C.sub.1-C.sub.4)alkyl or mono-N-- or
di-N,N--(C.sub.1-C.sub.6)alkylaminoalkyl, or --C(Y.sub.2)Y.sub.3
wherein Y.sub.2 is H or methyl and Y.sub.3 is mono-N-- or
di-N,N--(C.sub.1-C.sub.6)alkylamino, morpholino, piperidin-1-yl or
pyrrolidin-1-yl.
For additional examples of prodrug derivatives, see, for example,
a) Design of Prodrugs, edited by H. Bundgaard, (Elsevier, 1985) and
Methods in Enzymology, Vol. 42, p. 309-396, edited by K. Widder, et
al. (Academic Press, 1985); b) A Textbook of Drug Design and
Development, edited by Krogsgaard-Larsen and H. Bundgaard, Chapter
5 "Design and Application of Prodrugs," by H. Bundgaard p. 113-191
(1991); c) H. Bundgaard, Advanced Drug Delivery Reviews, 8:1-38
(1992); d) H. Bundgaard, et al., Journal of Pharmaceutical
Sciences, 77:285 (1988); and e) N. Kakeya, et al., Chem. Pharm.
Bull., 32:692 (1984), each of which is specifically incorporated
herein by reference.
Alternatively or additionally, compound of the invention may
possess a sufficiently acidic group, a sufficiently basic group, or
both functional groups, and accordingly react with any of a number
of inorganic or organic bases or acids to form a salt. Examples of
salts include those salts prepared by reaction of the compounds of
the present invention with a mineral or organic acid or an
inorganic base, such salts including, but not limited to, sulfates,
pyrosulfates, bisulfates, sulfites, bisulfites, phosphates,
monohydrogenphosphates, dihydrogenphosphates, metaphosphates,
pyrophosphates, chlorides, bromides, iodides, acetates,
propionates, decanoates, caprylates, acrylates, formates,
isobutyrates, caproates, heptanoates, propiolates, oxalates,
malonates, succinates, suberates, sebacates, fumarates, maleates,
butyn-1,4-dioates, hexyne-1,6-dioates, benzoates, chlorobenzoates,
methylbenzoates, dinitrobenzoates, hydroxybenzoates,
methoxybenzoates, phthalates, sulfonates, xylenesulfonates,
phenylacetates, phenylpropionates, phenylbutyrates, citrates,
lactates, .gamma.-hydroxybutyrates, glycollates, tartrates,
methanesulfonates, propanesulfonates, naphthalene-1-sulfonates,
naphthalene-2-sulfonates, and mandelates. Since a single compound
of the present invention may include more than one acidic or basic
moiety, the compounds of the present invention may include mono, di
or tri-salts in a single compound.
If the inventive compound is a base, the desired salt may be
prepared by any suitable method available in the art, for example,
by treatment of the free base with an acidic compound, for example
an inorganic acid such as hydrochloric acid, hydrobromic acid,
sulfuric acid, nitric acid, phosphoric acid and the like, or with
an organic acid, such as acetic acid, maleic acid, succinic acid,
mandelic acid, fumaric acid, malonic acid, pyruvic acid, oxalic
acid, glycolic acid, salicylic acid, a pyranosidyl acid such as
glucuronic acid or galacturonic acid, an alpha hydroxy acid such as
citric acid or tartaric acid, an amino acid such as aspartic acid
or glutamic acid, an aromatic acid such as benzoic acid or cinnamic
acid, a sulfonic acid such as p-toluenesulfonic acid or
ethanesulfonic acid, or the like.
If the inventive compound is an acid, the desired salt may be
prepared by any suitable method, for example, by treatment of the
free acid with an inorganic or organic base. Examples of suitable
inorganic salts include those formed with alkali and alkaline earth
metals such as lithium, sodium, potassium, barium and calcium.
Examples of suitable organic base salts include, for example,
ammonium, dibenzylammonium, benzylammonium, 2-hydroxyethylammonium,
bis(2-hydroxyethyl)ammonium, phenylethylbenzylamine,
dibenzylethylenediamine, and the like salts. Other salts of acidic
moieties may include, for example, those salts formed with
procaine, quinine and N-methylglucosamine, plus salts formed with
basic amino acids such as glycine, ornithine, histidine,
phenylglycine, lysine and arginine.
In certain embodiments, the salt is a "pharmaceutically acceptable
salt" which, unless otherwise indicated, includes salts that retain
the biological effectiveness of the corresponding free acid or base
of the specified compound and are not biologically or otherwise
undesirable.
The compounds of Formula I or Ia also include other salts of such
compounds which are not necessarily pharmaceutically acceptable
salts, and which may be useful as intermediates for preparing
and/or purifying compounds of Formula I or Ia and/or for separating
enantiomers of compounds of Formula I or Ia.
The present invention also embraces isotopically-labeled compounds
of the present invention which are identical to those recited
herein, but for the fact that one or more atoms are replaced by an
atom having an atomic mass or mass number different from the atomic
mass or mass number usually found in nature. All isotopes of any
particular atom or element as specified are contemplated within the
scope of the compounds of the invention, and their uses. Exemplary
isotopes that can be incorporated into compounds of the invention
include isotopes of hydrogen, carbon, nitrogen, oxygen, phosphorus,
sulfur, fluorine, chlorine and iodine, such as .sup.2H, .sup.3H,
.sup.11C, .sup.13C, .sup.14C, .sup.13N, .sup.15N, .sup.15O,
.sup.17O, .sup.18O, .sup.32P, .sup.33P, .sup.35S, .sup.18F,
.sup.36Cl, .sup.123I and .sup.125I. Certain isotopically-labeled
compounds of the present invention (e.g., those labeled with
.sup.3H and .sup.14C) are useful in compound and/or substrate
tissue distribution assays. Tritiated (i.e., .sup.3H) and carbon-14
(i.e., .sup.14C) isotopes are useful for their ease of preparation
and detectability. Further, substitution with heavier isotopes such
as deuterium (i.e., .sup.2H) may afford certain therapeutic
advantages resulting from greater metabolic stability (e.g.,
increased in vivo half-life or reduced dosage requirements) and
hence may be preferred in some circumstances. Positron emitting
isotopes such as .sup.15O, .sup.13N, .sup.11C and .sup.18F are
useful for positron emission tomography (PET) studies to examine
substrate receptor occupancy. Isotopically labeled compounds of the
present invention can generally be prepared by following procedures
analogous to those disclosed in the Schemes and/or in the Examples
herein below, by substituting an isotopically labeled reagent for a
non-isotopically labeled reagent.
Metabolites of Compounds of Formula I or Ia
Also falling within the scope of this invention are the in vivo
metabolic products of compounds of Formula I or Ia described
herein. A "metabolite" is a pharmacologically active product
produced through metabolism in the body of a specified compound or
salt thereof. Such products may result, for example, from the
oxidation, reduction, hydrolysis, amidation, deamidation,
esterification, deesterification, enzymatic cleavage, and the like,
of the administered compound. Accordingly, the invention includes
metabolites of compounds of Formula I or Ia, including compounds
produced by a process comprising contacting a compound of this
invention with a mammal for a period of time sufficient to yield a
metabolic product thereof.
Metabolites are identified, for example, by preparing a
radiolabelled (e.g., .sup.14C or .sup.3H) isotope of a compound of
the invention, administering it parenterally in a detectable dose
(e.g., greater than about 0.5 mg/kg) to an animal such as rat,
mouse, guinea pig, monkey, or to a human, allowing sufficient time
for metabolism to occur (typically about 30 seconds to 30 hours)
and isolating its conversion products from the urine, blood or
other biological samples. These products are easily isolated since
they are labeled (others are isolated by the use of antibodies
capable of binding epitopes surviving in the metabolite). The
metabolite structures are determined in conventional fashion, e.g.,
by MS, LC/MS or NMR analysis. In general, analysis of metabolites
is done in the same way as conventional drug metabolism studies
well known to those skilled in the art. The metabolites, so long as
they are not otherwise found in vivo, are useful in diagnostic
assays for therapeutic dosing of the compounds of the
invention.
Synthesis of Compounds of Formula I or Ia
Compounds of this invention may be synthesized by synthetic routes
that include processes analogous to those well known in the
chemical arts, particularly in light of the description contained
herein. The starting materials are generally available from
commercial sources such as Aldrich Chemicals (Milwaukee, Wis.) or
are readily prepared using methods well known to those skilled in
the art (e.g., prepared by methods generally described in Louis F.
Fieser and Mary Fieser, Reagents for Organic Synthesis, v. 1-19,
Wiley, N.Y. (1967-1999 ed.), or Beilsteins Handbuch der organischen
Chemie, 4, Aufl. ed. Springer-Verlag, Berlin, including
supplements).
Compounds of Formula I or Ia may be prepared singly or as compound
libraries comprising at least 2, for example 5 to 1,000 compounds,
or 10 to 100 compounds. Libraries of compounds of Formula I or Ia
may be prepared by a combinatorial `split and mix` approach or by
multiple parallel syntheses using either solution phase or solid
phase chemistry, by procedures known to those skilled in the art.
Thus according to a further aspect of the invention there is
provided a compound library comprising at least 2 compounds of
Formula I, or salts thereof.
For illustrative purposes, Schemes 1-4 and Schemes A-K show general
methods for preparing the compounds of the present invention as
well as key intermediates. For a more detailed description of the
individual reaction steps, see the Examples section below. Those
skilled in the art will appreciate that other synthetic routes may
be used to synthesize the inventive compounds. Although specific
starting materials and reagents are depicted in the Schemes and
discussed below, other starting materials and reagents can be
easily substituted to provide a variety of derivatives and/or
reaction conditions. In addition, many of the compounds prepared by
the methods described below can be further modified in light of
this disclosure using conventional chemistry well known to those
skilled in the art.
##STR00040##
Scheme 1 shows a method of preparing compound (106) of Formula I
wherein R.sup.1 and R.sup.5 are H. According to Scheme 1, treatment
of the ketoester (101) with formamidine in the presence of a base
such as sodium ethoxide provides the 4-hydroxypyrimidine (102).
Transformation of the hydroxyl group of compound (102) to halogen
group such as Cl may be realized by the treatment of compound (102)
with a halogenating reagent such as POCl.sub.3 to provide compound
(103). Replacement of the chloro group of compound (103) with
piperazine yields the intermediate (104). Deprotection of the
intermediate (104) and followed by coupling with an appropriate
amino acid provides compound (106).
##STR00041##
Scheme 2 shows a method of preparing compounds (116) and (119) of
Formula I wherein R.sup.1 is Me and R.sup.5 is H. According to
Scheme 2, Michael addition of a thioglycolate (107) to a crotonate
(108) provides the diester (109). Intramolecular cyclization of the
diester (109) in the presence of a base such as NaOEt gives the
ketoester (110). Pyrimidine formation may be accomplished by the
treatment of the ketoester (110) with the formamidine and a base
such as sodium ethoxide to provide compound (III). Chlorination of
the hydroxypyrimidine (111) with a halogenating reagent such as
POCl.sub.3 and followed by an S.sub.NAr reaction with a protected
piperidine (112) produces the racemic intermediate (113). The
enantiomerically pure compounds (114) and (117) can be separated by
chiral HPLC. After deprotection, the 4-piperazinyl pyrimidines
(115) and (118) can be coupled with a suitable amino acid to
provide compounds (116) and (119), respectively.
##STR00042##
Scheme 3 shows a method of preparing compound (23) of Formula I
wherein R.sup.1 and R.sup.5 are Me. According to Scheme 3,
S.sub.NAr reaction of compound (112) (prepared according to Scheme
2) with 3-(S)-1-PG-piperazine (where PG is an amine protecting
group) in solvent such as alcohol, DMF or NMP at elevated
temperatures, such as a temperature between about 80-180.degree.
C., gives the intermediate (120). Chiral separation of
diastereomers (120) may be achieved by chiral HPLC. The single
diastereomer (121) is deprotected and coupled with a suitable amino
acid to give compound (123).
##STR00043##
Scheme 4 shows a method of preparing compound (130) of Formula I
wherein R.sup.1 is ethyl and R.sup.5 is methyl. According to Scheme
4, Michael addition of a thioester (117) to a pentenoate ester
(124) forms an intermediate which undergoes cyclization in situ
under basic conditions to give the ketoester (125). Formation of
pyrimidine (126) is achieved by treating compound (125) with
formamidine under basic conditions. Chlorination of the pyrimidine
(126) gives compound (127). S.sub.NAr reaction of compound (127)
with a protected piperazine group provides compound (128). After
deprotection of compound (128), the resulting compound (129) is
coupled with a suitable amino acid to provide compound (130).
Accordingly, another aspect of the invention provides a method of
preparing compounds of Formula I, comprising:
reacting a compound having the formula:
##STR00044## wherein R.sup.1, R.sup.2, R.sup.5, and X are as
defined herein, with a compound having the formula:
##STR00045## wherein R.sup.6, R.sup.7, R.sup.8, R.sup.a, R.sup.b;
R.sup.c, R.sup.d, G, n, m and p are as defined herein.
Accordingly, another aspect of the invention provides a method of
preparing compounds of Formula Ia, comprising:
reacting a compound having the formula:
##STR00046## wherein R.sup.1, R.sup.2, and R.sup.5 are as defined
herein, with a compound having the formula:
##STR00047## wherein R.sup.6, R.sup.7, R.sup.8, R.sup.a, R.sup.b,
R.sup.c, R.sup.d, G, n, m and p are as defined herein.
The amino acids used in the synthesis of compounds of Formula I as
illustrated in Schemes 1-4 are either commercially available or may
be prepared according to the methods disclosed herein. For example,
in certain embodiments the amino acids used to prepare compounds of
Formula I include .beta.-phenylglycine amino acids having the
Formula 1A, .gamma.-phenylglycine amino acids having the Formula
2A, .beta.-phenylalanine amino acids having the Formula 3A, and
.gamma.-phenylalanine amino acids having the Formula 4A.
##STR00048##
Methods of preparing amino acids of Formulas 1A-4A are shown in
Schemes A-K.
##STR00049##
Scheme A illustrates a method of preparing optionally substituted
.beta.-phenylglycine amino acids 25 and 26 of the Formula 1 wherein
R.sup.8 is H, and R.sup.6, R.sup.9 and t are as defined herein and
R.sup.7 is H or an amine protecting group. According to Scheme A,
the acid 20 is converted to an ester 21 wherein R' is alkyl using
standard conditions such as treatment with an appropriate alcohol
(e.g. MeOH) in the presence of a catalytic amount of an acid such
as concentrated H.sub.2SO.sub.4 or a coupling agent such as
DCC/DMAP; or alternatively by treatment with an appropriate
electrophile (e.g., MeI, EtBr, BnBr) in the presence of a base such
as NEt.sub.3/DMAP at an appropriate temperature (e.g., -20.degree.
C. to 100.degree. C.). The appropriate choice of ester is
determined by the conditions required to reform the acid at the end
of the synthesis, with many appropriate examples and conditions
being listed in `Protective Groups in Organic Synthesis` by Greene
and Wuts, Wiley-Interscience, third edition, Chapter 5.
Introduction of the hydroxymethyl group to provide compound 22 may
be performed by treatment with an appropriate aldehyde (e.g.,
formaldehyde) in the presence of base such as NaOEt at an
appropriate temperature (e.g., -20.degree. C. to room temperature).
Activation of the alcohol group of compound 22 to form a leaving
group (e.g., a mesylate, tosylate, halide) may be accomplished by
treatment with, for example, methanesulphonyl chloride in the
presence of excess base such as NEt.sub.3, DIPEA, or DBU at an
appropriate temperature (e.g., -20.degree. C. to room temperature).
In many cases the olefin 24 can be isolated directly from this
procedure, in other cases warming (30.degree. C. to 100.degree. C.)
or additional base (e.g. DBU in the case of halide) may be required
to complete the elimination to provide compound 24. The activated
olefin 24 may be treated with the desired primary amine (e.g.,
ethylamine) in a suitable solvent, such as THF, at an appropriate
temperature (e.g., -20.degree. C. to reflux) to generate the
aminoester intermediate. In the case wherein compound 24 has an
electron rich aromatic ring or electron poor/bulky primary amine,
heating (e.g. 30-240.degree. C. in a sealed tube) or microwave
chemistry may be required. Protection of the amine group (for
example as Boc-group) may be accomplished using Boc.sub.2O under
standard conditions to provide compound 23 wherein Pg is a
protecting group. Alternative protecting groups may be used, and
many appropriate examples are listed in `Protective Groups in
Organic Synthesis` by Greene and Wuts, Wiley-Interscience, third
edition, Chapter 7. Saponification of the ester 23 to form the
protected amino acid 25 may be accomplished using conditions
appropriate for the ester (e.g., aqueous LiOH for methyl esters,
hydrogenation for benzyl esters, acid for t-butyl esters).
Alternatively, the activated olefin 24 may be treated with a
secondary amine (e.g., diethylamine) in a suitable solvent such as
THF at an appropriate temperature (e.g., -20.degree. C. to reflux)
to generate the aminoester intermediate (not shown). In the case
wherein compound 24 has an electron rich aromatic ring or electron
poor/bulky secondary amine, heating (e.g., 30-240.degree. C. in a
sealed tube) or microwave chemistry may be required. Saponification
of the ester to form the amino acid 26 may be accomplished using
conditions appropriate for the ester (e.g., aqueous LiOH for methyl
esters, hydrogenation for benzyl esters, acid for t-butyl esters,
etc.).
##STR00050##
Scheme B shows a method of preparing optionally substituted
.beta.-phenylglycine amino acids 30 and 31 of Formula 1 wherein
R.sup.8 is OH, R.sup.c and R.sup.d are H, and R.sup.6, R.sup.9 and
t are as defined herein and R.sup.7 is as defined herein or an
amine protecting group. Oxidation of the unsaturated ester 24
(prepared according to Scheme A), wherein t is 0-4 and R' is alkyl,
using a standard oxidizing agent such as MCPBA at an appropriate
temperature (room temperature to reflux) provides the epoxide
intermediate 28. Intermediate 28 may be treated with an appropriate
amine, typically at high temperature (e.g., 50-300.degree. C.) and
high pressure (e.g., in a sealed tube or a bomb) to give the amino
alcohol 29 or 30. If a secondary amine is used (such as in the
preparation of compound 30), then deprotection of the ester using
conditions listed in `Protective Groups in Organic Synthesis` by
Greene and Wuts, Wiley-Interscience, third edition, Chapter 5 may
be used (e.g., LiOH for a methyl ester, hydrogenation for a benzyl
ester, etc). When a primary amine is used (such as in the
preparation of compound 29), protection of the amine (e.g., as a
Boc-group using Boc anhydride) followed by deprotection of the
ester (using the above conditions) provide the hydroxylated amino
acid 31.
##STR00051##
Scheme C shows a method of preparing optionally substituted
.beta.-phenylglycine amino acids 36 of the Formula 1 wherein
R.sup.8 is methyl, R.sup.c and R.sup.d are H, R.sup.6 is H, R.sup.7
is H or an amine protecting group, and R.sup.9 and t are as defined
herein. The ester 32, wherein R''' is alkyl, can be treated with a
base (e.g. NaOtBu) at an appropriate temperature (e.g., 0.degree.
C. to reflux) to form the anion, followed by addition of an
electrophile (e.g., tert-butyl 2-bromoacetate) at an appropriate
temperature (e.g, 78.degree. C. to room temperature) to give the
homologated ester 33. Saponification of the t-butyl ester of
compound 33 using an appropriate acid such as TFA or HCl at an
appropriate temperature (e.g, 0.degree. C. to reflux) provides
compound 34. A Curtius rearrangement of compound 34 using, for
example, DPPA in the presence of mild base such as NEt.sub.3 at an
appropriate temperature (e.g., 0.degree. C. to reflux), followed by
treatment of the reactive intermediate with an alcohol (e.g.
tBuOH), optionally in the presence of a Lewis acid (e.g.
SnCl.sub.2) at higher temperature (e.g., 40-200.degree. C.)
provides compound 35 wherein Pg is an amine protecting group. The
choice of alcohol used to prepare compound 35 determines the amine
protecting group (e.g. tBuOH provides the Boc-amine). Deprotection
of the ester group of compound 35 using standard conditions (e.g.,
with LiOH when the protecting group is a methyl ester,
hydrogenation for a benzyl ester, etc.) gives the acid compound
36.
##STR00052##
Scheme D shows a method of preparing optionally substituted
.gamma.-phenylglycine amino acids 40 of Formula 2 wherein R.sup.c,
R.sup.d, R.sup.9 and t are as defined herein, R.sup.6 is H, and
R.sup.7 is an amine protecting group such as Boc. The starting
unsaturated ester 24, prepared according to Scheme A, can be
treated with a substituted nitromethane derivative (e.g.
nitroethane) in the presence of a base such as DBU at an
appropriate temperature (e.g., 0.degree. C. to room temperature) to
give the homologated adduct 37. The nitro group of compound 37 can
be reduced using standard conditions (e.g., hydrogenation, Zn/acid,
etc.) at an appropriate temperature (e.g., room temperature to
reflux), and the resulting intermediate can be cyclized to give the
lactam intermediate 38. Protection of the amine, for example with a
Boc-group to provide compound 39, may be accomplished using
Boc.sub.2O under standard conditions. Alternative protecting groups
may be used, and many appropriate examples are listed in
`Protective Groups in Organic Synthesis` by Greene and Wuts,
Wiley-Interscience, third edition, Chapter 7. Treatment of compound
39 with an aqueous base such as LiOH or KOH at an appropriate
temperature (e.g., 0 to 100.degree. C.) effects ring opening of the
lactam to give the appropriately substituted, protected amino acid
compound 40.
##STR00053##
Scheme E shows a method of making optionally substituted
.gamma.-phenylglycine amino acids 44 of Formula 2 wherein R.sup.8
is methyl, R.sup.c and R.sup.d are H, R.sup.6 is H, R.sup.7 is an
amine protecting group, and R.sup.9 and t are defined herein. The
ester 32, wherein R''' is alkyl and t is 0-4, can be treated with a
suitable base such as KOtBu at an appropriate temperature (e.g.,
0.degree. C. to reflux) to form the anion, followed by addition of
an acrylate unit (e.g., t-butylacrylate) at a temperature ranging
from -78.degree. C. to room temperature to give the homologated
ester 41. Saponification of the t-butyl ester of compound 41 by
treatment with a suitable acid such as TFA or HCl at an appropriate
temperature (e.g, 0.degree. C. to reflux) provides compound 42. A
Curtius rearrangement of compound 42 using, for example, DPPA in
the presence of mild base such as NEt.sub.3 at an appropriate
temperature (e.g., 0.degree. C. to reflux), followed by treatment
of the reactive intermediate with an appropriate alcohol (e.g.
tBuOH), optionally in the presence of a Lewis acid (e.g.
SnCl.sub.2) at elevated temperatures (e.g. 40-200.degree. C.)
provides compound 43. The choice of alcohol determines the amine
protecting group of compound 43 (e.g., tBuOH provides the
Boc-amine). Deprotection of the ester of compound 43 under standard
conditions (e.g., LiOH for a methyl ester, hydrogenation for a
benzyl ester, etc.) gives the acid 44.
In an alternative to Scheme E, R.sup.8 may be hydrogen.
##STR00054##
Scheme F shows a method of preparing optionally substituted
.beta.-phenylalanine amino acids 48, 49 and 50 of Formula 3 wherein
R.sup.6 is H, R.sup.7 is an amine protecting group, R.sup.c and
R.sup.d are H, and R.sup.9 and t are as defined herein. An
appropriately substituted aldehyde 45 can be treated with a
cyanoacetate of the formula CN--CH.sub.2CO.sub.2R''' wherein R'''
is alkyl (e.g., ethyl 2-cyanoacetate) in the presence of a suitable
base such as piperidine at an appropriate temperature (e.g., room
temperature to reflux) to give the unsaturated ester 46. Reduction
of the olefin and the nitrile groups of compound 46 to provide
compound 47 may be accomplished in a number of ways. For example,
the olefin may be reduced with any agent known to effect
1,4-reductions, such as NaBH.sub.4. The nitrile may be reduced
using agents such as LiAlH.sub.4 or NaBH.sub.4 in the presence of a
Lewis acid such as BF.sub.3.OEt.sub.2 or TFA. A number of
alternative reducing agents may be used, such as those listed in
`Reductions in Organic Chemistry` by Hudlicky, ACS monograph,
2.sup.nd edition, Chapter 18. If desired, the primary amine 47 can
be monoalkylated or bisalkylated at this stage using standard
conditions (e.g., reductive amination using an appropriate
aldehyde, Lewis acid and reducing agent) to provide intermediates
(not shown) en route to compounds 48 and 49. To prepare primary and
secondary amines, protection may be accomplished using any number
of protecting groups (e.g. `Protective Groups in Organic Synthesis`
by Greene and Wuts, Wiley-Interscience, third edition, Chapter 7),
for example as a Boc-group using Boc anhydride at 0.degree. C. to
room temperature. Cleavage of the ester group to form the amino
acid 48, 49 or 50 may be accomplished using an aqueous bases such
as LiOH or KOH, or any of the alternative reagents listed in the
aforementioned `Protecting Groups` text (e.g., hydrogenation for a
benzyl ester).
##STR00055##
Scheme G shows a method of preparing optionally substituted
.alpha.-phenylalanine amino acids 54 of Formula 4 wherein R.sup.6
is H, R.sup.7 is an amine protecting group, and R.sup.9 and t are
as defined herein. An appropriately substituted acid 51 may be
reduced to the benzyl alcohol 52 using for example LiAlH.sub.4 at a
temperature ranging from room temperature to reflux. The alcohol
group of compound 52 can be activated as a leaving group (e.g.
halide, mesylate, etc.) using, for example, PBr.sub.3,
MsCl/NEt.sub.3, etc. Displacement of this leaving group using a
protected glycine derivative such as ethyl
2-(diphenylmethyleneamino)acetate in the presence of strong base
such as LDA, nBuLi provides the amino ester intermediate 53 wherein
R.sup.1 is alkyl and Pg is a protecting group. Appropriate
protecting groups are listed in `Protective Groups in Organic
Synthesis` by Greene and Wuts, Wiley-Interscience). The amine
protecting group may be changed at this stage, for example to
introduce a Boc-group. Subsequent deprotection of the ester 53
(e.g., using 3N HCl, LiOH, hydrogenation for a benzyl ester, etc.)
at an appropriate temperature (e.g., 0.degree. C. to reflux)
provides the desired N-protected amino acid 54.
##STR00056##
Scheme H shows a method of preparing optionally substituted
.gamma.-phenylglycine amino acids 56 of Formula 2 wherein R.sup.c
and R.sup.d are H, R.sup.6 and R.sup.8 together with the atoms to
which they are attached form a spirocyclic heterocyclic ring,
R.sup.7 is an amine protecting group, and R.sup.9 and t are as
defined herein. According to Scheme H, the unsaturated ester 24 can
be treated with a suitably protected glycine derivative (e.g.,
benzylglycine) and formaldehyde under dry conditions (e.g., with
addition of molecular sieves) at an appropriate temperature (e.g.,
room temperature to reflux) to generate compound 55. Cleavage of
the benzyl group using standard conditions (e.g., via
hydrogenation, 1-chloroethylformate, etc.) followed by addition of
an amine protecting group such as a Boc-group and cleavage of the
ester under standard conditions (e.g. LiOH for a methyl ester, acid
for a t-butyl ester, etc., at 0.degree. C. to reflux) provides the
N-protected amino acid 56.
##STR00057##
Scheme I shows a method of preparing optionally substituted
.beta.-phenylalanine amino acids 61 and 62 of Formula 3 wherein
R.sup.c and R.sup.d are H, R.sup.6 and R.sup.b together with the
atoms to which they are attached form a heterocyclic ring, and
R.sup.7, R.sup.9 and t are as defined herein. The acid 57 is
converted to an ester 58 using standard conditions such as
treatment with an appropriate alcohol (e.g., MeOH) in the presence
of either catalytic acid (e.g. concentrated H.sub.2SO.sub.4 or
TMSCl) or a coupling agent (e.g. DCC/DMAP); or alternatively by
treatment with an appropriate electrophile (e.g. MeI, EtBr, BnBr)
in the presence of a suitable base such as NEt.sub.3/DMAP at
appropriate temperatures (e.g., -20.degree. C. to 100.degree. C.).
The appropriate choice of ester is determined by the conditions
required to reform the acid at the end of the synthesis, such as
described in `Protective Groups in Organic Synthesis` by Greene and
Wuts, Wiley-Interscience, third edition, Chapter 5. Cyclization of
compound 58 to provide compound 59 may be achieved using, for
example,
N-(methoxymethyl)(phenyl)-N-((trimethylsilyl)methyl)methanamine in
the presence of TFA. This particular set of reagents generates the
benzylamine, which can be cleaved to provide compound 60 under
standard conditions such as hydrogenation at -20.degree. C. to
50.degree. C. or any other standard conditions such as those listed
in `Protective Groups in Organic Synthesis` by Greene and Wuts,
Wiley-Interscience, third edition, Chapter 7. Protection of the
free amine of compound 60 with an alternative protecting group
(e.g., Boc) using reagents listed in the aforementioned text, such
as Boc-anhydride, followed by cleavage of the ester using standard
conditions appropriate for the ester (e.g. aqueous LiOH for methyl
esters, hydrogenation for benzyl esters, acid for t-butyl esters)
provides the acid compound 61. Alternatively, the free amine can be
functionalized further (e.g. using alkylation, reductive amination,
or acylation conditions), followed by ester cleavage to generate
the tertiary amino acid compound 62.
##STR00058##
Either enantiomer of the beta-amino acids may be prepared using a
procedure such as that shown in Scheme J. A 2-phenylacetate coupled
with an appropriate chiral auxiliary (R*) (for example, an Evans'
auxiliary or a Sultam) with the appropriate stereochemistry to
generate the desired chemistry at the beta-position of the amino
acid may be treated with an imine or iminium ion synthon (e.g.
prepared in situ by the presence of a Lewis acid (e.g. TiCl.sub.4)
and an appropriately substituted alkoxymethanamine or
N-(alkoxymethyl)amide/carbamate at -100.degree. C. to 50.degree.
C.). The asymmetric addition may require the presence of Lewis
acids (e.g. TiCl.sub.4), amine bases (e.g. Hunig's base) and lower
temperatures (e.g. -100.degree. C. to 0.degree. C.) to generate the
best levels of stereochemical induction. If the
diastereoselectivity is lower than required, the separate
diastereomers may be separated at this stage by (for example)
chromatography or crystallization. Cleavage of the chiral
auxillary, using methods known to cleave the chosen auxiliary (e.g.
LiOH/H.sub.2O.sub.2 at -50.degree. C. to 50.degree. C. for the
Evans auxillary) then leads to the desired N-protected beta-amino
acid with the desired stereochemistry at the beta-position.
Additionally, if R.sup.6 is also a protecting group (e.g.
2,4-dimethoxybenzyl), it may be removed in the presence of the
Boc-group (e.g. hydrogenation or DDQ, etc.) to give the Boc-amino
acid, which upon removal of the Boc-group would provide the primary
amine, which may be further functionalized by alkylation, acylation
or reductive amination (either prior to or after coupling with the
pyrimidine-piperazine unit).
##STR00059##
Scheme K shows representative methods of forming the single
enantiomers of the gamma amino acids wherein R.sup.c, R.sup.d, and
R.sup.9 are as defined herein t is 0 to 4, R.sup.6 is H, and
R.sup.7 is an amine protecting group such as Boc. In one possible
method, the racemic amino acid is subject to chiral chromatographic
separation using a chiral stationary phase. Alternatively, a
diastereomeric mixture may be prepared which could be separated by
conventional chromatographic techniques. For example, activation of
the racemic amino acid (e.g. COCl.sub.2, base) and introduction of
a chiral auxiliary, R* (e.g. an Evans' oxazolidinone) in the
presence of a basic amine (e.g. Hunig's base) at -20.degree. C. to
50.degree. C. gives the diastereomeric mixture. This mixture may be
separated using standard conditions (e.g. column chromatography,
HPLC, SFC, etc.) to give the individual diastereomers. These may be
converted to the desired acids by cleavage of the chiral auxiliary
(in the case of an Evans' auxiliary, by using (for example)
LiOH/HOOH at -15.degree. C. to room temperature to give the single
enantiomers of the gamma-amino acids. The temperature may need to
be kept low so as to prevent racemization of the newly separated
chiral center.
In preparing compounds of Formula I or Ia, protection of remote
functionalities (e.g., primary or secondary amines, etc.) of
intermediates may be necessary. The need for such protection will
vary depending on the nature of the remote functionality and the
conditions of the preparation methods. Suitable amino-protecting
groups (NH-Pg) include acetyl, trifluoroacetyl, t-butoxycarbonyl
(BOC), benzyloxycarbonyl (CBz) and 9-fluorenylmethyleneoxycarbonyl
(Fmoc). The need for such protection is readily determined by one
skilled in the art. For a general description of protecting groups
and their use, see T. W. Greene, Protective Groups in Organic
Synthesis, John Wiley & Sons, New York, 1991.
Methods of Separation
In any of the synthetic methods for preparing compounds of Formula
I or Ia, it may be advantageous to separate reaction products from
one another and/or from starting materials. The desired products of
each step or series of steps is separated and/or purified to the
desired degree of homogeneity by the techniques common in the art.
Typically such separations involve multiphase extraction,
crystallization from a solvent or solvent mixture, distillation,
sublimation, or chromatography. Chromatography can involve any
number of methods including, for example: reverse-phase and normal
phase; size exclusion; ion exchange; high, medium and low pressure
liquid chromatography methods and apparatus; small scale
analytical; simulated moving bed (SMB) and preparative thin or
thick layer chromatography, as well as techniques of small scale
thin layer and flash chromatography.
Another class of separation methods involves treatment of a
reaction mixture with a reagent selected to bind to or render
otherwise separable a desired product, unreacted starting material,
reaction by product, or the like. Such reagents include adsorbents
or absorbents such as activated carbon, molecular sieves, ion
exchange media, or the like. Alternatively, the reagents can be
acids in the case of a basic material, bases in the case of an
acidic material, binding reagents such as antibodies, binding
proteins, selective chelators such as crown ethers, liquid/liquid
ion extraction reagents (LIX), or the like.
Selection of appropriate methods of separation depends on the
nature of the materials involved. For example, boiling point and
molecular weight in distillation and sublimation, presence or
absence of polar functional groups in chromatography, stability of
materials in acidic and basic media in multiphase extraction, and
the like. One skilled in the art will apply techniques most likely
to achieve the desired separation.
Diastereomeric mixtures can be separated into their individual
diastereomers on the basis of their physical chemical differences
by methods well known to those skilled in the art, such as by
chromatography and/or fractional crystallization. Enantiomers can
be separated by converting the enantiomeric mixture into a
diastereomeric mixture by reaction with an appropriate optically
active compound (e.g., chiral auxiliary such as a chiral alcohol or
Mosher's acid chloride), separating the diastereomers and
converting (e.g., hydrolyzing) the individual diastereoisomers to
the corresponding pure enantiomers. Also, some of the compounds of
the present invention may be atropisomers (e.g., substituted
biaryls) and are considered as part of this invention. Enantiomers
can also be separated by use of a chiral HPLC column.
A single stereoisomer, e.g., an enantiomer, substantially free of
its stereoisomer may be obtained by resolution of the racemic
mixture using a method such as formation of diastereomers using
optically active resolving agents (Eliel, E. and Wilen, S.
"Stereochemistry of Organic Compounds," John Wiley & Sons,
Inc., New York, 1994; Lochmuller, C. H., J. Chromatogr., (1975)
113(3):283-302). Racemic mixtures of chiral compounds of the
invention can be separated and isolated by any suitable method,
including: (1) formation of ionic, diastereomeric salts with chiral
compounds and separation by fractional crystallization or other
methods, (2) formation of diastereomeric compounds with chiral
derivatizing reagents, separation of the diastereomers, and
conversion to the pure stereoisomers, and (3) separation of the
substantially pure or enriched stereoisomers directly under chiral
conditions. See: "Drug Stereochemistry, Analytical Methods and
Pharmacology," Irving W. Wainer, Ed., Marcel Dekker, Inc., New York
(1993).
Under method (1), diastereomeric salts can be formed by reaction of
enantiomerically pure chiral bases such as brucine, quinine,
ephedrine, strychnine, .alpha.-methyl-.beta.-phenylethylamine
(amphetamine), and the like with asymmetric compounds bearing
acidic functionality, such as carboxylic acid and sulfonic acid.
The diastereomeric salts may be induced to separate by fractional
crystallization or ionic chromatography. For separation of the
optical isomers of amino compounds, addition of chiral carboxylic
or sulfonic acids, such as camphorsulfonic acid, tartaric acid,
mandelic acid, or lactic acid can result in formation of the
diastereomeric salts.
Alternatively, by method (2), the substrate to be resolved is
reacted with one enantiomer of a chiral compound to form a
diastereomeric pair (E. and Wilen, S. "Stereochemistry of Organic
Compounds", John Wiley & Sons, Inc., 1994, p. 322).
Diastereomeric compounds can be formed by reacting asymmetric
compounds with enantiomerically pure chiral derivatizing reagents,
such as menthyl derivatives, followed by separation of the
diastereomers and hydrolysis to yield the pure or enriched
enantiomer. A method of determining optical purity involves making
chiral esters, such as a menthyl ester, e.g., (-)menthyl
chloroformate in the presence of base, or Mosher ester,
.alpha.-methoxy-.alpha.-(trifluoromethyl)phenyl acetate (Jacob III.
J. Org. Chem., (1982) 47:4165), of the racemic mixture, and
analyzing the .sup.1H NMR spectrum for the presence of the two
atropisomeric enantiomers or diastereomers. Stable diastereomers of
atropisomeric compounds can be separated and isolated by normal-
and reverse-phase chromatography following methods for separation
of atropisomeric naphthyl-isoquinolines (WO 96/15111). By method
(3), a racemic mixture of two enantiomers can be separated by
chromatography using a chiral stationary phase ("Chiral Liquid
Chromatography" (1989) W. J. Lough, Ed., Chapman and Hall, New
York; Okamoto, J. of Chromatogr., (1990) 513:375-378). Enriched or
purified enantiomers can be distinguished by methods used to
distinguish other chiral molecules with asymmetric carbon atoms,
such as optical rotation and circular dichroism.
Methods of Treatment with Compounds of Formula I or Ia
The compounds of the present invention can be used as prophylactics
or therapeutic agents for treating diseases or disorders mediated
by modulation or regulation of AKT protein kinases, tyrosine
kinases, additional serine/threonine kinases, and/or dual
specificity kinases. AKT protein kinase mediated conditions that
can be treated according to the methods of this invention include,
but are not limited to, inflammatory, hyperproliferative
cardiovascular, neurodegenerative, gynecological, and
dermatological diseases and disorders.
In one embodiment, said pharmaceutical composition is for the
treatment of hyperproliferative disorders, including cancers of the
following categories: (1) Cardiac: sarcoma (angiosarcoma,
fibrosarcoma, rhabdomyosarcoma, liposarcoma), myxoma, rhabdomyoma,
fibroma, lipoma and teratoma; (2) Lung: bronchogenic carcinoma
(squamous cell, undifferentiated small cell, undifferentiated large
cell, adenocarcinoma), alveolar (bronchiolar) carcinoma, bronchial
adenoma, sarcoma, lymphoma, chondromatous hamartoma, mesothelioma,
non-small cell lung, small cell lung; (3) Gastrointestinal:
esophagus (squamous cell carcinoma, adenocarcinoma, leiomyosarcoma,
lymphoma), stomach (carcinoma, lymphoma, leiomyosarcoma), pancreas
(ductal adenocarcinoma, insulinoma, glucagonoma, gastrinoma,
carcinoid tumors, vipoma), small bowel (adenocarcinoma, lymphoma,
carcinoid tumors, Karposi's sarcoma, leiomyoma, hemangioma, lipoma,
neurofibroma, fibroma), large bowel (adenocarcinoma, tubular
adenoma, villous adenoma, hamartoma, leiomyoma); (4) Genitourinary
tract: kidney (adenocarcinoma, Wilm's tumor [nephroblastoma],
lymphoma, leukemia), bladder and urethra (squamous cell carcinoma,
transitional cell carcinoma, adenocarcinoma), prostate
(adenocarcinoma, sarcoma), testis (seminoma, teratoma, embryonal
carcinoma, teratocarcinoma, choriocarcinoma, sarcoma, interstitial
cell carcinoma, fibroma, fibroadenoma, adenomatoid tumors, lipoma);
(5) Liver: hepatoma (hepatocellular carcinoma), cholangiocarcinoma,
hepatoblastoma, angiosarcoma, hepatocellular adenoma, hemangioma;
(6) Bone: osteogenic sarcoma (osteosarcoma), fibrosarcoma,
malignant fibrous histiocytoma, chondrosarcoma, Ewing's sarcoma,
malignant lymphoma (reticulum cell sarcoma), multiple myeloma,
malignant giant cell tumor chordoma, osteochronfroma
(osteocartilaginous exostoses), benign chondroma, chondroblastoma,
chondromyxofibroma, osteoid osteoma and giant cell tumors; (7)
Nervous system: skull (osteoma, hemangioma, granuloma, xanthoma,
osteitis deformans), meninges (meningioma, meningiosarcoma,
gliomatosis), brain (astrocytoma, medulloblastoma, glioma,
ependymoma, germinoma [pinealoma], glioblastoma multiform.
oligodendroglioma, schwannoma, retinoblastoma, congenital tumors),
spinal cord neurofibroma, meningioma, glioma, sarcoma); (8)
Gynecological: uterus (endometrial carcinoma), cervix (cervical
carcinoma, pre-tumor cervical dysplasia), ovaries (ovarian
carcinoma [serous cystadenocarcinoma, mucinous cystadenocarcinoma,
unclassified carcinoma], granulosa-thecal cell tumors,
Sertoli-Leydig cell tumors, dysgerminoma, malignant teratoma),
vulva (squamous cell carcinoma, intraepithelial carcinoma,
adenocarcinoma, fibrosarcoma, melanoma), vagina (clear cell
carcinoma, squamous cell carcinoma, botryoid sarcoma (embryonal
rhabdomyosarcoma), fallopian tubes (carcinoma); (9) Hematologic:
blood (myeloid leukemia [acute and chronic], acute lymphoblastic
leukemia, chronic lymphocytic leukemia, myeloproliferative
diseases, multiple myeloma, myelodysplastic syndrome), Hodgkin's
disease, non-Hodgkin's lymphoma [malignant lymphoma]; (10) Skin:
advanced melanoma, malignant melanoma, basal cell carcinoma,
squamous cell carcinoma, Karposi's sarcoma, moles dysplastic nevi,
lipoma, angioma, dermatofibroma, keloids, psoriasis; (11) Adrenal
glands: neuroblastoma; (12) Breast: metastatic breast; breast
adenocarcinoma; (13) Colon; (14) Oral cavity; (15) Hairy cell
leukemia; (16) Head and neck; (17) and others including refractory
metastatic disease; Kaposi's sarcoma; Bannayan-Zonana syndrome; and
Cowden disease or Lhermitte-Duclos disease, among other kinds of
hyperproliferative disorders.
Compounds and methods of this invention can be also used to treat
diseases and conditions such as rheumatoid arthritis,
osteoarthritis, Chron's disease, angiofibroma, ocular diseases
(e.g., retinal vascularisation, diabetic retinopathy, age-related
macular degeneration, macular degeneration, etc.), multiple
sclerosis, obesity, Alzheimer's disease, restenosis, autoimmune
diseases, allergy, asthma, endometriosis, atherosclerosis, vein
graft stenosis, peri-anastomatic prothetic graft stenosis, prostate
hyperplasia, chronic obstructive pulmonary disease, psoriasis,
inhibition of neurological damage due to tissue repair, scar tissue
formation (and can aid in wound healing), multiple sclerosis,
inflammatory bowel disease, infections, particularly bacterial,
viral, retroviral or parasitic infections (by increasing
apoptosis), pulmonary disease, neoplasm, Parkinson's disease,
transplant rejection (as an immunosupressant), septic shock,
etc.
Accordingly, another aspect of this invention provides a method of
treating diseases or medical conditions in a mammal mediated by AKT
protein kinases, comprising administering to said mammal one or
more compounds of Formula I or Ia or a pharmaceutically acceptable
salt or prodrug thereof in an amount effective to treat or prevent
said disorder.
The phrase "effective amount" means an amount of compound that,
when administered to a mammal in need of such treatment, is
sufficient to (i) treat or prevent a particular disease, condition,
or disorder mediated by the activity of one or more AKT protein
kinases, tyrosine kinases, additional serine/threonine kinases,
and/or dual specificity kinases, (ii) attenuate, ameliorate, or
eliminate one or more symptoms of the particular disease,
condition, or disorder, or (iii) prevent or delay the onset of one
or more symptoms of the particular disease, condition, or disorder
described herein. In the case of cancer, an effective amount of the
drug may reduce the number of cancer cells; reduce the tumor size;
inhibit (i.e., slow to some extent and preferably stop) cancer cell
infiltration into peripheral organs; inhibit (i.e., slow to some
extent and preferably stop) tumor metastasis; inhibit, to some
extent, tumor growth; and/or relieve to some extent one or more of
the symptoms associated with the cancer. To the extent the drug may
prevent growth and/or kill existing cancer cells, it may be
cytostatic and/or cytotoxic. For cancer therapy, efficacy can be
measured, for example, by assessing the time to disease progression
(TTP) and/or determining the response rate (RR).
The amount of a compound of Formula I or Ia that will correspond to
such an amount will vary depending upon factors such as the
particular compound, disease condition and its severity, the
identity (e.g., weight) of the mammal in need of treatment, but can
nevertheless be routinely determined by one skilled in the art.
"Treating" is intended to mean at least the mitigation of a disease
condition in a mammal, such as a human, that is affected, at least
in part, by the activity of one or more AKT protein kinases,
tyrosine kinases, additional serine/threonine kinases, and/or dual
specificity kinases. The terms "treat" and "treatment" refer to
both therapeutic treatment and prophylactic or preventative
measures, wherein the object is to prevent or slow down (lessen) an
undesired physiological change or disorder. For purposes of this
invention, beneficial or desired clinical results include, but are
not limited to, alleviation of symptoms, diminishment of extent of
disease, stabilized (i.e., not worsening) state of disease, delay
or slowing of disease progression, amelioration or palliation of
the disease state, and remission (whether partial or total),
whether detectable or undetectable. "Treatment" can also mean
prolonging survival as compared to expected survival if not
receiving treatment. Those in need of treatment include those
already with the condition or disorder as well as those found to be
predisposed to having the disease condition but have not yet been
diagnosed as having it; modulating and/or inhibiting the disease
condition. The terms "treating", "treat", or "treatment" embrace
both preventative, i.e., prophylactic, and palliative
treatment.
As used herein, the term "mammal" refers to a warm-blooded animal
that has or is at risk of developing a disease described herein and
includes, but is not limited to, guinea pigs, dogs, cats, rats,
mice, hamsters, and primates, including humans.
This invention also provides compounds of Formula I or Ia for use
in the treatment of AKT protein kinase-mediated conditions.
An additional aspect of the invention is the use of a compound of
Formula I or Ia in the preparation of a medicament for therapy,
such as for the treatment or prevention of AKT protein
kinase-mediated conditions.
Combination Therapy
The compounds of the present invention can be used in combination
with one or more additional drugs such as described below. The dose
of the second drug can be appropriately selected based on a
clinically employed dose. The proportion of the compound of the
present invention and the second drug can be appropriately
determined according to the administration subject, the
administration route, the target disease, the clinical condition,
the combination, and other factors. In cases where the
administration subject is a human, for instance, the second drug
may be used in an amount of 0.01 to 100 parts by weight per part by
weight of the compound of the present invention.
The second compound of the pharmaceutical combination formulation
or dosing regimen preferably has complementary activities to the
compound of this invention such that they do not adversely affect
each other. Such drugs are suitably present in combination in
amounts that are effective for the purpose intended. Accordingly,
another aspect of the present invention provides a composition
comprising a compound of this invention in combination with a
second drug, such as described herein.
A compound of this invention and the additional pharmaceutically
active drug(s) may be administered together in a unitary
pharmaceutical composition or separately and, when administered
separately this may occur simultaneously or sequentially in any
order. Such sequential administration may be close in time or
remote in time. The amounts of the compound of this invention and
the second drug(s) and the relative timings of administration will
be selected in order to achieve the desired combined therapeutic
effect.
The combination therapy may provide "synergy" and prove
"synergistic", i.e., the effect achieved when the active
ingredients used together is greater than the sum of the effects
that results from using the compounds separately. A synergistic
effect may be attained when the active ingredients are: (1)
co-formulated and administered or delivered simultaneously in a
combined, unit dosage formulation; (2) delivered by alternation or
in parallel as separate formulations; or (3) by some other regimen.
When delivered in alternation therapy, a synergistic effect may be
attained when the compounds are administered or delivered
sequentially, e.g., by different injections in separate syringes.
In general, during alternation therapy, an effective dosage of each
active ingredient is administered sequentially, i.e., serially,
whereas in combination therapy, effective dosages of two or more
active ingredients are administered together.
A "chemotherapeutic agent" is a chemical compound useful in the
treatment of cancer, regardless of mechanism of action.
Chemotherapeutic agents include compounds used in "targeted
therapy" and conventional chemotherapy.
Examples of chemotherapeutic agents include Erlotinib
(TARCEVA.RTM., Genentech/OSI Pharm.), Bortezomib (VELCADE.RTM.,
Millennium Pharm.), Fulvestrant (FASLODEX.RTM., AstraZeneca),
Sutent (SU11248, Pfizer), Letrozole (FEMARA.RTM., Novartis),
Imatinib mesylate (GLEEVEC.RTM., Novartis), PTK787/ZK 222584
(Novartis), Oxaliplatin (Eloxatin.RTM., Sanofi), 5-FU
(5-fluorouracil), Leucovorin, Rapamycin (Sirolimus, RAPAMUNE.RTM.,
Wyeth), Lapatinib (TYKERB.RTM., GSK572016, Glaxo Smith Kline),
Lonafarnib (SCH 66336), Sorafenib (BAY43-9006, Bayer Labs),
Irinotecan (CAMPTOSAR.RTM., Pfizer) and Gefitinib (IRESSA.RTM.,
AstraZeneca), AG1478, AG1571 (SU 5271; Sugen), alkylating agents
such as thiotepa and CYTOXAN.RTM. cyclosphosphamide; alkyl
sulfonates such as busulfan, improsulfan and piposulfan; aziridines
such as benzodopa, carboquone, meturedopa, and uredopa;
ethylenimines and methylamelamines including altretamine,
triethylenemelamine, triethylenephosphoramide,
triethylenethiophosphoramide and trimethylomelamine; acetogenins
(especially bullatacin and bullatacinone); a camptothecin
(including the synthetic analog topotecan); bryostatin;
callystatin; CC-1065 (including its adozelesin, carzelesin and
bizelesin synthetic analogs); cryptophycins (particularly
cryptophycin 1 and cryptophycin 8); dolastatin; duocarmycin
(including the synthetic analogs, KW-2189 and CB1-TM1);
eleutherobin; pancratistatin; a sarcodictyin; spongistatin;
nitrogen mustards such as chlorambucil, chlornaphazine,
chlorophosphamide, estramustine, ifosfamide, mechlorethamine,
mechlorethamine oxide hydrochloride, melphalan, novembichin,
phenesterine, prednimustine, trofosfamide, uracil mustard;
nitrosureas such as carmustine, chlorozotocin, fotemustine,
lomustine, nimustine, and ranimnustine; antibiotics such as the
enediyne antibiotics (e.g., calicheamicin, especially calicheamicin
gamma1I and calicheamicin omegaI1 (Angew Chem. Intl. Ed. Engl.
(1994) 33:183-186); dynemicin, including dynemicin A;
bisphosphonates, such as clodronate; an esperamicin; as well as
neocarzinostatin chromophore and related chromoprotein enediyne
antibiotic chromophores), aclacinomysins, actinomycin, authramycin,
azaserine, bleomycins, cactinomycin, carabicin, caminomycin,
carzinophilin, chromomycinis, dactinomycin, daunorubicin,
detorubicin, 6-diazo-5-oxo-L-norleucine, ADRIAMYCIN.RTM.
(doxorubicin), morpholino-doxorubicin, cyanomorpholino-doxorubicin,
2-pyrrolino-doxorubicin and deoxydoxorubicin), epirubicin,
esorubicin, idarubicin, marcellomycin, mitomycins such as mitomycin
C, mycophenolic acid, nogalamycin, olivomycins, peplomycin,
porfiromycin, puromycin, quelamycin, rodorubicin, streptonigrin,
streptozocin, tubercidin, ubenimex, zinostatin, zorubicin;
anti-metabolites such as methotrexate and 5-fluorouracil (5-FU);
folic acid analogs such as denopterin, methotrexate, pteropterin,
trimetrexate; purine analogs such as fludarabine, 6-mercaptopurine,
thiamiprine, thioguanine; pyrimidine analogs such as ancitabine,
azacitidine, 6-azauridine, carmofur, cytarabine, dideoxyuridine,
doxifluridine, enocitabine, floxuridine; androgens such as
calusterone, dromostanolone propionate, epitiostanol, mepitiostane,
testolactone; anti-adrenals such as aminoglutethimide, mitotane,
trilostane; folic acid replenisher such as frolinic acid;
aceglatone; aldophosphamide glycoside; aminolevulinic acid;
eniluracil; amsacrine; bestrabucil; bisantrene; edatraxate;
defofamine; demecolcine; diaziquone; elformithine; elliptinium
acetate; an epothilone; etoglucid; gallium nitrate; hydroxyurea;
lentinan; lonidainine; maytansinoids such as maytansine and
ansamitocins; mitoguazone; mitoxantrone; mopidanmol; nitraerine;
pentostatin; phenamet; pirarubicin; losoxantrone; podophyllinic
acid; 2-ethylhydrazide; procarbazine; PSK.RTM. polysaccharide
complex (JHS Natural Products, Eugene, Oreg.); razoxane; rhizoxin;
sizofuran; spirogermanium; tenuazonic acid; triaziquone;
2,2',2''-trichlorotriethylamine; trichothecenes (especially T-2
toxin, verracurin A, roridin A and anguidine); urethan; vindesine;
dacarbazine; mannomustine; mitobronitol; mitolactol; pipobroman;
gacytosine; arabinoside ("Ara-C"); cyclophosphamide; thiotepa;
taxoids, e.g., TAXOL.RTM. (paclitaxel; Bristol-Myers Squibb
Oncology, Princeton, N.J.), ABRAXANE.TM. (Cremophor-free),
albumin-engineered nanoparticle formulations of paclitaxel
(American Pharmaceutical Partners, Schaumberg, Ill.), and
TAXOTERE.RTM. (doxetaxel; Rhone-Poulenc Rorer, Antony, France);
chloranmbucil; GEMZAR.RTM. (gemcitabine); 6-thioguanine;
mercaptopurine; methotrexate; platinum analogs such as cisplatin
and carboplatin; vinblastine; etoposide (VP-16); ifosfamide;
mitoxantrone; vincristine; NAVELBINE.RTM. (vinorelbine);
novantrone; teniposide; edatrexate; daunomycin; aminopterin;
capecitabine (XELODA.RTM.); ibandronate; CPT-11; topoisomerase
inhibitor RFS 2000; difluoromethylornithine (DMFO); retinoids such
as retinoic acid; and pharmaceutically acceptable salts, acids and
derivatives of any of the above.
Also included in the definition of "chemotherapeutic agent" are:
(i) anti-hormonal agents that act to regulate or inhibit hormone
action on tumors such as anti-estrogens and selective estrogen
receptor modulators (SERMs), including, for example, tamoxifen
(including NOLVADEX.RTM.; tamoxifen citrate), raloxifene,
droloxifene, 4-hydroxytamoxifen, trioxifene, keoxifene, LY117018,
onapristone, and FARESTON.RTM. (toremifine citrate); (ii) aromatase
inhibitors that inhibit the enzyme aromatase, which regulates
estrogen production in the adrenal glands, such as, for example,
4(5)-imidazoles, aminoglutethimide, MEGASE.RTM. (megestrol
acetate), AROMASIN.RTM. (exemestane; Pfizer), formestanie,
fadrozole, RIVISOR.RTM. (vorozole), FEMARA.RTM. (letrozole;
Novartis), and ARIMIDEX.RTM. (anastrozole; AstraZeneca); (iii)
anti-androgens such as flutamide, nilutamide, bicalutamide,
leuprolide, and goserelin; as well as troxacitabine (a
1,3-dioxolane nucleoside cytosine analog); (iv) protein kinase
inhibitors; (v) lipid kinase inhibitors; (vi) antisense
oligonucleotides, particularly those which inhibit expression of
genes in signaling pathways implicated in aberrant cell
proliferation, such as, for example, PKC-alpha, Ralf and H-Ras;
(vii) ribozymes such as VEGF expression inhibitors (e.g.,
ANGIOZYME.RTM.) and HER2 expression inhibitors; (viii) vaccines
such as gene therapy vaccines, for example, ALLOVECTIN.RTM.,
LEUVECTIN.RTM., and VAXID.RTM.; PROLEUKIN.RTM. rIL-2; a
topoisomerase 1 inhibitor such as LURTOTECAN.RTM.; ABARELIX.RTM.
rmRH; (ix) anti-angiogenic agents such as bevacizumab
(AVASTIN.RTM., Genentech); and (x) pharmaceutically acceptable
salts, acids and derivatives of any of the above.
Also included in the definition of "chemotherapeutic agent" are
therapeutic antibodies such as alemtuzumab (Campath), bevacizumab
(AVASTIN.RTM., Genentech); cetuximab (ERBITUX.RTM., Imclone);
panitumumab (VECTIBIX.RTM., Amgen), rituximab (RITUXAN.RTM.,
Genentech/Biogen Idec), pertuzumab (OMNITARG.RTM., 2C4, Genentech),
trastuzumab (HERCEPTIN.RTM., Genentech), tositumomab (Bexxar,
Corixia), and the antibody drug conjugate, gemtuzumab ozogamicin
(MYLOTARG.RTM., Wyeth).
Humanized monoclonal antibodies with therapeutic potential as
chemotherapeutic agents in combination with the PI3K inhibitors of
the invention include: alemtuzumab, apolizumab, aselizumab,
atlizumab, bapineuzumab, bevacizumab, bivatuzumab mertansine,
cantuzumab mertansine, cedelizumab, certolizumab pegol,
cidfusituzumab, cidtuzumab, daclizumab, eculizumab, efalizumab,
epratuzumab, erlizumab, felvizumab, fontolizumab, gemtuzumab
ozogamicin, inotuzumab ozogamicin, ipilimumab, labetuzumab,
lintuzumab, matuzumab, mepolizumab, motavizumab, motovizumab,
natalizumab, nimotuzumab, nolovizumab, numavizumab, ocrelizumab,
omalizumab, palivizumab, pascolizumab, pecfusituzumab, pectuzumab,
pertuzumab, pexelizumab, ralivizumab, ranibizumab, reslivizumab,
reslizumab, resyvizumab, rovelizumab, ruplizumab, sibrotuzumab,
siplizumab, sontuzumab, tacatuzumab tetraxetan, tadocizumab,
talizumab, tefibazumab, tocilizumab, toralizumab, trastuzumab,
tucotuzumab celmoleukin, tucusituzumab, umavizumab, urtoxazumab,
and visilizumab.
Routes of Administration
The compounds of the invention may be administered by any route
appropriate to the condition to be treated. Suitable routes include
oral, parenteral (including subcutaneous, intramuscular,
intravenous, intraarterial, intradermal, intrathecal and epidural),
transdermal, rectal, nasal, topical (including buccal and
sublingual), vaginal, intraperitoneal, intrapulmonary and
intranasal. It will be appreciated that the preferred route may
vary with for example the condition of the recipient. Where the
compound is administered orally, it may be formulated as a pill,
capsule, tablet, etc. with a pharmaceutically acceptable carrier or
excipient. Where the compound is administered parenterally, it may
be formulated with a pharmaceutically acceptable parenteral vehicle
and in a unit dosage injectable form, as detailed below.
Pharmaceutical Formulations
In order to use a compound of this invention for the therapeutic
treatment (including prophylactic treatment) of mammals including
humans, it is normally formulated in accordance with standard
pharmaceutical practice as a pharmaceutical composition. According
to this aspect of the invention there is provided a pharmaceutical
composition that comprises a compound of this invention. In certain
embodiments, the pharmaceutical composition comprises a compound of
Formula I or Ia in association with a pharmaceutically acceptable
diluent or carrier.
The pharmaceutical compositions of the invention are formulated,
dosed and administered in a fashion, i.e., amounts, concentrations,
schedules, course, vehicles and route of administration, consistent
with good medical practice. Factors for consideration in this
context include the particular disorder being treated, the
particular mammal being treated, the clinical condition of the
individual patient, the cause of the disorder, the site of delivery
of the agent, the method of administration, the scheduling of
administration, and other factors known to medical practitioners.
The therapeutically effective amount of the compound to be
administered will be governed by such considerations, and is the
minimum amount necessary to prevent, ameliorate, or treat the
disorder. The compound of the present invention is typically
formulated into pharmaceutical dosage forms to provide an easily
controllable dosage of the drug and to enable patient compliance
with the prescribed regimen.
The composition for use herein is preferably sterile. In
particular, formulations to be used for in vivo administration must
be sterile. Such sterilization is readily accomplished, for
example, by filtration through sterile filtration membranes. The
compound ordinarily can be stored as a solid composition, a
lyophilized formulation or as an aqueous solution.
Pharmaceutical formulations of the compounds of the present
invention may be prepared for various routes and types of
administration. For example, a compound of this invention having
the desired degree of purity may optionally be mixed with
pharmaceutically acceptable diluents, carriers, excipients or
stabilizers (Remington's Pharmaceutical Sciences (1980) 16th
edition, Osol, A. Ed.), in the form of a lyophilized formulation, a
milled powder, or an aqueous solution. Formulation may be conducted
by mixing at ambient temperature at the appropriate pH, and at the
desired degree of purity, with physiologically acceptable carriers,
i.e., carriers that are non-toxic to recipients at the dosages and
concentrations employed. The pH of the formulation depends mainly
on the particular use and the concentration of compound, but may
range from about 3 to about 8. Formulation in an acetate buffer at
pH 5 is a suitable embodiment. The formulations may be prepared
using conventional dissolution and mixing procedures. For example,
the bulk drug substance (i.e., compound of the present invention or
stabilized form of the compound (e.g., complex with a cyclodextrin
derivative or other known complexation agent) is dissolved in a
suitable solvent in the presence of one or more excipients.
The particular carrier, diluent or excipient used will depend upon
the means and purpose for which the compound of the present
invention is being applied. Solvents are generally selected based
on solvents recognized by persons skilled in the art as safe (GRAS)
to be administered to a mammal. In general, safe solvents are
non-toxic aqueous solvents such as water and other non-toxic
solvents that are soluble or miscible in water. Suitable aqueous
solvents include water, ethanol, propylene glycol, polyethylene
glycols (e.g., PEG 400, PEG 300), etc. and mixtures thereof.
Acceptable diluents, carriers, excipients and stabilizers are
nontoxic to recipients at the dosages and concentrations employed,
and include buffers such as phosphate, citrate and other organic
acids; antioxidants including ascorbic acid and methionine;
preservatives (such as octadecyldimethylbenzyl ammonium chloride;
hexamethonium chloride; benzalkonium chloride, benzethonium
chloride; phenol, butyl or benzyl alcohol; alkyl parabens such as
methyl or propyl paraben; catechol; resorcinol; cyclohexanol;
3-pentanol; and m-cresol); low molecular weight (less than about 10
residues) polypeptides; proteins, such as serum albumin, gelatin,
or immunoglobulins; hydrophilic polymers such as
polyvinylpyrrolidone; amino acids such as glycine, glutamine,
asparagine, histidine, arginine, or lysine; monosaccharides,
disaccharides and other carbohydrates including glucose, mannose,
or dextrins; chelating agents such as EDTA; sugars such as sucrose,
mannitol, trehalose or sorbitol; salt-forming counter-ions such as
sodium; metal complexes (e.g., Zn-protein complexes); and/or
non-ionic surfactants such as TWEEN.TM., PLURONICS.TM. or
polyethylene glycol (PEG). The formulations may also include one or
more stabilizing agents, surfactants, wetting agents, lubricating
agents, emulsifiers, suspending agents, preservatives,
antioxidants, opaquing agents, glidants, processing aids,
colorants, sweeteners, perfuming agents, flavoring agents and other
known additives to provide an elegant presentation of the drug
(i.e., a compound of the present invention or pharmaceutical
composition thereof) or aid in the manufacturing of the
pharmaceutical product (i.e., medicament). The active
pharmaceutical ingredients may also be entrapped in microcapsules
prepared, for example, by coacervation techniques or by interfacial
polymerization, for example, hydroxymethylcellulose or
gelatin-microcapsules and poly-(methylmethacrylate) microcapsules,
respectively, in colloidal drug delivery systems (for example,
liposomes, albumin microspheres, microemulsions, nanoparticles and
nanocapsules) or in macroemulsions. Such techniques are disclosed
in Remington's Pharmaceutical Sciences 16th edition, Osol, A. Ed.
(1980). A "liposome" is a small vesicle composed of various types
of lipids, phospholipids and/or surfactant which is useful for
delivery of a drug (such as a compound of Formula I and,
optionally, an additional therapeutic agent) to a mammal. The
components of the liposome are commonly arranged in a bilayer
formation, similar to the lipid arrangement of biological
membranes.
Sustained-release preparations of compounds of this invention may
be prepared. Suitable examples of sustained-release preparations
include semipermeable matrices of solid hydrophobic polymers
containing a compound of Formula I or Ia, which matrices are in the
form of shaped articles, e.g., films, or microcapsules. Examples of
sustained-release matrices include polyesters, hydrogels (for
example, poly(2-hydroxyethyl-methacrylate), or poly(vinylalcohol)),
polylactides (U.S. Pat. No. 3,773,919), copolymers of L-glutamic
acid and gamma-ethyl-L-glutamate, non-degradable ethylene-vinyl
acetate, degradable lactic acid-glycolic acid copolymers such as
the LUPRON DEPOT.TM. (injectable microspheres composed of lactic
acid-glycolic acid copolymer and leuprolide acetate) and
poly-D-(-)-3-hydroxybutyric acid.
The pharmaceutical compositions of compounds of this invention may
be in the form of a sterile injectable preparation, such as a
sterile injectable aqueous or oleaginous suspension. This
suspension may be formulated according to the known art using those
suitable dispersing or wetting agents and suspending agents which
have been mentioned above. The sterile injectable preparation may
also be a sterile injectable solution or suspension in a non-toxic
parenterally acceptable diluent or solvent, such as a solution in
1,3-butanediol or prepared as a lyophilized powder. Among the
acceptable vehicles and solvents that may be employed are water,
Ringer's solution and isotonic sodium chloride solution. In
addition, sterile fixed oils may conventionally be employed as a
solvent or suspending medium. For this purpose any bland fixed oil
may be employed including synthetic mono- or diglycerides. In
addition, fatty acids such as oleic acid may likewise be used in
the preparation of injectables.
Formulations suitable for parenteral administration include aqueous
and non-aqueous sterile injection solutions which may contain
anti-oxidants, buffers, bacteriostats and solutes which render the
formulation isotonic with the blood of the intended recipient; and
aqueous and non-aqueous sterile suspensions which may include
suspending agents and thickening agents.
The compositions of the invention may also be in a form suitable
for oral use (for example as tablets, lozenges, hard or soft
capsules, aqueous or oily suspensions, emulsions, dispersible
powders or granules, syrups or elixirs), for topical use (for
example as creams, ointments, gels, or aqueous or oily solutions or
suspensions), for administration by inhalation (for example as a
finely divided powder or a liquid aerosol), for administration by
insufflation (for example as a finely divided powder)
Suitable pharmaceutically-acceptable excipients for a tablet
formulation include, for example, inert diluents such as lactose,
sodium carbonate, calcium phosphate or calcium carbonate,
granulating and disintegrating agents such as corn starch or
algenic acid; binding agents such as starch; lubricating agents
such as magnesium stearate, stearic acid or talc; preservative
agents such as ethyl or propyl p-hydroxybenzoate, and
anti-oxidants, such as ascorbic acid. Tablet formulations may be
uncoated or coated either to modify their disintegration and the
subsequent absorption of the active ingredient within the
gastrointestinal tract, or to improve their stability and/or
appearance, in either case, using conventional coating agents and
procedures well known in the art.
Compositions for oral use may be in the form of hard gelatin
capsules in which the active ingredient is mixed with an inert
solid diluent, for example, calcium carbonate, calcium phosphate or
kaolin, or as soft gelatin capsules in which the active ingredient
is mixed with water or an oil such as peanut oil, liquid paraffin,
or olive oil.
Aqueous suspensions generally contain the active ingredient in
finely powdered form together with one or more suspending agents,
such as sodium carboxymethylcellulose, methylcellulose,
hydroxypropylmethylcellulose, sodium alginate,
polyvinyl-pyrrolidone, gum tragacanth and gum acacia; dispersing or
wetting agents such as lecithin or condensation products of an
alkylene oxide with fatty acids (for example polyoxethylene
stearate), or condensation products of ethylene oxide with long
chain aliphatic alcohols, for example heptadecaethyleneoxycetanol,
or condensation products of ethylene oxide with partial esters
derived from fatty acids and a hexitol such as polyoxyethylene
sorbitol monooleate, or condensation products of ethylene oxide
with partial esters derived from fatty acids and hexitol
anhydrides, for example polyethylene sorbitan monooleate. The
aqueous suspensions may also contain one or more preservatives
(such as ethyl or propyl p-hydroxybenzoate, anti-oxidants (such as
ascorbic acid), coloring agents, flavoring agents, and/or
sweetening agents (such as sucrose, saccharine or aspartame).
Oily suspensions may be formulated by suspending the active
ingredient in a vegetable oil (such as arachis oil, olive oil,
sesame oil or coconut oil) or in a mineral oil (such as liquid
paraffin). The oily suspensions may also contain a thickening agent
such as beeswax, hard paraffin or cetyl alcohol. Sweetening agents
such as those set out above, and flavoring agents may be added to
provide a palatable oral preparation. These compositions may be
preserved by the addition of an anti-oxidant such as ascorbic
acid.
Dispersible powders and granules suitable for preparation of an
aqueous suspension by the addition of water generally contain the
active ingredient together with a dispersing or wetting agent,
suspending agent and one or more preservatives. Suitable dispersing
or wetting agents and suspending agents are exemplified by those
already mentioned above. Additional excipients such as sweetening,
flavoring and coloring agents, may also be present.
The pharmaceutical compositions of the invention may also be in the
form of oil-in-water emulsions. The oily phase may be a vegetable
oil, such as olive oil or arachis oil, or a mineral oil, such as
for example liquid paraffin or a mixture of any of these. Suitable
emulsifying agents may be, for example, naturally-occurring gums
such as gum acacia or gum tragacanth, naturally-occurring
phosphatides such as soya bean, lecithin, esters or partial esters
derived from fatty acids and hexitol anhydrides (for example
sorbitan monooleate) and condensation products of the said partial
esters with ethylene oxide such as polyoxyethylene sorbitan
monooleate. The emulsions may also contain sweetening, flavoring
and preservative agents.
Syrups and elixirs may be formulated with sweetening agents such as
glycerol, propylene glycol, sorbitol, aspartame or sucrose, and may
also contain a demulcent, preservative, flavoring and/or coloring
agent.
Suppository formulations may be prepared by mixing the active
ingredient with a suitable non-irritating excipient that is solid
at ordinary temperatures but liquid at the rectal temperature and
will therefore melt in the rectum to release the drug. Suitable
excipients include, for example, cocoa butter and polyethylene
glycols. Formulations suitable for vaginal administration may be
presented as pessaries, tampons, creams, gels, pastes, foams or
spray formulations containing in addition to the active ingredient
such carriers as are known in the art to be appropriate.
Topical formulations, such as creams, ointments, gels and aqueous
or oily solutions or suspensions, may generally be obtained by
formulating an active ingredient with a conventional, topically
acceptable, vehicle or diluent using conventional procedures well
known in the art.
Compositions for transdermal administration may be in the form of
those transdermal skin patches that are well known to those of
ordinary skill in the art.
Formulations suitable for intrapulmonary or nasal administration
have a particle size for example in the range of 0.1 to 500 microns
(including particle sizes in a range between 0.1 and 500 microns in
increments microns such as 0.5, 1, 30 microns, 35 microns, etc.),
which is administered by rapid inhalation through the nasal passage
or by inhalation through the mouth so as to reach the alveolar
sacs. Suitable formulations include aqueous or oily solutions of
the active ingredient. Formulations suitable for aerosol or dry
powder administration may be prepared according to conventional
methods and may be delivered with other therapeutic agents such as
compounds heretofore used in the treatment or prophylaxis disorders
as described below.
The pharmaceutical composition (or formulation) for application may
be packaged in a variety of ways depending upon the method used for
administering the drug. For example, an article for distribution
can include a container having deposited therein the pharmaceutical
formulation in an appropriate form. Suitable containers are well
known to those skilled in the art and include materials such as
bottles (plastic and glass), sachets, ampoules, plastic bags, metal
cylinders, and the like. The container may also include a
tamper-proof assemblage to prevent indiscreet access to the
contents of the package. In addition, the container has deposited
thereon a label that describes the contents of the container. The
label may also include appropriate warnings. The formulations may
also be packaged in unit-dose or multi-dose containers, for example
sealed ampoules and vials, and may be stored in a freeze-dried
(lyophilized) condition requiring only the addition of the sterile
liquid carrier, for example water, for injection immediately prior
to use. Extemporaneous injection solutions and suspensions are
prepared from sterile powders, granules and tablets of the kind
previously described. Preferred unit dosage formulations are those
containing a daily dose or unit daily sub-dose, as herein above
recited, or an appropriate fraction thereof, of the active
ingredient.
The invention further provides veterinary compositions comprising
at least one active ingredient as above defined together with a
veterinary carrier therefore. Veterinary carriers are materials
useful for the purpose of administering the composition and may be
solid, liquid or gaseous materials which are otherwise inert or
acceptable in the veterinary art and are compatible with the active
ingredient. These veterinary compositions may be administered
parenterally, orally or by any other desired route.
The amount of a compound of this invention that is combined with
one or more excipients to produce a single dosage form will
necessarily vary depending upon the subject treated, the severity
of the disorder or condition, the rate of administration, the
disposition of the compound and the discretion of the prescribing
physician. In one embodiment, a suitable amount of a compound of
this invention is administered to a mammal in need thereof.
Administration in one embodiment occurs in an amount between about
0.001 mg/kg of body weight to about 60 mg/kg of body weight per
day. In another embodiment, administration occurs in an amount
between 0.5 mg/kg of body weight to about 40 mg/kg of body weight
per day. In some instances, dosage levels below the lower limit of
the aforesaid range may be more than adequate, while in other cases
still larger doses may be employed without causing any harmful side
effect, provided that such larger doses are first divided into
several small doses for administration throughout the day. For
further information on routes of administration and dosage regimes,
see Chapter 25.3 in Volume 5 of Comprehensive Medicinal Chemistry
(Corwin Hansch; Chairman of Editorial Board), Pergamon Press 1990,
which is specifically incorporated herein by reference.
Articles of Manufacture
In another embodiment of the invention, an article of manufacture,
or "kit", containing materials useful for the treatment of the
disorders described above is provided. In one embodiment, the kit
comprises a container comprising a compound of this invention.
Suitable containers include, for example, bottles, vials, syringes,
blister pack, etc. The container may be formed from a variety of
materials such as glass or plastic. The container may hold a
compound of this invention or a formulation thereof which is
effective for treating the condition and may have a sterile access
port (for example, the container may be an intravenous solution bag
or a vial having a stopper pierceable by a hypodermic injection
needle).
The kit may further comprise a label or package insert on or
associated with the container. The term "package insert" is used to
refer to instructions customarily included in commercial packages
of therapeutic products, that contain information about the
indications, usage, dosage, administration, contraindications
and/or warnings concerning the use of such therapeutic products. In
one embodiment, the label or package inserts indicates that the
composition comprising a compound of this invention can be used to
treat a disorder mediated, for example, by AKT kinase. The label or
package insert may also indicate that the composition can be used
to treat other disorders.
In certain embodiments, the kits are suitable for the delivery of
solid oral forms of a compound of this invention, such as tablets
or capsules. Such a kit preferably includes a number of unit
dosages. Such kits can include a card having the dosages oriented
in the order of their intended use. An example of such a kit is a
"blister pack". Blister packs are well known in the packaging
industry and are widely used for packaging pharmaceutical unit
dosage forms. If desired, a memory aid can be provided, for example
in the form of numbers, letters, or other markings or with a
calendar insert, designating the days in the treatment schedule in
which the dosages can be administered.
According to another embodiment, a kit may comprise (a) a first
container with a compound of this invention contained therein; and
(b) a second container with a second pharmaceutical formulation
contained therein, wherein the second pharmaceutical formulation
comprises a second compound useful for treating a disorder mediated
by AKT kinase. Alternatively, or additionally, the kit may further
comprise a third container comprising a pharmaceutically-acceptable
buffer, such as bacteriostatic water for injection (BWFI),
phosphate-buffered saline, Ringer's solution and dextrose solution.
It may further include other materials desirable from a commercial
and user standpoint, including other buffers, diluents, filters,
needles, and syringes.
The kit may further comprise directions for the administration of
the compound of this invention and, if present, the second
pharmaceutical formulation. For example, if the kit comprises a
first composition comprising a compound of this invention and a
second pharmaceutical formulation, the kit may further comprise
directions for the simultaneous, sequential or separate
administration of the first and second pharmaceutical compositions
to a patient in need thereof.
In certain other embodiments wherein the kit comprises a
composition of this invention and a second therapeutic agent, the
kit may comprise a container for containing the separate
compositions such as a divided bottle or a divided foil packet,
however, the separate compositions may also be contained within a
single, undivided container. In certain embodiments, the kit
comprises directions for the administration of the separate
components. The kit form is particularly advantageous when the
separate components are preferably administered in different dosage
forms (e.g., oral and parenteral), are administered at different
dosage intervals, or when titration of the individual components of
the combination is desired by the prescribing physician.
Accordingly, a further aspect of this invention provides a kit for
treating a disorder or disease mediated by Akt kinase, wherein said
kit comprises a) a first pharmaceutical composition comprising a
compound of this invention or a pharmaceutically acceptable salt
thereof; and b) instructions for use.
In certain embodiments, the kit further comprises (c) a second
pharmaceutical composition, wherein the second pharmaceutical
composition comprises a second compound suitable for treating a
disorder or disease mediated by Akt kinase. In certain embodiments
comprising a second pharmaceutical composition, the kit further
comprises instructions for the simultaneous, sequential or separate
administration of said first and second pharmaceutical compositions
to a patient in need thereof. In certain embodiments, said first
and second pharmaceutical compositions are contained in separate
containers. In other embodiments, said first and second
pharmaceutical compositions are contained in the same
container.
Although the compounds of Formula I or Ia are primarily of value as
therapeutic agents for use in mammals, they are also useful
whenever it is required to control AKT protein kinases, tyrosine
kinases, additional serine/threonine kinases, and/or dual
specificity kinases. Thus, they are useful as pharmacological
standards for use in the development of new biological tests and in
the search for new pharmacological agents.
The activity of the compounds of this invention may be assayed for
AKT protein kinases, tyrosine kinases, additional serine/threonine
kinases, and/or dual specificity kinases in vitro, in vivo, or in a
cell line. In vitro assays include assays that determine inhibition
of the kinase activity. Alternate in vitro assays quantitate the
ability of the inhibitor to bind to kinases and may be measured
either by radiolabelling the inhibitor prior to binding, isolating
the inhibitor/kinase complex and determining the amount of
radiolabel bound, or by running a competition experiment where new
inhibitors are incubated with known radioligands. These and other
useful in vitro and cell culture assays are well known to those of
skill in the art.
Although the invention has been described and illustrated with a
certain degree of particularity, it is understood that the present
disclosure has been made only by way of example, and that numerous
changes in the combination and arrangement of parts can be resorted
to by those skilled in the art without departing from the spirit
and scope of the invention, as hereinafter claimed.
BIOLOGICAL EXAMPLES
AKT-1 Kinase Assay
The activity of the compounds described in the present invention
may be determined by the following kinase assay, which measures the
phosphorylation of a fluorescently-labeled peptide by full-length
human recombinant active AKT-1 by fluorescent polarization using a
commercially available IMAP kit.
The assay materials are obtained from an IMAP AKT Assay Bulk Kit,
product #R8059, from Molecular Devices, Sunnyvale, Calif. The kit
materials include an IMAP Reaction Buffer (5.times.). The diluted
1.times.IMAP Reaction Buffer contained 10 mM Tris-HCl, pH 7.2, 10
mM MgCl.sub.2, 0.1% BSA, 0.05% NaN.sub.3. DTT is routinely added to
a final concentration of 1 mM immediately prior to use. Also
included is IMAP Binding Buffer (5.times.), and IMAP Binding
Reagent. The Binding Solution is prepared as a 1:400 dilution of
IMAP Binding Reagent into 1.times.IMAP Binding Buffer.
The fluorescein-labeled AKT Substrate (Crosstide) has the sequence
(F1)-GRPRTSSFAEG. A stock solution of 20 .mu.M is made up in
1.times.IMAP Reaction Buffer.
The plates used include a Costar 3657 (382-well made of
polypropylene and having a white, v-bottom) that is used for
compound dilution and for preparing the compound-ATP mixture. The
assay plate is a Packard ProxyPlate.TM.-384 F.
The AKT-1 used is made from full-length, human recombinant AKT-1
that is activated with PDK1 and MAP kinase 2.
To perform the assay, stock solutions of compounds at 10 mM in DMSO
are prepared. The stock solutions and the control compound are
serially diluted 1:2 nine times into DMSO (10 .mu.L of compound+10
.mu.L of DMSO) to give 50.times. dilution series over the desired
dosing range. Next, 2.1-.mu.L aliquots of the compounds in DMSO are
transferred to a Costar 3657 plate containing 50 .mu.L of 10.4
.mu.M ATP in 1.times.IMAP Reaction Buffer containing 1 mM DTT.
After thorough mixing, 2.5-.mu.L aliquots are transferred to a
ProxyPlate.TM.-384 F plate.
The assay is initiated by the addition of 2.5-.mu.L aliquots of a
solution containing 200 nM of fluorescently-labeled peptide
substrate and 4 nM AKT-1. The plate is centrifuged for 1 minute at
1000 g and incubated for 60 minute at ambient temperature. The
reaction is then quenched by the addition of 15 .mu.L of Binding
Solution, centrifuged again and incubated for an additional 30
minutes at ambient temperature prior to reading on a Victor 1420
Multilabel HTS Counter configured to measure fluorescence
polarization.
The compounds of Examples 1-74 were tested in the above assay and
found to have an IC.sub.50 of less than 10 .mu.M.
Preparative Examples
In order to illustrate the invention, the following examples are
included. However, it is to be understood that these examples do
not limit the invention and are only meant to suggest a method of
practicing the invention. Persons skilled in the art will recognize
that the chemical reactions described may be readily adapted to
prepare a number of other compounds of the invention, and
alternative methods for preparing the compounds of this invention
are deemed to be within the scope of this invention. For example,
the synthesis of non-exemplified compounds according to the
invention may be successfully performed by modifications apparent
to those skilled in the art, e.g., by appropriately protecting
interfering groups, by utilizing other suitable reagents known in
the art other than those described, and/or by making routine
modifications of reaction conditions. Alternatively, other
reactions disclosed herein or known in the art will be recognized
as having applicability for preparing other compounds of the
invention.
In the examples described below, unless otherwise indicated all
temperatures are set forth in degrees Celsius. Reagents were
purchased from commercial suppliers such as Aldrich Chemical
Company, Lancaster, TCI or Maybridge, and were used without further
purification unless otherwise indicated. Tetrahydrofuran (THF),
dichloromethane (DCM), toluene, and dioxane were purchased from
Aldrich in Sure seal bottles and used as received.
The reactions set forth below were done generally under a positive
pressure of nitrogen or argon or with a drying tube (unless
otherwise stated) in anhydrous solvents, and the reaction flasks
were typically fitted with rubber septa for the introduction of
substrates and reagents via syringe. Glassware was oven dried
and/or heat dried.
.sup.1H NMR spectra were recorded on a Varian instrument operating
at 400 MHz. .sup.1H-NMR spectra were obtained as CDCl.sub.3,
CD.sub.3OD, D.sub.2O or d.sub.6-DMSO solutions (reported in ppm),
using tetramethylsilane (0.00 ppm) or residual solvent (CDCl.sub.3:
7.25 ppm; CD.sub.3OD: 3.31 ppm; D.sub.2O: 4.79 ppm; d.sub.6-DMSO:
2.50 ppm) as the reference standard. When peak multiplicities are
reported, the following abbreviations are used: s (singlet), d
(doublet), t (triplet), m (multiplet), br (broadened), dd (doublet
of doublets), dt (doublet of triplets). Coupling constants, when
given, are reported in Hertz (Hz).
Example 1
##STR00060##
Preparation of
(R)-2-amino-3-(4-chloro-3-fluorophenyl)-1-(4-((S)-5-methyl-5,7-dihydrothi-
eno[3,4-d]pyrimidin-4-yl)piperazin-1-yl)propan-1-one
dihydrochloride
Step 1:
To a mixture of methyl thioglycolate (45 mL, 503.2 mmol) and
piperidine (0.8 mL) at 0.degree. C. was slowly added methyl
crotonate (67 mL, 631.7 mmol). Additional piperidine (0.8 mL) was
added in two portions after ten and twenty minutes. After stirring
for 15 hours, the mixture was purified by vacuum distillation. The
fraction was collected at 110-112.degree. C. to give methyl
3-(2-methoxy-2-oxoethylthio)butanoate (92 g, 89%). .sup.1H NMR
(CDCl.sub.3, 400 MHz) .delta. 3.75 (s, 3H), 3.70 (s, 3H), 3.38-3.44
(m, 3H), 2.71-2.46 (m, 2H), 1.36 (d, J=6.8 Hz, 3H).
Step 2:
A three neck flask was charged with NaOEt (21%, 200 mL, 537 mmol)
in ethanol. The solvent was removed under vacuum and to the residue
was added toluene (500 mL). The mixture was heated to reflux and
methyl 3-(2-methoxy-2-oxoethylthio)butanoate (92 g, 446 mmol) was
added dropwise. After addition was complete, the mixture was
refluxed for 4 hours. After cooling, the mixture was poured into a
mixture of acetic acid (200 g) and crushed ice (200 g). The mixture
was stirred overnight and then diluted with ethyl acetate (500 mL).
The organic phase was separated and washed with saturated
Na.sub.2CO.sub.3 and brine and then dried. The solvent was removed
to afford crude methyl
2-methyl-4-oxo-tetrahydrothiophene-3-carboxylate (77.7 g, 99%).
.sup.1H NMR (CDCl.sub.3, 400 MHz) .delta. 11.23-11.15 (d, 1H),
7.27-7.16 (m, 2H), 4.33-4.12 (m, 2H), 3.95-3.68 (m, 2H). 3.60-3.15
(m, 1H), 2.60-2.20 (m, 1H).
Step 3:
To a solution of formamidine HCl salt (37.3 g, 463 mmol) in ethanol
(300 mL) was slowly added NaOEt (21%, 169 mL, 453 mmol). The
mixture was stirred at room temperature for 1 hour and then
filtered. To the filtrate was added methyl
2-methyl-4-oxo-tetrahydrothiophene-3-carboxylate (79 g, 453 mmol).
The mixture was stirred at room temperature for 1 hour and then
refluxed overnight. After cooling, the solvent was removed and the
residue was purified by silica gel chromatography, eluted with
Hexane/ethyl acetate (2:1-0:1)-DCM/MeOH (20:1) to afford
5-methyl-5,7-dihydrothieno[3,4-d]pyrimidin-4-ol (36 g, 47%).
.sup.1H NMR (CDCl.sub.3, 400 MHz) .delta. 12.83 (s, 1H), 4.68 (m,
1H), 4.32-4.08 (m, 2H), 1.66 (m, 3H). MS (APCI+) [M+H].sup.+
169.
Step 4:
5-Methyl-5,7-dihydrothieno[3,4-d]pyrimidin-4-ol (10 g, 59.54 mmol)
in POCl.sub.3 (100 mL) was heated to reflux for 15 minutes. After
cooling, excess POCl.sub.3 was removed under vacuum. The residue
was dissolved in CH.sub.2Cl.sub.2 (100 mL) and saturated
NaHCO.sub.3 (400 mL) was added at 0.degree. C. The reaction mixture
was stirred for 1 hour. The aqueous phase was extracted with DCM
(3.times.250 mL). The organic phase was combined, dried and
concentrated. The residue was purified by silica gel
chromatography, eluting with Hexane/ethyl acetate (4:1) to give
4-chloro-5-methyl-5,7-dihydrothieno[3,4-d]pyrimidine (6 g, 54%).
.sup.1H NMR (CDCl.sub.3, 400 MHz) .delta. 8.80 (s, 1H), 4.68 (m,
1H), 4.44 (m, 1H), 4.13 (d, J=16.8 Hz, 2H), 1.68 (d, J=7.2 Hz,
3H).
Step 5:
A solution of 4-chloro-5-methyl-5,7-dihydrothieno[3,4-d]pyrimidine
(4 g, 21 mmol) and 1-Boc-piperazine (8.5 g, 46 mmol) in NMP (20 mL)
was heated to 120.degree. C. overnight. After cooling, the mixture
was diluted with ethyl acetate (500 mL) and washed with water
(6.times.300 mL). The organic phase was dried and concentrated. The
residue was purified by silica gel chromatography, eluting with
Hexane/ethyl acetate (2:1) to provide tert-butyl
4-(5-methyl-5,7-dihydrothieno[3,4-d]pyrimidin-4-yl)piperazine-1-carboxyla-
te (5 g, 69%). The crude material was purified by chiral separation
on chiral HPLC (ODH, 250.times.20 mm, 100% acetonitrile, 15 mL/min)
to give (R)-tert-butyl
4-(5-methyl-5,7-dihydrothieno[3,4-d]pyrimidin-4-yl)piperazine-1-carboxyla-
te (retention time: 4.016 min) and (S)-tert-butyl
4-(5-methyl-5,7-dihydrothieno[3,4-d]pyrimidin-4-yl)piperazine-1-carboxyla-
te (retention time: 4.551 min). .sup.1H NMR (CDCl.sub.3, 400 MHz)
.delta. 8.53 (s, 1H), 4.83 (m, 1H), 4.18 (m, 2H), 3.73-3.56 (m,
4H), 3.51-3.43 (m, 4H), 1.50 (m, 9H). MS (APCI+) [M+H].sup.+
337.
Step 6:
To a solution of (5)-tert-butyl
4-(5-methyl-5,7-dihydrothieno[3,4-d]pyrimidin-4-yl)piperazine-1-carboxyla-
te (1.89 g, 5.62 mmol) in DCM (40 mL) was added HCl (4M in dioxane,
8 mL). The mixture was stirred at room temperature overnight. The
solvent was removed to afford
(S)-5-methyl-4-(piperazin-1-yl)-5,7-dihydrothieno[3,4-d]pyrimidine
as the HCl salt. MS (APCI+) [M+H].sup.+ 237.
Step 7:
1,1,3,3-tetramethylguanidine (2.11 ml, 16.8 mmol) was added to a
0.degree. C. solution of methyl
2-(tert-butoxycarbonyl)-2-(dimethoxyphosphoryl)-acetate (5.00 g,
16.8 mmol) in DCM (70 mL). The reaction mixture stirred at
0.degree. C. for 30 minutes, then a solution of
4-chloro-3-fluorobenzaldehyde (2.67 g, 16.8 mmol) in DCM (10 mL)
was added by syringe. The reaction mixture was stirred for 10
minutes. The reaction mixture was then warmed to room temperature
and stirred for 1 hour. H.sub.2O was then added, and the mixture
was extracted with DCM. The combined extracts were dried
(Na.sub.2SO.sub.4), filtered, and concentrated. The resulting
solids were recrystallized from IPA to give (Z)-methyl
2-(tert-butoxycarbonyl)-3-(4-chloro-3-fluorophenyl)acrylate (3.76
g, 67.8% yield) as a white powder (2 crops). LCMS (APCI.sup.-) m/z
328 [M-H].sup.-.
Step 8:
In each of 8 Argonaut Endeavor.TM. reaction tubes was dissolved
(Z)-methyl
2-(tert-butoxycarbonyl)-3-(4-chloro-3-fluorophenyl)acrylate (200
mg) and Rh--(R,R)-[Et-DuPhos(COD)]OTf (about 4 mg) in 1:1
MeOH:EtOAc (3 mL; degassed 1 hour with nitrogen prior to use). The
reaction mixtures were put on the Endeavor.TM. under 40 psi H.sub.2
and stirred for 12 hours at room temperature. All of the reaction
mixtures were then combined and concentrated to give (R)-methyl
2-(tert-butoxycarbonylamino)-3-(4-chloro-3-fluorophenyl)propanoate
(1.52 g, 94.4% yield) as a pale yellow solid, which was used
without further purification in next step.
Step 9:
LiOH--H.sub.2O (0.6246 g, 14.88 mmol) was added to a solution of
(R)-methyl
2-(tert-butoxycarbonylamino)-3-(4-chloro-3-fluorophenyl)propanoate
(1.646 g, 4.961 mmol) in 1:1 THF:H.sub.2O (26 mL). The reaction
mixture was stirred at room temperature for 2 hours, after which it
was diluted with H.sub.2O and washed with EtOAc. The aqueous layer
was then acidified with solid KHSO.sub.4 and extracted with DCM.
The combined extracts were dried (Na.sub.2SO.sub.4), filtered,
concentrated, and then re-concentrated from DCM/hexanes to give
(R)-2-(tert-butoxycarbonylamino)-3-(4-chloro-3-fluorophenyl)propanoic
acid (1.31 g, 83.10% yield) as a white powder. LCMS (APCI.sup.-)
m/z 316 [M-H].sup.-.
Step 10:
To a solution of
(S)-5-methyl-4-(piperazin-1-yl)-5,7-dihydrothieno[3,4-d]pyrimidine
dihydrochloride (50 mg, 0.16 mmol) and
(R)-2-(tert-butoxycarbonyl)-3-(4-chloro-3-fluorophenyl)propanoic
acid (51 mg, 0.16 mmol) in DCM (10 mL) and triethylamine (2 mL) was
added HBTU (61 mg, 0.16 mmol). The mixture was stirred at room
temperature for 1 hour. The solvent was removed and the residue was
dissolved in ethyl acetate (100 mL) and washed with water
(5.times.50 mL). The organic phase was dried and concentrated, and
the residue was purified by silica gel chromatography, eluting with
DCM/MeOH (50:1) to give tert-butyl
(R)-3-(4-chloro-3-fluorophenyl)-1-(4-((S)-5-methyl-5,7-dihydrothieno[3,4--
d]pyrimidin-4-yl)piperazin-1-yl)-1-oxopropan-2-ylcarbamate (86 mg,
85%). .sup.1H NMR (CDCl.sub.3, 400 MHz) .delta. 8.55 (s, 1H), 7.30
(m, 2H), 7.01 (d, J=10 Hz, 1H), 6.94 (d, J=8 Hz), 5.38 (d, J=8.8
Hz, 1H), 4.84-4.76 (m, 2H), 4.25-4.15 (m, 2H), 3.81 (m, 1H), 3.73
(m, 1H), 3.51 (m, 2H), 3.42 (m, 2H), 3.02-2.90 (m, 4H), 1.48 (d,
J=6.8 Hz), 1.42 (d, J=4 Hz, 9H). MS (APCI+) [M+H].sup.+ 536.
Step 8:
Treatment of tert-butyl
(R)-3-(4-chloro-3-fluorophenyl)-1-(4-((S)-5-methyl-5,7-dihydrothieno[3,4--
d]pyrimidin-4-yl)piperazin-1-yl)-1-oxopropan-2-ylcarbamate with HCl
(4M in dioxane, 2 mL) in DCM (5 mL) for 6 hours gave
(R)-2-amino-3-(4-chloro-3-fluorophenyl)-1-(4-((S)-5-methyl-5,7-dihydrothi-
eno[3,4-d]pyrimidin-4-yl)piperazin-1-yl)propan-1-one
dihydrochloride after removal of the solvent. MS (APCI+)
[M+H].sup.+ 436.
Example 2
##STR00061##
Preparation of
2-(4-chlorophenyl)-1-(4-((S)-5-methyl-5,7-dihydrothieno[3,4-d]pyrimidin-4-
-yl)piperazin-1-yl)-3-(pyrrolidin-1-yl)propan-1-one
dihydrochloride
Step 1:
Methyl 2-(4-chlorophenyl)acrylate (500 mg, 2.54 mmol) was diluted
in THF (6.0 mL) and treated with pyrrolidine (233 uL, 2.80 mmol) at
0.degree. C. After 1 hour, the crude LCMS indicated that the
reaction was complete (LCMS (APCI+) [M+H].sup.+ 268.1; Rf: 2.13
min). The solution was treated with water (2.0 mL) and
LiOH--H.sub.2O (320 mg, 7.63 mmol), respectively, and the reaction
was allowed to stir overnight to completion by LCMS analysis. The
mixture was partitioned between water and ethyl acetate. The
aqueous was washed again with ethyl acetate, and the organics were
discarded. The aqueous was treated with excess 3N HCl solution
(3.82 mL) and washed with ethyl acetate. The separated aqueous was
concentrated in vacuo to afford
2-(4-chlorophenyl)-3-(pyrrolidin-1-yl)propanoic acid-HCl-3LiCl salt
as a white solid (1.15 g). MS (APCI+) [M+H].sup.+ 254.1; Rf: 1.30
min.
Step 2:
To a solution of
(S)-5-methyl-4-(piperazin-1-yl)-5,7-dihydrothieno[3,4-d]pyrimidine
dihydrochloride (1 g, 3.23 mmol) and
2-(4-chlorophenyl)-3-(pyrrolidin-1-yl)propanoic acid (2 g, 7.88
mmol) in DCM (40 mL) were added HBTU (1.5 g, 3.96 mmol) and
triethylamine (2.75 mL, 19.8 mmol). The mixture was stirred at room
temperature for 1 hour. The solvent was removed, and the residue
was dissolved in ethyl acetate (200 mL) and washed with brine
(5.times.100 mL) and water (3.times.100 mL). The organic phase was
dried and concentrated. The residue was purified by silica gel
chromatography, eluting with ethyl acetate-DCM/MeOH (20:1) to give
2-(4-chlorophenyl)-1-(4-((S)-5-methyl-5,7-dihydrothieno[3,4-d]pyrimidin-4-
-yl)piperazin-1-yl)-3-(pyrrolidin-1-yl)propan-1-one (0.713 g,
46.7%). .sup.1H NMR (CDCl.sub.3, 400 MHz) .delta. 8.47 (s, 1H),
7.38-7.28 (m, 4H), 4.75 (m, 1H), 4.54 (m, 1H), 4.17 (m, 2H),
3.88-3.25 (m, 14H), 2.12 (m, 4H), 1.43 (m, 3H). MS (APCI+)
[M+H].sup.+ 473.
Step 3:
Treatment of
2-(4-chlorophenyl)-1-(4-((S)-5-methyl-5,7-dihydrothieno[3,4-d]pyrimidin-4-
-yl)piperazin-1-yl)-3-(pyrrolidin-1-yl)propan-1-one with HCl (4M in
dioxane, 5 mL) in DCM (20 mL) gave
2-(4-chlorophenyl)-1-(4-((S)-5-methyl-5,7-dihydrothieno[3,4-d]pyrimidin-4-
-yl)piperazin-1-yl)-3-(pyrrolidin-1-yl)propan-1-one as the HCl
salt. MS (APCI+) [M+H].sup.+ 473.
Example 3
##STR00062##
Preparation of
2-(4-chlorophenyl)-3-(isopropylamino)-1-(4-((S)-5-methyl-5,7-dihydrothien-
o[3,4-d]pyrimidin-4-yl)piperazin-1-yl)propan-1-one
dihydrochloride
Step 1:
To a solution of
(S)-5-methyl-4-(piperazin-1-yl)-5,7-dihydrothieno[3,4-d]pyrimidine
dihydrochloride (0.5 g, 1.62 mmol) and
3-(tert-butoxycarbonyl(isopropyl)amino)-2-(4-chlorophenyl)propanoic
acid (0.7 g, 2.05 mmol) in DCM (40 mL) were added HBTU (1.0 g, 2.64
mmol) and triethylamine (1.38 mL, 9.88 mL). The mixture was stirred
at room temperature for 1 hour. The solvent was removed, and the
residue was dissolved in ethyl acetate (200 mL) and washed with
brine (5.times.100 mL) and water (3.times.100 mL). The organic
phase was dried and concentrated. The residue was purified by
silica gel chromatography, eluting with Hexane/ethyl acetate
(2:1-0:1) to give tert-butyl
2-(4-chlorophenyl)-3-(4-((S)-5-methyl-5,7-dihydrothieno[3,4-d]pyrimidin-4-
-yl)piperazin-1-yl)-3-oxopropyl(isopropyl)carbamate (0.63 g, 70%).
.sup.1H NMR (CDCl.sub.3, 400 MHz) .delta. 8.50 (d, J=5.6 Hz, 1H),
7.31-7.23 (m, 4H), 4.76 (m, 1H), 4.18 (m, 3H), 4.92-3.25 (m, 10H),
1.48 (m, 12H), 0.99 (m, 3H), 0.69 (m, 3H). MS (APCI+) [M+H].sup.+
561.
Step 2:
Treatment of tert-butyl
2-(4-chlorophenyl)-3-(4-((S)-5-methyl-5,7-dihydrothieno[3,4-d]pyrimidin-4-
-yl)piperazin-1-yl)-3-oxopropyl(isopropyl)carbamate with HCl (4M in
dioxane, 6 mL) in DCM (20 mL) for 6 hours gave the
2-(4-chlorophenyl)-3-(isopropylamino)-1-(4-((S)-5-methyl-5,7-dihydrothien-
o[3,4-d]pyrimidin-4-yl)piperazin-1-yl)propan-1-one dihydrochloride.
MS (APCI+) [M+H].sup.+ 461.
Example 4
##STR00063##
Preparation of
4-amino-2-(4-chlorophenyl)-4-methyl-1-(4-((S)-5-methyl-5,7-dihydrothieno[-
3,4-d]pyrimidin-4-yl)piperazin-1-yl)pentan-1-one
dihydrochloride
Step 1:
1,8-Diazabicyclo[5.4.0]undec-7-ene (33.68 ml, 225.2 mmol) was added
to a solution of methyl 2-(4-chlorophenyl)acrylate (36.9 g, 187.7
mmol) and 2-nitropropane (20.23 ml, 225.2 mmol) in CH.sub.3CN (500
mL) at 0.degree. C. under nitrogen. The reaction mixture was warmed
to room temperature and stirred overnight. The solution was
concentrated in vacuo and subjected to column chromatography (20%
EtOAc/hexane) to give methyl
2-(4-chlorophenyl)-4-methyl-4-nitropentanoate (52.9 g, 98.66%
yield) as a colorless oil. Concentrated HCl (10 ml) was added
dropwise over 2 minutes to a suspension of the methyl
2-(4-chlorophenyl)-4-methyl-4-nitropentanoate (10 g, 35.0 mmol) and
zinc (6.41 ml, 700 mmol) in EtOH (250 mL) at 40.degree. C. The
suspension was stirred at 40.degree. C. overnight. LCMS shows
desired product and reduced (but non-cyclized) product. The
temperature was increased to 50.degree. C. for 8 hours. There was
no change by LCMS, so the reaction mixture was diluted with EtOAc
(200 ml) and filtered. The filtrate was concentrated in vacuo,
taken up into EtOAc/EtOH (500 ml, 9:1), washed with bicarbonate
solution, dried over Na.sub.2SO.sub.4 and concentrated in vacuo.
The crude product contained 2-3 compounds, however, the
3-(4-chlorophenyl)-5,5-dimethylpyrrolidin-2-one (6.7 g, 85.6%
yield) was the major one. Used as-is in the next step. LCMS
(APCI.sup.+) [M-Boc+H].sup.+ 224.1; Rt: 2.90 min.
Step 2:
Lithium bis(trimethylsilyl)amide (36 ml, 36 mmol) was added to a
stirred solution of 3-(4-chlorophenyl)-5,5-dimethylpyrrolidin-2-one
(6.7 g, 30 mmol) in THF (200 ml) at -78.degree. C. under nitrogen.
The solution was stirred at -78.degree. C. for 30 minutes. Then a
solution of di-tert-butyl dicarbonate (7.6 ml, 33 mmol) in THF (30
ml) was added in a single portion. The solution was warmed to room
temperature and allowed to stir overnight. The reaction was poured
into 0.5M HCl solution and extracted with ethyl acetate twice. The
combined organic portions were washed with water, separated, dried
over MgSO.sub.4, filtered, and concentrated in vacuo to afford the
near-pure product (excess Boc2O) as a colorless oil. Col (20%
EtOAc/hexane) to give pure tert-butyl
4-(4-chlorophenyl)-2,2-dimethyl-5-oxopyrrolidine-1-carboxylate.
LCMS (APCI+) [M-Boc+H]+ 224.1; Rt: 3.68 min.
Step 3:
Lithium hydroxide hydrate (6.44 ml, 232 mmol) was added to a
stirred solution of tert-butyl
4-(4-chlorophenyl)-2,2-dimethyl-5-oxopyrrolidine-1-carboxylate (7.5
g, 23.2 mmol) in THF/MeOH/H.sub.2O (30 mL/30 mL/30 mL) at room
temperature. The reaction mixture was stirred overnight and then
concentrated in vacuo. The reaction mixture was taken up into water
(200 mL), washed with EtOAc (100 mL), acidified with concentrated
HCl and extracted into EtOAc (2.times.200 mL). The product was
dried over Na.sub.2SO.sub.4 and concentrated in vacuo. The residual
HCl was removed by evaporating from toluene to give
4-(tert-butoxycarbonylamino)-2-(4-chlorophenyl)-4-methylpentanoic
acid (5.0 g, 63.2% yield) as a white solid. LCMS (APCI.sup.+)
[M-Boc+H].sup.+ 242.0; Rt: 2.8 min.
Step 4:
To a solution of
(S)-5-methyl-4-(piperazin-1-yl)-5,7-dihydrothieno[3,4-d]pyrimidine
dihydrochloride (0.22 g, 0.71 mmol) and
4-(tert-butoxycarbonyl)-2-(4-chlorophenyl)-4-methylpentanoic acid
(0.24 g, 0.71 mmol) in DCM (20 mL) were added HBTU (0.40 g, 1.10
mmol) and triethylamine (1 mL, 7.1 mmol). The mixture was stirred
at room temperature for 1 hour. The solvent was removed, and the
residue was dissolved in ethyl acetate (200 mL) and washed with
brine (5.times.100 mL) and water (3.times.100 mL). The organic
phase was dried and concentrated. The residue was purified by
silica gel chromatography, eluting with Hexane/ethyl acetate
(2:1-0:1) to give tert-butyl
4-(4-chlorophenyl)-2-methyl-5-(4-((S)-5-methyl-5,7-dihydrothieno[3,4-d]py-
rimidin-4-yl)piperazin-1-yl)-5-oxopentan-2-ylcarbamate (0.23 g,
58%). .sup.1H NMR (CDCl.sub.3, 400 MHz) .delta. 8.51 (d, J=5.6 Hz,
1H), 7.29-7.20 (m, 4H), 4.75 (m, 1H), 4.67 (s, 1H), 4.24-4.09 (m,
2H), 4.02 (m, 1H), 3.80-3.30 (m, 7H), 2.68 (m, 1H), 1.97 (m, 1H),
1.48 (d, J=6.4 Hz, 3H), 1.42 (s, 9H), 1.29-1.21 (m, 6H). MS (APCI+)
[M+H].sup.+ 561.
Step 5:
Treatment of tert-butyl
4-(4-chlorophenyl)-2-methyl-5-(4-((S)-5-methyl-5,7-dihydrothieno[3,4-d]py-
rimidin-4-yl)piperazin-1-yl)-5-oxopentan-2-ylcarbamate with HCl (4M
in dioxane, 4 mL) in DCM (10 mL) for 6 hours gave
4-amino-2-(4-chlorophenyl)-4-methyl-1-(4-((S)-5-methyl-5,7-dihydrothieno[-
3,4-d]pyrimidin-4-yl)piperazin-1-yl)pentan-1-one dihydrochloride.
MS (APCI+) [M+H].sup.+ 461.
Example 5
##STR00064##
Preparation of
(R)-2-amino-3-(4-chlorophenyl)-1-((S)-3-methyl-4-((S)-5-methyl-5,7-dihydr-
othieno[3,4-d]pyrimidin-4-yl)piperazin-1-yl)propan-1-one
dihydrochloride
Step 1:
To a solution of
4-chloro-5-methyl-5,7-dihydrothieno[3,4-d]pyrimidine (5 g, 27 mmol)
and 2-(S)-methyl-4-Boc-piperazine (5.4 g, 27 mmol) in NMP (20 mL)
was added DIEA (5 mL, 29 mmol). The mixture was heated to
120.degree. C. for 24 hours. After cooling, the mixture was diluted
with ethyl acetate (500 mL) and washed with water (6.times.200 mL).
The organic phase was dried and concentrated to afford
(3S)-tert-butyl
3-methyl-4-(5-methyl-5,7-dihydrothieno[3,4-d]pyrimidin-4-yl)piperazine-1--
carboxylate (6 g, 64%). .sup.1H NMR (CDCl.sub.3, 400 MHz) .delta.
8.55 (s, 1H), 4.81 (m, 1H), 4.45 (m, 1H). 4.18 (m, 3H), 3.90 (m,
1H), 3.75 (m, 1H), 3.44-3.29 (m, 2H), 2.96 (m, 1H), 1.52 (m, 12H),
1.14 (d, J=6.4 Hz, 3H). MS (APCI+) [M+H].sup.+ 351. The residue was
purified by chiral HPLC separation (OD 250.times.20 mm;
acetonitrile, 2 mL/min). The first peak (RT=3.93 min) was
(S)-tert-butyl
3-methyl-4-((R)-5-methyl-5,7-dihydrothieno[3,4-d]pyrimidin-4-yl)piperazin-
e-1-carboxylate and the secondary (RT=4.26 min) was (S)-tert-butyl
3-methyl-4-((S)-5-methyl-5,7-dihydrothieno[3,4-d]pyrimidin-4-yl)piperazin-
e-1-carboxylate.
Step 2:
To a solution of (S)-tert-butyl
3-methyl-4-((S)-5-methyl-5,7-dihydrothieno[3,4-d]pyrimidin-4-yl)piperazin-
e-1-carboxylate (2 g, 5.71 mmol) in DCM (20 mL) was added HCl (4M
in dioxane, 6 mL). The mixture was stirred at room temperature
overnight. The solvent was removed to afford
(S)-5-methyl-4-((S)-2-methylpiperazin-1-yl)-5,7-dihydrothieno[3,4-d]pyrim-
idine (2.0 g, 99%). MS (APCI+) [M+H].sup.+ 251.
Step 3:
To a solution of
(S)-5-methyl-4-((S)-2-methylpiperazin-1-yl)-5,7-dihydrothieno[3,4-d]pyrim-
idine (0.5 g, 1.5 mmol) and
(R)-2-(tert-butoxycarbonylamino)-3-(4-chlorophenyl)propanoic acid
(0.46 g, 1.5 mmol) in DCM (30 mL) and triethylamine (5 mL) was
added HBTU (0.59 g, 1.5 mmol). The mixture was stirred at room
temperature for 2 hours. The solvent was removed and the residue
was dissolved in ethyl acetate (200 mL) and washed with water
(6.times.100 mL). The organic phase was dried and concentrated. The
residue was purified by silica gel chromatography, eluting with
DCM/MeOH (20:1) to afford tert-butyl
(R)-3-(4-chlorophenyl)-1-(S)-3-methyl-4-((S)-5-methyl-5,7-dihydrothieno[3-
,4-d]pyrimidin-4-yl)piperazin-1-yl)-1-oxopropan-2-ylcarbamate (0.48
g, 70%). .sup.1H NMR (CDCl.sub.3, 400 MHz) .delta. 8.52 (s, 1H),
7.28-7.09 (m, 4H), 5.43-5.18 (m, 1H), 4.86-4.71 (m, 2H), 4.41-4.33
(m, 1H), 4.26-4.10 (m, 2H), 3.95-3.74 (m, 1H), 3.25-2.65 (m, 2H),
1.46 (m, 12H), 1.25 (m, 3H). MS (APCI+) [M+H].sup.+ 532.
Step 4:
tert-Butyl
(R)-3-(4-chlorophenyl)-1-((S)-3-methyl-4-((S)-5-methyl-5,7-dihydrothieno[-
3,4-d]pyrimidin-4-yl)piperazin-1-yl)-1-oxopropan-2-ylcarbamate was
treated with HCl (4M in dioxane, 4 mL) in DCM to afford
(R)-2-amino-3-(4-chlorophenyl)-1-((S)-3-methyl-4-((S)-5-methyl-5,7-dihydr-
othieno[3,4-d]pyrimidin-4-yl)piperazin-1-yl)propan-1-one
dihydrochloride. MS (APCI+) [M+H].sup.+ 432.
Example 6
##STR00065##
Preparation of
(R)-2-amino-3-(4-chloro-3-fluorophenyl)-1-((S)-3-methyl-4-((S)-5-methyl-5-
,7-dihydrothieno[3,4-d]pyrimidin-4-yl)piperazin-1-yl)propan-1-one
dihydrochloride
Step 1:
To a solution of
(S)-5-methyl-4-((S)-2-methylpiperazin-1-yl)-5,7-dihydrothieno[3,4-d]pyrim-
idine (0.5 g, 1.5 mmol) and
(R)-2-(tert-butoxycarbonylamino)-3-(4-chloro-3-fluorophenyl)propanoic
acid (0.49 g, 1.5 mmol) in DCM (30 mL) and triethylamine (5 mL) was
added HBTU (0.59 g, 1.5 mmol). The mixture was stirred at room
temperature for 2 hours. The solvent was removed and the residue
was dissolved in ethyl acetate (200 mL) and washed with water
(6.times.100 mL). The organic phase was dried and concentrated. The
residue was purified by silica gel chromatography, eluting with
DCM/MeOH (20:1) to afford tert-butyl
(R)-3-(4-chloro-3-fluorophenyl)-1-(S)-3-methyl-4-((S)-5-methyl-5,7-dihydr-
othieno[3,4-d]pyrimidin-4-yl)piperazin-1-yl)-1-oxopropan-2-ylcarbamate
(0.5 g, 70%). .sup.1H NMR (CDCl.sub.3, 400 MHz) .delta. 8.53 (s,
1H), 7.32-7.27 (m, 2H), 6.98 (d, J=9.6 Hz, 1H), 6.90 (d, J=8.4 Hz,
1H), 5.44-5.20 (m, 1H), 4.75-4.70 (m, 2H), 4.40-3.80 (m, 6H),
3.40-2.82 (m, 2H), 1.50-1.00 (m, 15H). MS (APCI+) [M+H].sup.+
550.
Step 2:
tert-Butyl
(R)-3-(4-chloro-3-fluorophenyl)-1-(S)-3-methyl-4-((S)-5-methyl-5,7-dihydr-
othieno[3,4-d]pyrimidin-4-yl)piperazin-1-yl)-1-oxopropan-2-ylcarbamate
was treated with HCl (4M in dioxane, 4 mL) in DCM to afford
(R)-2-amino-3-(4-chloro-3-fluorophenyl)-1-(S)-3-methyl-4-((S)-5-methyl-5,-
7-dihydrothieno[3,4-d]pyrimidin-4-yl)piperazin-1-yl)propan-1-one
dihydrochloride. MS (APCI+) [M+H].sup.+ 450.
Example 7
##STR00066##
Preparation of
(R)-2-amino-3-(4-fluorophenyl)-1-((S)-3-methyl-4-((S)-5-methyl-5,7-dihydr-
othieno[3,4-d]pyrimidin-4-yl)piperazin-1-yl)propan-1-one
dihydrochloride
Step 1:
To a solution of
(S)-5-methyl-4-((S)-2-methylpiperazin-1-yl)-5,7-dihydrothieno[3,4-d]pyrim-
idine dihydrochloride (30 mg, 0.093 mmol) and
(R)-2-(tert-butoxycarbonylamino)-3-(4-fluorophenyl)propanoic acid
(26 mg, 0.093 mmol) in DCM (6 mL) and triethylamine (1 mL) was
added HBTU (35 mg, 0.093 mmol). The mixture was stirred at room
temperature for 2 hours. The solvent was removed and the residue
was purified by silica gel chromatography, eluting with
Hexane/ethyl acetate (2:1) to afford tert-butyl
(R)-3-(4-fluorophenyl)-1-(S)-3-methyl-4-((S)-5-methyl-5,7-dihydrothieno[3-
,4-d]pyrimidin-4-yl)piperazin-1-yl)-1-oxopropan-2-ylcarbamate (26
mg, 52%). .sup.1H NMR (CDCl.sub.3, 400 MHz) .delta. 8.51 (s, 1H),
7.30-6.90 (m, 5H), 5.37-5.13 (m, 1H), 4.90-4.60 (m, 2H), 4.40-4.02
(m, 4H), 4.00-3.70 (m, 2H), 3.40-2.60 (m, 2H), 1.45-1.00 (m, 15H).
MS (APCI+) [M+H].sup.+ 515.
Step 2:
tert-Butyl
(R)-3-(4-fluorophenyl)-1-((S)-3-methyl-4-((S)-5-methyl-5,7-dihydrothieno[-
3,4-d]pyrimidin-4-yl)piperazin-1-yl)-1-oxopropan-2-ylcarbamate was
treated with HCl (4M in dioxane, 2 mL) in DCM (5 mL) afford
(R)-2-amino-3-(4-fluorophenyl)-1-((S)-3-methyl-4-((S)-5-methyl-5,7-dihydr-
othieno[3,4-d]pyrimidin-4-yl)piperazin-1-yl)propan-1-one
dihydrochloride (20 mg, 52%). MS (APCI+) [M+H].sup.+ 415.
Example 8
##STR00067##
Preparation of
(R)-2-amino-3-(3,4-difluorophenyl)-1-(S)-3-methyl-4-((S)-5-methyl-5,7-dih-
ydrothieno[3,4-d]pyrimidin-4-yl)piperazin-1-yl)propan-1-one
dihydrochloride
Step 1:
To a solution of
(S)-5-methyl-4-((S)-2-methylpiperazin-1-yl)-5,7-dihydrothieno[3,4-d]pyrim-
idine dihydrochloride (30 mg, 0.093 mmol) and
(R)-2-(tert-butoxycarbonylamino)-3-(3,4-difluorophenyl)propanoic
acid (28 mg, 0.093 mmol) in DCM (6 mL) and triethylamine (1 mL) was
added HBTU (35 mg, 0.093 mmol). The mixture was stirred at room
temperature for 2 hours. The solvent was removed and the residue
was purified by silica gel chromatography, eluting with
Hexane/ethyl acetate (2:1) to afford tert-butyl
(R)-3-(3,4-difluorophenyl)-1-(S)-3-methyl-4-((S)-5-methyl-5,7-dihydrothie-
no[3,4-d]pyrimidin-4-yl)piperazin-1-yl)-1-oxopropan-2-ylcarbamate
(24 mg, 45%). .sup.1H NMR (CDCl.sub.3, 400 MHz) .delta. 8.53 (s,
1H), 7.08-6.82 (m, 3H), 5.40-5.00 (m, 1H), 4.90-4.64 (m, 2H),
4.42-3.65 (m, 6H), 3.44-2.65 (m, 4H), 1.60-0.80 (m, 15H). MS
(APCI+) [M+H].sup.+ 534.
Step 2:
tert-Butyl
(R)-3-(3,4-difluorophenyl)-1-(S)-3-methyl-4-((S)-5-methyl-5,7-dihydrothie-
no[3,4-d]pyrimidin-4-yl)piperazin-1-yl)-1-oxopropan-2-ylcarbamate
was treated with HCl (4M in dioxane, 2 mL) in DCM (5 mL) to afford
(R)-2-amino-3-(3,4-difluorophenyl)-1-(S)-3-methyl-4-((S)-5-methyl-5,7-dih-
ydrothieno[3,4-d]pyrimidin-4-yl)piperazin-1-yl)propan-1-one
dihydrochloride (18 mg, 45%). MS (APCI+) [M+H].sup.+ 434.
Example 9
##STR00068##
Preparation of
(2R)-2-amino-3-(4-chlorophenyl)-1-(4-(5-ethyl-5,7-dihydrothieno[3,4-d]pyr-
imidin-4-yl)piperazin-1-yl)propan-1-one dihydrochloride
Step 1:
To a solution of methyl thioglycolate (10 mL, 106 mmol) and methyl
2-pentenoate (12 g, 106 mmol) in THF (200 mL) at 0.degree. C. was
added NaH (60%, 4.2 g, 106 mmol) portionwise. The mixture was
stirred at room temperature for 6 hours and then quenched with
saturated NH.sub.4Cl (50 mL). The aqueous phase was extracted with
ether (3.times.100 mL), and the combined organic phases were dried
and concentrated to afford a mixture of methyl
2-ethyl-4-oxo-tetrahydrothiophene-3-carboxylate and methyl
5-ethyl-3-oxo-tetrahydrothiophene-2-carboxylate (20 g, 50%).
.sup.1H NMR (CDCl.sub.3, 400 MHz) .delta. 4.20 (m, 1H), 3.75 (m,
2H), 3.45-3.20 (m, 1H), 3.20-2.80 (m, 1H), 2.62-2.22 (m, 1H),
1.90-1.60 (m, 2H), 1.05-0.80 (m, 6H).
Step 2:
To a solution of formamidine HCl salt (10 g, 124 mmol) in ethanol
(100 mL) was added NaOEt (21%, 46 mL) slowly. After addition was
complete, the reaction mixture was stirred at room temperature for
30 minutes and then filtered. The filtrate was added to the mixture
of methyl 2-ethyl-4-oxo-tetrahydrothiophene-3-carboxylate and
methyl 5-ethyl-3-oxo-tetrahydrothiophene-2-carboxylate (20 g, 106
mmol) in ethanol (100 mL). The mixture was refluxed overnight. The
solvent was removed and the residue was purified by silica gel
chromatography, eluting with ethyl acetate-DCM/MeOH (20:1) to give
a mixture of 5-ethyl-5,7-dihydrothieno[3,4-d]pyrimidin-4-ol and
6-ethyl-6,7-dihydrothieno[3,2-d]pyrimidin-4-ol (4.5 g, 46%). MS
(APCI+) [M+H].sup.+ 183.
Step 3:
To a solution of a mixture of
5-ethyl-5,7-dihydrothieno[3,4-d]pyrimidin-4-ol and
6-ethyl-6,7-dihydrothieno[3,2-d]pyrimidin-4-ol (2.32 g, 12.8 mmol)
in 1,2-dichloroethane (50 mL) and diisopropylethylamine (4 mL) was
added POCl.sub.3 (4 mL), and the mixture was refluxed overnight.
The solvent was removed and the residue was purified by silica gel
chromatography, eluting with Hexane/ethyl acetate (9:1-4:1) to give
4-chloro-5-ethyl-5,7-dihydrothieno[3,4-d]pyrimidine (0.49 g, 28%).
.sup.1H NMR (CDCl.sub.3, 400 MHz) .delta. 8.73 (s, 1H), 4.44 (m,
1H), 4.32-4.00 (m, 2H), 2.08 (m, 1H), 1.75 (m, 1H), 0.93 (m,
3H).
Step 4:
To a solution of
4-chloro-5-ethyl-5,7-dihydrothieno[3,4-d]pyrimidine (0.3 g, 1.5
mmol) in n-BuOH (30 mL) was added 1-Boc-piperazine (0.8 g, 4.3
mmol), and the mixture was refluxed for 30 hours. The solvent was
removed and the residue was purified by silica gel chromatography,
eluting with Hexane/ethyl acetate (4:1-1:1) to give tert-butyl
4-(5-ethyl-5,7-dihydrothieno[3,4-d]pyrimidin-4-yl)piperazine-1-carboxylat-
e (0.23 g, 44%). .sup.1H NMR (CDCl.sub.3, 400 MHz) .delta. 8.54 (s,
1H), 4.61 (d, J=8.8 Hz, 1H), 4.10 (m, 2H), 3.80-3.60 (m, 8H), 2.02
(m, 1H), 1.60 (m, 1H), 1.49 (s, 9H), 0.95 (m, 3H). MS (APCI+)
[M+H].sup.+ 351.
Step 5:
Treatment of tert-butyl
4-(5-ethyl-5,7-dihydrothieno[3,4-d]pyrimidin-4-yl)piperazine-1-carboxylat-
e with HCl (4M in dioxane, 3 mL) in DCM (10 mL) gave
5-ethyl-4-(piperazin-1-yl)-5,7-dihydrothieno[3,4-d]pyrimidine
dihydrochloride (0.21 g, 99%). MS (APCI+) [M+H].sup.+ 251.
Step 6:
To a solution of
5-ethyl-4-(piperazin-1-yl)-5,7-dihydrothieno[3,4-d]pyrimidine
dihydrochloride (50 mg, 0.15 mmol) and
(R)-2-(tert-butoxycarbonylamino)-3-(4-chlorophenyl)propanoic acid
(46 mg, 0.15 mmol) in DCM (10 mL) and triethylamine (1 mL) was
added HBTU (59 mg, 0.15 mmol). The mixture was stirred at room
temperature for 3 hours. The solvent was removed and the residue
was purified by silica gel chromatography, eluting with DCM/ethyl
acetate (1:1) to give tert-butyl
(R)-3-(4-chlorophenyl)-1-(4-(5-ethyl-5,7-dihydrothieno[3,4-d]pyrimidin-4--
yl)piperazin-1-yl)-1-oxopropan-2-ylcarbamate (50 mg, 60%). .sup.1H
NMR (CDCl.sub.3, 400 MHz) .delta. 8.53 (s, 1H), 7.26-7.14 (m, 4H),
5.36 (m, 1H), 4.82 (m, 1H), 4.62 (m, 1H), 4.14 (m, 1H), 3.80-2.90
(m, 8H), 1.94 (m, 1H). 1.68 (m, 1H), 1.54 (m, 1H), 1.42 (s, 9H),
0.94 (m, 3H). MS (APCI+) [M+H].sup.+ 533.
Step 7:
Treatment of tert-butyl
(R)-3-(4-chlorophenyl)-1-(4-(5-ethyl-5,7-dihydrothieno[3,4-d]pyrimidin-4--
yl)piperazin-1-yl)-1-oxopropan-2-ylcarbamate with HCl (4M in
dioxane, 2 mL) in DCM (3 mL) gave the
(2R)-2-amino-3-(4-chlorophenyl)-1-(4-(5-ethyl-5,7-dihydrothieno[3,4-d]pyr-
imidin-4-yl)piperazin-1-yl)propan-1-one dihydrochloride. MS (APCI+)
[M+H].sup.+ 433.
Example 10
##STR00069##
Preparation of
(2R)-2-amino-3-(4-chloro-3-fluorophenyl)-1-(4-(5-ethyl-5,7-dihydrothieno[-
3,4-d]pyrimidin-4-yl)piperazin-1-yl)propan-1-one
dihydrochloride
Step 1:
To a solution of
5-ethyl-4-(piperazin-1-yl)-5,7-dihydrothieno[3,4-d]pyrimidine
dihydrochloride (50 mg, 0.15 mmol) and
(R)-2-(tert-butoxycarbonylamino)-3-(4-chloro-3-fluorophenyl)propanoic
acid (49 mg, 0.15 mmol) in DCM (10 mL) and triethylamine (1 mL) was
added HBTU (59 mg, 0.15 mmol). The mixture was stirred at room
temperature for 3 hours. The solvent was removed and the residue
was purified by silica gel chromatography, eluting with DCM/ethyl
acetate (1:1) to give tert-butyl
(R)-3-(4-chloro-3-fluorophenyl)-1-(4-(5-ethyl-5,7-dihydrothieno[3,4-d]pyr-
imidin-4-yl)piperazin-1-yl)-1-oxopropan-2-ylcarbamate (80 mg, 90%).
.sup.1H NMR (CDCl.sub.3, 400 MHz) .delta. 8.54 (s, 1H), 7.40-6.90
(m, 3H), 5.36 (m, 1H), 4.82 (m, 1H), 4.65 (m, 1H), 4.12 (m, 1H),
3.90-3.18 (m, 8H), 3.04-2.89 (m, 2H). 1.95 (m, 1H), 1.57 (m, 1H),
1.42 (s, 9H), 0.94 (m, 3H). MS (APCI+) [M+H].sup.+ 551.
Step 2:
Treatment of tert-butyl
(R)-3-(4-chloro-3-fluorophenyl)-1-(4-(5-ethyl-5,7-dihydrothieno[3,4-d]pyr-
imidin-4-yl)piperazin-1-yl)-1-oxopropan-2-ylcarbamate with HCl (4M
in dioxane, 2 mL) in DCM (3 mL) gave
(2R)-2-amino-3-(4-chloro-3-fluorophenyl)-1-(4-(5-ethyl-5,7-dihydrothieno[-
3,4-d]pyrimidin-4-yl)piperazin-1-yl)propan-1-one dihydrochloride.
MS (APCI+) [M+H].sup.+ 451.
Example 11
##STR00070##
Preparation of
(R)-2-amino-3-(4-chlorophenyl)-1-(4-(5,7-dihydrothieno[3,4-d]pyrimidin-4--
yl)piperazin-1-yl)propan-1-one dihydrochloride
Step 1:
To a solution of formamidine HCl salt (3.70 g, 46.0 mmol) in
ethanol (200 mL) was added NaOEt in ethanol (21% wt, 17.2 mL, 46.0
mmol). The mixture was stirred at room temperature for 1 hour. The
ethyl 4-oxotetrahydrothiophene-3-carboxylate (8.0 g, 46.0 mmol) was
added. The mixture was stirred at room temperature for 4 hours and
then refluxed overnight. After cooling, the solvent was removed and
the residue was washed with a small amount of water and
CH.sub.2Cl.sub.2 to afford 5,7-dihydrothieno[3,4-d]pyrimidin-4-ol
as light brown solid (2.5 g, 35%). .sup.1H NMR (d.sub.6-DMSO, 400
MHz) .delta. 12.59 (s, 1H), 8.13 (s, 1H), 4.12 (s, 2H), 3.96 (s,
2H). MS (APCI+) [M+H].sup.+ 155.
Step 2:
To a solution of the 5,7-dihydrothieno[3,4-d]pyrimidin-4-ol (0.50
g, 3.2 mmol) in DCE (50 mL) was added DIEA (0.42 g, 3.2 mmol) and
POCl.sub.3 (1.5 g, 9.8 mmol). The mix was refluxed overnight. After
cooling, the solvent was removed and the residue was subject to
silica gel chromatography, eluting with hexane/ethyl acetate (4:1)
to give 4-chloro-5,7-dihydrothieno[3,4-d]pyrimidine (0.45 g, 80%).
.sup.1H NMR (CDCl.sub.3, 400 MHz) .delta. 8.84 (s, 1H), 4.37 (s,
2H), 4.27 (s, 2H).
Step 3:
The mixture of 4-chloro-5,7-dihydrothieno[3,4-d]pyrimidine (2.0 g,
11.6 mmol) and 1-Boc-piperazine (5.0 g, 26.8 mmol) in isopropanol
(50 mL) was refluxed for 12 hours. The solvent was removed and the
residue was subject to silica gel chromatography, eluting with
hexane/ethyl acetate (1:1) to give tert-butyl
4-(5,7-dihydrothieno[3,4-d]pyrimidin-4-yl)piperazine-1-carboxylate
(3.3 g, 89%). .sup.1H NMR (CDCl.sub.3, 400 MHz) .delta. 8.49 (s,
1H), 4.68 (m, 1H), 4.25 (s, 2H), 4.16 (s, 2H), 1.49 (s, 9H). MS
(APCI+) [M+H].sup.+ 323.
Step 4:
To a solution of tert-butyl
4-(5,7-dihydrothieno[3,4-d]pyrimidin-4-yl)piperazine-1-carboxylate
(0.41 g, 1.3 mmol) in CH.sub.2Cl.sub.2 (20 mL) was added HCl (4M in
dioxane, 5 mL). The mix was stirred at room temperature for 4
hours. The solvent was removed to afford
4-(piperazin-1-yl)-5,7-dihydrothieno[3,4-d]pyrimidine as HCl salt
(0.28 g, 99%). MS (APCI+) [M+H].sup.+ 223.
Step 5:
To a solution of
4-(piperazin-1-yl)-5,7-dihydrothieno[3,4-d]pyrimidine (0.28 g, 1.3
mmol) in CH.sub.2Cl.sub.2 (20 mL) was added triethylamine (5 mL)
and (R)-2-(tert-butoxycarbonylamino)-3-(4-chlorophenyl)propanoic
acid (0.38 g, 1.3 mmol). After stirring for 30 minutes, HBTU (0.57
g, 1.5 mmol) was added. The mix was stirred at room temperature for
1 hour. The solvent was removed and the residue was subject to
silica gel chromatography, eluting with hexane/ethyl acetate (1:1)
to give (R)-tert-butyl
3-(4-chlorophenyl)-1-(4-(5,7-dihydrothieno[3,4-d]pyrimidin-4-yl)piperazin-
-1-yl)-1-oxopropan-2-ylcarbamate (0.62 g, 98%). .sup.1H NMR
(CDCl.sub.3, 400 MHz) .delta. 8.49 (s, 1H), 5.38-5.35 (m, 1H),
3.70-3.50 (m, 6H), 3.27-3.13 (m, 2H), 2.98-2.92 (m, 2H), 1.42 (s,
9H). MS (APCI+) [M+H].sup.+ 505.
Step 6:
To a solution of (R)-tert-butyl
3-(4-chlorophenyl)-1-(4-(5,7-dihydrothieno[3,4-d]pyrimidin-4-yl)piperazin-
-1-yl)-1-oxopropan-2-ylcarbamate (30 mg, 0.06 mmol) in
CH.sub.2Cl.sub.2 (10 mL) was added HCl (4M in dioxane, 2 mL). The
mixture was stirred at room temperature for 4 hours. The solvent
was removed to afford
(R)-2-amino-3-(4-chlorophenyl)-1-(4-(5,7-dihydrothieno[3,4-d]pyrimidin-4--
yl)piperazin-1-yl)propan-1-one dihydrochloride (30 mg, 99%). MS
(APCI+) [M+H].sup.+ 405.
Example 12
##STR00071##
Preparation of
(R)-2-amino-3-(4-chloro-3-fluorophenyl)-1-(4-((R)-5-methyl-5,7-dihydrothi-
eno[3,4-d]pyrimidin-4-yl)piperazin-1-yl)propan-1-one
dihydrochloride
Step 1:
To a solution of (R)-tert-butyl
4-(5-methyl-5,7-dihydrothieno[3,4-d]pyrimidin-4-yl)piperazine-1-carboxyla-
te (prepared according to Example 1, Steps 1-5) (1.05 g, 3.12 mmol)
in CH.sub.2Cl.sub.2 (20 mL) was added HCl (4M, in dioxane, 4 mL).
The mixture was stirred at room temperature overnight. The solvent
was removed to afford
(R)-5-methyl-4-(piperazin-1-yl)-5,7-dihydrothieno[3,4-d]pyrimidine
as HCl salt (0.74 g, 99%). MS (APCI+) [M+H].sup.+ 237.
Step 2:
To a solution of
(R)-5-methyl-4-(piperazin-1-yl)-5,7-dihydrothieno[3,4-d]pyrimidine
dihydrochloride (30 mg, 0.097 mmol) and
(R)-2-(tert-butoxycarbonylamino)-3-(4-chloro-3-fluorophenyl)propanoic
acid (31 mg, 0.097 mmol) in CH.sub.2Cl.sub.2 (5 mL) and
triethylamine (1 mL) was added HBTU (37 mg, 0.097 mmol). The
mixture was stirred at room temperature for 1 hour. The solvent was
removed and the residue was dissolved in ethyl acetate (100 mL) and
washed with water (5.times.50 mL). The organic phase was dried and
concentrated. The residue was subject to silica gel chromatography,
eluting with CH.sub.2Cl.sub.2/MeOH (50:1) to give tert-butyl
(R)-3-(4-chloro-3-fluorophenyl)-1-(4-((R)-5-methyl-5,7-dihydrothieno[3,4--
d]pyrimidin-4-yl)piperazin-1-yl)-1-oxopropan-2-ylcarbamate (44 mg,
85%). MS (APCI+) [M+H].sup.+ 536.
Step 3:
Treatment of the tert-butyl
(R)-3-(4-chloro-3-fluorophenyl)-1-(4-((R)-5-methyl-5,7-dihydrothieno[3,4--
d]pyrimidin-4-yl)piperazin-1-yl)-1-oxopropan-2-ylcarbamate with HCl
(4M in dioxane, 2 mL) in CH.sub.2Cl.sub.2 (5 mL) for 6 hours gave
the
(R)-2-amino-3-(4-chloro-3-fluorophenyl)-1-(4-((R)-5-methyl-5,7-dihydrothi-
eno[3,4-d]pyrimidin-4-yl)piperazin-1-yl)propan-1-one
dihydrochloride after removal of the solvent. MS (APCI+)
[M+H].sup.+ 436.
Example 13
##STR00072##
Preparation of
2-(4-fluorophenyl)-3-(isopropylamino)-1-(4-((S)-5-methyl-5,7-dihydrothien-
o[3,4-d]pyrimidin-4-yl)piperazin-1-yl)propan-1-one
dihydrochloride
Step 1: Methyl 2-(4-fluorophenyl)acetate (5.0 g, 29.73 mmol), NaOMe
(0.08031 g, 1.487 mmol) and paraformaldehyde (0.9374 g, 31.22 mmol)
were dissolved/suspended in 200 mL of DMSO and allowed to stir
overnight at ambient temperature. The reaction was quenched with
the addition of 1000 mL of ice-cold water. The reaction was
neutralized with the addition of HCl solution, and the aqueous
layer was extracted with ethyl acetate. The combined organic layers
were washed with water twice, once with brine, separated, dried
over MgSO.sub.4, filtered, and concentrated in vacuo to afford the
crude product as a yellow oil. Column chromatography on silica gel
eluting with 25:75 hexanes:ethyl acetate afforded methyl
2-(4-fluorophenyl)-3-hydroxypropanoate (3.0 g, 50.91% yield) as a
colorless oil.
Step 2: Methanesulfonyl chloride (1.230 mL, 15.89 mmol) and TEA
(4.642 mL, 33.30 mmol) was added to a stirred solution of methyl
2-(4-fluorophenyl)-3-hydroxypropanoate (3 g, 15.14 mmol) in THF
(150 mL) at 0.degree. C. under nitrogen. The reaction mixture was
allowed to warm to room temperature and stirred at room temperature
for 2 days. The resulting suspension was diluted with Et.sub.2O
(200 mL), filtered and concentrated in vacuo to give a colorless
oil containing the intermediate compound, methyl
2-(4-fluorophenyl)acrylate. .sup.1H NMR (CDCl.sub.3, 400 MHz) 7.39
(dd, J 8.4 and 5.4 Hz, 2H), 7.04 (app. t, J=8.6 Hz, 2H), 6.36 (s,
1H), 5.87 (s, 1H), 3.83 (s, 1H.) The methyl
2-(4-fluorophenyl)acrylate was taken up into THF (150 mL) and
treated with isopropylamine (6.446 mL, 75.68 mmol). The reaction
mixture was stirred at room temperature for 2 hours, diluted with
EtOAc (200 mL), washed with saturated aqueous bicarbonate (100 mL),
dried over Na.sub.2SO.sub.4 and concentrated in vacuo to give pure
methyl 2-(4-fluorophenyl)-3-(isopropylamino)propanoate (3.6 g,
99.39% yield). LCMS (APCI+) [M+H].sup.+ 240.
Step 3: The crude methyl
2-(4-fluorophenyl)-3-(isopropylamino)propanoate (3.6 g, 15.04 mmol)
was dissolved in 100 mL of DCM and treated with Boc.sub.2O (4.148
mL, 18.05 mmol) at room temperature. The solution bubbled
vigorously for 5 minutes and was allowed to stir overnight to
completion by TLC analysis. The solution was concentrated in vacuo
to an oil, then re-dissolved in 50 mL of THF. The solution was
treated with water (20 mL) and LiOH--H.sub.2O (3.157 g, 75.22 mmol)
to afford an opaque solution. The mixture was allowed to stir at
room temperature overnight. The reaction mixture was concentrated
in vacuo, diluted with water (100 mL) and washed with diethyl ether
(2.times.100 mL). The aqueous was treated with 1M HCl solution
until pH 2-3, then extracted with ethyl acetate (3.times.100 mL).
The organic layers were combined, dried over Na.sub.2SO.sub.4,
filtered, and concentrated in vacuo to give
3-(tert-butoxycarbonyl)-2-(4-fluorophenyl)propanoic acid (4.8 g,
98.06% yield.) LCMS (APCI+) [M-Boc+H].sup.+ 226.
Step 4: DIPEA (0.089 mL, 0.51 mmol) was added to a stirred
suspension of
(S)-5-methyl-4-(piperazin-1-yl)-5,7-dihydrothieno[3,4-d]pyrimidine
dihydrochloride (40 mg, 0.13 mmol),
3-(tert-butoxycarbonyl(isopropyl)amino)-2-(4-fluorophenyl)propanoic
acid (50 mg, 0.15 mmol) and
O-(1H-Benzotriazol-1-yl)-N,N,N',N'-tetramethyluronium
hexafluorophosphate (58 mg, 0.15 mmol) in DCM (10 mL) at room
temperature. The reaction mixture was stirred at room temperature
for 4 hours, diluted with EtOAc, washed with saturated aqueous
bicarbonate and then 1N HCl. The combined organic layers were dried
over Na.sub.2SO.sub.4 and concentrated in vacuo. The residue was
purified by silica gel chromatography (75% EtOAc/hexanes) to give
tert-butyl
2-(4-fluorophenyl)-3-(4-((S)-5-methyl-5,7-dihydrothieno[3,4-d]pyrimidin-4-
-yl)piperazin-1-yl)-3-oxopropyl(isopropyl)carbamate (50 mg, 72%
yield) as a mixture of 2 diastereomers. LCMS (APCI+)
[M-Boc+H].sup.+ 444.
Step 5: HCl (4N in dioxane) was added to a solution of tert-butyl
2-(4-fluorophenyl)-3-(4-((S)-5-methyl-5,7-dihydrothieno[3,4-d]pyrimidin-4-
-yl)piperazin-1-yl)-3-oxopropyl(isopropyl)carbamate (50 mg, 0.092
mmol) in Et.sub.2O (4 mL) and DCM (0.5 mL) at room temperature. The
reaction mixture was stirred at room temperature for 4 hours. The
reaction mixture was concentrated in vacuo. The residue was taken
up into DCM (1 mL), and precipitated with Et.sub.2O (15 mL), and
the solids were filtered under nitrogen to give
2-(4-fluorophenyl)-3-(isopropylamino)-1-(4-((S)-5-methyl-5,7-dihydrothien-
o[3,4-d]pyrimidin-4-yl)piperazin-1-yl)propan-1-one dihydrochloride
(30 mg, 63% yield) as a mixture of 2 diastereomers. LCMS (APCI+)
[M+H].sup.+ 444.
Example 14
##STR00073##
Preparation of
2-(3,4-difluorophenyl)-3-(isopropylamino)-1-(4-((S)-5-methyl-5,7-dihydrot-
hieno[3,4-d]pyrimidin-4-yl)piperazin-1-yl)propan-1-one
dihydrochloride
Step 1:
3-(tert-Butoxycarbonyl(isopropyl)amino)-2-(3,4-difluorophenyl)pro-
panoic acid was prepared according to the procedures of Example 13,
steps 1-3, starting from methyl 2-(4-fluorophenyl)acetate. LCMS
(APCI+) [M-Boc+H].sup.+ 244.
Step 2: DIPEA (0.14 mL, 0.81 mmol) was added to a stirred
suspension of
(S)-5-methyl-4-(piperazin-1-yl)-5,7-dihydrothieno[3,4-d]pyrimidine
dihydrochloride (50 mg, 0.16 mmol),
3-(tert-butoxycarbonyl(isopropyl)amino)-2-(3,4-difluorophenyl)propanoic
acid (111 mg, 0.32 mmol) and
O-(1H-Benzotriazol-1-yl)-N,N,N',N'-tetramethyluronium
hexafluorophosphate (74 mg, 0.19 mmol) in DCM (10 mL) at room
temperature. The reaction mixture was stirred at room temperature
for 4 hours, diluted with EtOAc, washed with saturated aqueous
bicarbonate and then 1N HCl. The combined organic layers were dried
over Na.sub.2SO.sub.4 and concentrated in vacuo. The residue was
purified by silica gel chromatography (75% EtOAc/hexanes) to give
tert-butyl
difluorophenyl)-3-(4-((S)-5-methyl-5,7-dihydrothieno[3,4-d]pyrimidin-4-yl-
)piperazin-1-yl)-3-oxopropyl(isopropyl)carbamate (50 mg, 55% yield)
as a mixture of 2 diastereomers. LCMS (APCI+) [M+H].sup.+ 562.
Step 3: HCl (4N in dioxane, 5 mL) was added to a solution of
tert-butyl
difluorophenyl)-3-(4-((S)-5-methyl-5,7-dihydrothieno[3,4-d]pyrimidin-4-yl-
)piperazin-1-yl)-3-oxopropyl(isopropyl)carbamate (50 mg, 0.089
mmol) in Et.sub.2O (4 mL) and DCM (1 mL) at room temperature. The
reaction mixture was stirred at room temperature for 4 hours. The
reaction mixture was concentrated in vacuo. The residue was taken
up into DCM (1 mL), precipitated with Et.sub.2O and filtered under
nitrogen to give
2-(3,4-difluorophenyl)-3-(isopropylamino)-1-(4-((S)-5-methyl-5,7-dihydrot-
hieno[3,4-d]pyrimidin-4-yl)piperazin-1-yl)propan-1-one
dihydrochloride (38 mg, 80% yield) as a mixture of 2 diastereomers.
LCMS (APCI+) [M+H].sup.+ 462.
Example 15
##STR00074##
Preparation of
(S)-2-(4-chlorophenyl)-3-(isopropylamino)-1-(4-((S)-5-methyl-5,7-dihydrot-
hieno[3,4-d]pyrimidin-4-yl)piperazin-1-yl)propan-1-one
dihydrochloride and
(R)-2-(4-chlorophenyl)-3-(isopropylamino)-1-(4-((S)-5-methyl-5,7-dihydrot-
hieno[3,4-d]pyrimidin-4-yl)piperazin-1-yl)propan-1-one
dihydrochloride
Step 1: tert-Butyl
2-(4-chlorophenyl)-3-(4-((S)-5-methyl-5,7-dihydrothieno[3,4-d]pyrimidin-4-
-yl)piperazin-1-yl)-3-oxopropyl(isopropyl)carbamate (prepared
according to Example 3, Step 1) was separated on a Chiralcel OD
column (Chiral Technologies, West Chester, Pa.) using 10%
EtOH/hexane as the mobile phase. The first peak to elute was
tert-butyl
(R)-2-(4-chlorophenyl)-3-(4-((S)-5-methyl-5,7-dihydrothieno[3,4-d]pyrimid-
in-4-yl)piperazin-1-yl)-3-oxopropyl(isopropyl)carbamate; the
second, tert-butyl
(S)-2-(4-chlorophenyl)-3-(4-((S)-5-methyl-5,7-dihydrothieno[3,4-d]pyrimid-
in-4-yl)piperazin-1-yl)-3-oxopropyl(isopropyl)carbamate.
Step 2: To a solution of tert-butyl
(S)-2-(4-chlorophenyl)-3-(4-((S)-5-methyl-5,7-dihydrothieno[3,4-d]pyrimid-
in-4-yl)piperazin-1-yl)-3-oxopropyl(isopropyl)carbamate (93 mg,
0.17 mmol) in DCM (10 mL) was added HCl (4M, 2 mL). The reaction
mixture was stirred at room temperature for 6 hours, and then the
solvent was removed to afford
(S)-2-(4-chlorophenyl)-3-(isopropylamino)-1-(4-((S)-5-methyl-5,7-d-
ihydrothieno[3,4-d]pyrimidin-4-yl)piperazin-1-yl)propan-1-one
dihydrochloride (76 mg, 100%.) LCMS (APCI+) [M+H].sup.+ 460 and
462.
Step 3: To a solution of tert-butyl
(R)-2-(4-chlorophenyl)-3-(4-((S)-5-methyl-5,7-dihydrothieno[3,4-d]pyrimid-
in-4-yl)piperazin-1-yl)-3-oxopropyl(isopropyl)carbamate (11 mg,
0.020 mmol) in DCM (10 mL) was added HCl (4M, 2 mL). The reaction
mixture was stirred at room temperature for 6 hours. The solvent
was removed to afford
(S)-2-(4-chlorophenyl)-3-(isopropylamino)-1-(4-((S)-5-methyl-5,7-d-
ihydrothieno[3,4-d]pyrimidin-4-yl)piperazin-1-yl)propan-1-one
dihydrochloride (9 mg, 100%). LCMS (APCI+) [M+H].sup.+ 460 and
462.
.sup.1H NMR (CDCl.sub.3): 8.51 (1H, s), 7.31 (2H, d, J=8.1 Hz),
7.22 (2H, d, J=8.2 Hz), 4.77-4.72 (1H, m), 4.17 (2H, app q, J=14.1
Hz), 4.00-3.94 (2H, m), 3.69-3.64 (1H, m), 3.59-3.45 (4H, m),
3.36-3.24 (2H, m), 2.89-2.76 (2H, m), 2.70 (1H, dd, J 11.3 and 5.1
Hz), 2.17 (1H, s), 1.46 (3H, d, J=7.0 Hz), 1.07 (3H, d, J=6.3 Hz),
1.03 (3H, d, J=6.3 Hz).
Example 16
##STR00075##
(2R)-2-amino-3-(4-chlorophenyl)-1-(4-(5-methyl-5,7-dihydrothieno[3,4-d]pyr-
imidin-4-yl)piperazin-1-yl)propan-1-one
LCMS: 418.2 [M+H.sup.+] (APCI+).
Example 17
##STR00076##
2-(4-chlorophenyl)-1-(4-(5-methyl-5,7-dihydrothieno[3,4-d]pyrimidin-4-yl)p-
iperazin-1-yl)-3-(pyrrolidin-1-yl)propan-1-one
LCMS: 472.2 [M+H.sup.+] (APCI+).
Example 18
##STR00077##
(2R)-2-amino-3-(4-chloro-3-fluorphenyl)-1-(4-(5-methyl-5,7-dihydrothieno[3-
,4-d]pyrimidin-4-yl)piperazin-1-yl)propan-1-one
LCMS: 436.2 [M+H.sup.+] (APCI+).
Example 19
##STR00078##
2-(4-chlorophenyl)-3-(isopropylamino)-1-(4-(5-methyl-5,7-dihydrothieno[3,4-
-d]pyrimidin-4-yl)piperazin-1-yl)propan-1-one
LCMS: 460.2 [M+H.sup.+] (APCI+).
LCMS: 423.2 [M+H.sup.+] (APCI+).
Example 20
##STR00079##
3-(1-aminocyclopropyl)-2-(4-chlorophenyl)-1-(4-(5-methyl-5,7-dihydrothieno-
[3,4-d]pyrimidin-4-yl)piperazin-1-yl)propan-1-one
Step 1:
LHMDS (1.0 M solution in THF, 13.1 mL, 13.1 mmol) was added
dropwise at -78.degree. C. under nitrogen to a stirred solution of
methyl 2-(4-chlorophenyl)acetate (2.20 g, 11.9 mmol) in THF (40
mL). The resulting solution was stirred at -78.degree. C. for 1
hour. A solution of 2-bromoacetonitrile (2.50 g, 20.9 mmol) in THF
(16 mL) was added dropwise. The reaction was stirred at -78.degree.
C. for 1 hour. The reaction was then warmed to room temperature and
stirred overnight. The reaction was then quenched with 1N HCl. The
mixture was extracted with EtOAc. The combined organic layers were
washed with brine, dried and concentrated. The residue was purified
by column chromatography (hexanes: EtOAc, 4:1) to give methyl
2-(4-chlorophenyl)-3-cyanopropanoate (2.60 g, 98%) as a white
solid. A solution of EtMgBr in THF (1.0 M, 8.0 mL, 8.0 mmol) was
added dropwise at room temperature to a stirred solution of this
methyl 2-(4-chlorophenyl)-3-cyanopropanoate (0.894 g, 4.00 mmol)
and Ti(i-PrO).sub.4 (1.30 mL, 4.40 mmol) in Et.sub.2O (20 mL).
After the mixture was stirred at room temperature for 1 hour, water
(4 mL) was added, followed by DCM (100 mL). The resulting
precipitate was filtered and washed with DCM. The combined
filtrates were dried and concentrated. The residue was purified by
column chromatography (hexanes:EtOAc, 1:1) to give
6-(4-chlorophenyl)-4-azaspiro[2.4]heptan-5-one (0.330 g, 37%) as a
white solid. LCMS (APCI+) [M-Boc+H].sup.+ 222.2; Rf: 2.44 min.
Step 2:
LHMDS (1.0 M solution in THF, 2.21 mL, 2.21 mmol) was added
dropwise at -78.degree. C. under nitrogen to a stirred solution of
the 6-(4-chlorophenyl)-4-azaspiro[2.4]heptan-5-one (0.409 g, 1.84
mmol) in THF (20 mL). The resulting solution was stirred at
-78.degree. C. for 30 minutes. A solution of Boc2O (0.443 g, 2.03
mmol) in THF (5 mL) was added all at once. The reaction was warmed
to room temperature and stirred for 2 hours. The reaction was then
quenched with 1N HCl and extracted with EtOAc. The combined organic
layers were washed with brine, dried and concentrated. The residue
was purified by column chromatography (hexanes:EtOAc, 4:1) to give
tert-butyl
6-(4-chlorophenyl)-5-oxo-4-azaspiro[2.4]heptane-4-carboxylate
(0.470 g, 79%).
Step 3:
A solution of LiOH hydrate (0.24 g, 5.7 mmol) in water (2 mL) was
added to a stirred solution of tert-butyl
6-(4-chlorophenyl)-5-oxo-4-azaspiro[2.4]heptane-4-carboxylate (0.46
g, 1.4 mmol) in MeOH (2 mL) and THF (2 mL). The reaction was
stirred at room temperature overnight. The solvents were evaporated
in vacuo. The residue was taken up in water and extracted with
ether (2.times.). The aqueous phase was acidified by 2N HCl and
extracted with EtOAc. The combined organic phases were washed with
brine, dried and concentrated to give
3-(1-(tert-butoxycarbonylamino)cyclopropyl)-2-(4-chlorophenyl)propanoic
acid (0.41 g, 84%) as a white solid. LCMS (APCI+) [M-Boc+H].sup.+
240.0; Rf: 2.38 min.
Step 4:
HBTU (0.031 g, 0.081 mmol) was added to a solution of
5-methyl-4-(piperazin-1-yl)-5,7-dihydrothieno[3,4-d]pyrimidine
dihydrochloride (0.025 g, 0.081 mmol) and
3-(1-(tert-butoxycarbonyl)cyclopropyl)-2-(4-chlorophenyl)propanoic
acid (0.027 g, 0.081 mmol) in DCM (5 mL) and TEA (1 mL). The
mixture was stirred at room temperature for 1 hour. The solvent was
removed, and the residue was subject to column chromatography,
eluted by DCM/MeOH (50:1) to give
3-(1-aminocyclopropyl)-2-(4-chlorophenyl)-1-(4-(5-methyl-5,7-dihy-
drothieno[3,4-d]pyrimidin-4-yl)piperazin-1-yl)propan-1-one (30 mg,
81%). LCMS (APCI+) [M+H].sup.+ 558.1; Rf: 3.35 min.
Step 5:
HCl in dioxane (4M, 1 mL) was added to a solution of tert-butyl
1-(2-(4-chlorophenyl)-3-(4-(5-methyl-5,7-dihydrothieno[3,4-d]pyrimidin-4--
yl)piperazin-1-yl)-3-oxopropyl)cyclopropylcarbamate (10 mg, 0.018
mmol) in DCM (3 mL). The mixture was stirred at room temperature
for 4 hours. The solvent was removed to afford
3-(1-aminocyclopropyl)-2-(4-chlorophenyl)-1-(4-(5-methyl-5,7-dihydrothien-
o[3,4-d]pyrimidin-4-yl)piperazin-1-yl)propan-1-one as the di-HCl
salt (8.2 mg, 100%).
LCMS: 458.1 [M+H.sup.+] (APCI+).
Example 21
##STR00080##
4-amino-2-(4-chlorophenyl)-4-methyl-1-(4-(5-methyl-5,7-dihydrothieno[3,4-d-
]pyrimidin-4-yl)piperazin-1-yl)pentan-1-one
LCMS: 460.2 [M+H.sup.+] (APCI+).
Example 22
##STR00081##
2-(1-aminocyclopropyl)-3-(4-chlorophenyl)-1-(4-(5-methyl-5,7-dihydrothieno-
[3,4-d]pyrimidin-4-yl)piperazin-1-yl)propan-1-one
Step 1:
A solution of ethyl 3-(4-chlorophenyl)-2-cyanoacrylate (6.2 g, 26
mmol) in 2-propanol (80 mL) was added dropwise to a stirred
suspension of NaBH.sub.4 (2.8 g, 74 mmol) in 2-propanol (20 mL).
The mixture was stirred at room temperature overnight. Excess
NaBH.sub.4 was destroyed with saturated NH.sub.4Cl, and most of the
2-propanol was removed in vacuo. The residue was partitioned
between EtOAc and water. The aqueous layer was extracted with
EtOAc. The combined organic layers were washed with brine, dried
and concentrated. The crude
2-(4-chlorobenzyl)-3-hydroxypropanenitrile was used without
purification. TBS-Cl (2.77 g, 18.4 mmol) in dry DMF (15 mL) was
added to a solution of the crude
2-(4-chlorobenzyl)-3-hydroxypropanenitrile (3.00 g, 15.3 mmol) and
imidazole (4.18 g, 61.3 mmol) in DMF (25 mL) at 0.degree. C. under
nitrogen. The reaction mixture was warmed to room temperature and
stirred overnight. The reaction mixture was partitioned between
ether and water. The organic layer was washed with brine, dried and
concentrated. The residue was purified by column (hexanes:EtOAc,
30:1) to give
3-(tert-butyldimethylsilyloxy)-2-(4-chlorobenzyl)propanenitrile
(3.70 g, 78%) as a colorless oil.
Step 2:
A solution of EtMgBr in THF (3.0M, 8.0 mL, 24 mmol) was added
dropwise at room temperature to a stirred solution of
3-(tert-butyldimethylsilyloxy)-2-(4-chlorobenzyl)propanenitrile
(3.7 g, 12 mmol) and Ti(i-PrO).sub.4 (3.9 mL, 13 mmol) in Et.sub.2O
(50 mL). After the mixture was stirred at room temperature for 1
hour, BF.sub.3OEt (3.0 mL, 24 mmol) was added at once. The mixture
was stirred for an additional 1 hour. A solution of 10% NaOH (10
mL) was added, followed by DCM (300 mL). The resulting precipitate
was filtered and washed with DCM. The combined filtrates were dried
and concentrated. The residue was purified by column chromatography
(30:1 DCM:MeOH) to give
1-(1-(tert-butyldimethylsilyloxy)-3-(4-chlorophenyl)propan-2-yl)cycloprop-
anamine (2.6 g, 64%) as a colorless oil. LCMS: 340.2 (M+H).sup.+
(APCI+); Rf: 3.17 min.
Step 3:
1-(1-(tert-Butyldimethylsilyloxy)-3-(4-chlorophenyl)propan-2-yl)cycloprop-
anamine (2.6 g, 7.6 mmol) was dissovled in THF (60 mL). Boc2O (2.0
g, 9.2 mmol), DMAP (93 mg, 0.76 mmol) and triethylamine (1.6 mL, 12
mmol) were added. The mixture was stirred at room temperature
overnight. The solvent was evaporated, and the residue partitioned
between EtOAc and water. The organic phase was separated and washed
with brine, dried and concentrated. The residue was purified by
column chromatography (hexanes:EtOAc, 6:1) to give tert-butyl
1-(1-(tert-butyldimethylsilyloxy)-3-(4-chlorophenyl)propan-2-yl)cycloprop-
ylcarbamate (2.0 g, 59%).
Step 4:
TBAF (2.80 g, 8.86 mmol) was added to a stirred solution of
tert-butyl
1-(1-(tert-butyldimethylsilyloxy)-3-(4-chlorophenyl)propan-2-yl)cycloprop-
ylcarbamate (1.95 g, 4.43 mmol) in THF (80 mL). The mixture was
stirred at room temperature for 2 hours. Saturated NH.sub.4Cl
solution was added to the reaction. The mixture was extracted with
ether. The combined organic layer was washed with brine, dried and
concentrated. The residue was purified by column (hexane:EtOAc,
20:1 to 4:1) to give tert-butyl
1-(1-(4-chlorophenyl)-3-hydroxypropan-2-yl)cyclopropylcarbamate
(1.25 g, 87%) as a white solid. LCMS: 325.9 [M+H.sup.+] (APCI+);
Rf: 3.75 min.
Step 5:
Triethylamine (2.14 mL, 15.4 mmol) was added to a stirred solution
of tert-butyl
1-(1-(4-chlorophenyl)-3-hydroxypropan-2-yl)cyclopropylcarbamate
(1.00 g, 3.07 mmol) in DCM (15 mL) at -15.degree. C. A solution of
pyridine-sulfur trioxide complex (2.44 g, 15.4 mmol) in DMSO (15
mL) was added to the above solution in one portion. The mixture was
stirred at the same temperature for 10 minutes, and then warmed to
0.degree. C. After stirring at 0.degree. C. for 1 hour, the mixture
was poured into cold brine solution, and extracted with ether. The
combined organic extracts were washed with 10% citric acid and
brine, dried and concentrated. The crude tert-butyl
1-(1-(4-chlorophenyl)-3-oxopropan-2-yl)cyclopropylcarbamate was
used in the next step without purification. LCMS: 323.7 [M+H.sup.+]
(APCI+); Rf: 3.77 min.
Step 6:
tert-Butyl
1-(1-(4-chlorophenyl)-3-oxopropan-2-yl)cyclopropylcarbamate (3.06
mmol), 2-methyl-2-butene (7.6 mL, 2.0M THF solution, 15.3 mmol) and
KH.sub.2PO.sub.4 (0.416 g, 3.06 mmol) were dissolved in t-BuOH (100
mL)-water (30 mL). Sodium chlorite (0.830 g, 9.17 mmol) was added
portionwise at 0.degree. C. The mixture was stirred at room
temperature for 2 hours and then acidified with 10% citric acid.
The reaction was extracted with EtOAc. The combined organic layers
were washed with brine, dried and concentrated to give
2-(1-(tert-butoxycarbonylamino)cyclopropyl)-3-(4-chlorophenyl)propanoic
acid as a white solid. LCMS: 339.9 [M+H.sup.+] (APCI+).
Step 7:
HBTU (0.031 g, 0.081 mmol) was added to a solution of the
5-methyl-4-(piperazin-1-yl)-5,7-dihydrothieno[3,4-d]pyrimidine
dihydrochloride (0.025 g, 0.081 mmol) and amino acid (0.027 g,
0.081 mmol) in DCM (5 mL) and TEA (1 mL). The mixture was stirred
at room temperature for 1 hour. The solvent was removed, and the
residue was subject to column chromatography, eluted by DCM/MeOH
(50:1). The resulting product in DCM (5 mL) was treated with HCl
(4M, 2 mL) for 6 hours. The solvent was removed to afford
2-(1-aminocyclopropyl)-3-(4-chlorophenyl)-1-(4-(5-methyl-5,7-dihydrothien-
o[3,4-d]pyrimidin-4-yl)piperazin-1-yl)propan-1-one as the di-HCl
salt.
LCMS: 458.2 [M+H.sup.+] (APCI+).
Example 23
##STR00082##
(2R)-2-amino-3-(4-fluorophenyl)-1-(4-(5-methyl-5,7-dihydrothieno[3,4-d]pyr-
imidin-4-yl)piperazin-1-yl)propan-1-one
LCMS: 402.2 [M+H.sup.+] (APCI+).
Example 24
##STR00083##
(2R)-2-amino-3-(3,4-difluorophenyl)-1-(4-(5-methyl-5,7-dihydrothieno[3,4-d-
]pyrimidin-4-yl)piperazin-1-yl)propan-1-one
LCMS: 420.2 [M+H.sup.+] (APCI+).
Example 25
##STR00084##
2-(4-chlorophenyl)-3-(1-(dimethylamino)cyclopropyl)-1-(4-(5-methyl-5,7-dih-
ydrothieno[3,4-d]pyrimidin-4-yl)piperazin-1-yl)propan-1-one
LCMS: 486.3 [M+H.sup.+] (APCI+).
Example 26
##STR00085##
(4-(3-chlorophenyl)piperidin-4-yl)(4-(5-methyl-5,7-dihydrothieno[3,4-d]pyr-
imidin-4-yl)piperazin-1-yl)methanone
Step 1:
60% NaH (2.31 g, 57.7 mmol) was added in 2 portions to a 0.degree.
C. solution of 2-(3-chlorophenyl)acetonitrile (3.50 g, 23.1 mmol)
and 15-crown-5 (0.509 g, 2.31 mmol) in DMF (80 mL). The reaction
mixture was warmed to room temperature while stirring for 35
minutes and then cooled back to 0.degree. C. NaI (3.46 g, 23.1
mmol) was added, followed by the addition of a solution of freshly
prepared tert-butyl bis(2-chloroethyl)carbamate (5.59 g, 23.1 mmol)
in DMF (10 mL) by syringe. The reaction mixture warmed back to room
temperature and stirred overnight (16 hours). The reaction mixture
was poured into iced saturated NH.sub.4Cl and extracted with EtOAc.
The extracts were dried (Na.sub.2SO.sub.4), filtered, and
concentrated. The crude was flashed on silica (Biotage 40L, 9:1
hex:EA until prod, then gradient to 4:1 hexane:EtOAc) to give
tert-butyl 4-(3-chlorophenyl)-4-cyanopiperidine-1-carboxylate (5.91
g, 79.8% yield) as a yellow foam. LC/MS (APCI+) m/z 221
[M-Boc+H].sup.+.
Step 2:
tert-Butyl 4-(3-chlorophenyl)-4-cyanopiperidine-1-carboxylate (5.91
g, 18.42 mmol) was dissolved in concentrated HCl (153.5 ml, 1842
mmol). The reaction mixture stirred at reflux over a weekend. The
reaction mixture was cooled to room temperature and washed with
ether. The aqueous portion was concentrated on a rotary evaporator,
and the solids were dried on a high vacuum line. The solids were
dissolved in H.sub.2O (35 mL), 10% NaOH (29.47 g, 73.69 mmol), and
dioxane (30 mL). Solid Boc2O (4.222 g, 19.34 mmol) was added, and
reaction mixture stirred at room temperature overnight (14 hours).
The reaction mixture was diluted with H.sub.2O and washed with
ether. The aqueous portion was acidified with solid KHSO.sub.4,
then extracted with DCM. The combined extracts were dried
(Na.sub.2SO.sub.4), filtered, and concentrated to give
1-(tert-butoxycarbonyl)-4-(3-chlorophenyl)piperidine-4-carboxylic
acid (4.73 g, 75.56% yield) as a white powder. HPLC>98%. LC/MS
(APCI-) m/z 338 [M-H].sup.-.
Step 3:
HBTU (0.07726 g, 0.2037 mmol) was added to a solution of
(R)-5-methyl-4-(piperazin-1-yl)-5,7-dihydrothieno[3,4-d]pyrimidine
dihydrochloride (0.030 g, 0.09701 mmol),
1-(tert-butoxycarbonyl)-4-(3-chlorophenyl)piperidine-4-carboxylic
acid (0.06593 g, 0.1940 mmol), and DIEA (0.06759 ml, 0.3880 mmol)
in DCM (2.5 mL). The reaction mixture was stirred overnight (18
hours), after which, saturated NaHCO.sub.3 was added. The mixture
was extracted with DCM, and the extracts were dried
(Na.sub.2SO.sub.4), filtered, and concentrated. The crude was
flashed on Biotage 12M (DCM flushed to remove DIEA, then 2:1 to 1:1
DCM:EA; top spot [by-prod] eluted quickly, then 2nd spot [prod]) to
give (R)-tert-butyl
4-(3-chlorophenyl)-4-(4-(5-methyl-5,7-dihydrothieno[3,4-d]pyrimidin-4-yl)-
piperazine-1-carbonyl)piperidine-1-carboxylate. This was dissolved
in dioxane (2 mL), and 4M HCl/dioxane (0.7275 ml, 2.910 mmol) was
added, causing slow precipitation. The reaction mixture was stirred
at room temperature overnight (18 hours), after which it was
concentrated to dryness. The solids were dissolved in minimal MeOH,
and then the product was triturated by the addition of ether. The
resulting solids were isolated by filtration thru medium frit
funnel with nitrogen pressure, rinsed with ether, and dried in
vacuo to give
(R)-(4-(3-chlorophenyl)piperidin-4-yl)(4-(5-methyl-5,7-dihydrothieno[3,4--
d]pyrimidin-4-yl)piperazin-1-yl)methanone dihydrochloride (0.029 g,
56.31% yield) as a pale yellow powder.
LCMS: 458.1 [M+H.sup.+] (APCI+).
Example 27
##STR00086##
(R)-2-amino-3-(4-chlorophenyl)-1-(4-((S)-5-methyl-5,7-dihydrothieno[3,4-d]-
pyrimidin-4-yl)piperazin-1-yl)propan-1-one
LCMS: 418.2 [M+H.sup.+] (APCI+).
Example 28
##STR00087##
(R)-2-amino-3-(4-fluorophenyl)-1-(4-((S)-5-methyl-5,7-dihydrothieno[3,4-d]-
pyrimidin-4-yl)piperazin-1-yl)propan-1-one
LCMS: 402.2 [M+H.sup.+] (APCI+).
Example 29
##STR00088##
(R)-2-amino-3-(3,4-difluorophenyl)-1-(4-((S)-5-methyl-5,7-dihydrothieno[3,-
4-d]pyrimidin-4-yl)piperazin-1-yl)propan-1-one
LCMS: 420.2 [M+H.sup.+] (APCI+).
LCMS: 423.2 [M+H.sup.+] (APCI+).
Example 30
##STR00089##
2-(1-aminocyclopropyl-2-(4-chlorophenyl)-1-(4-((S)-5-methyl-5,7-dihydrothi-
eno[3,4-d]pyrimidin-4-yl)piperazin-1-yl)ethanone
Step 1:
TBS-Cl (2.29 g, 15.2 mmol) in dry DMF (12 mL) was added to a
solution of 2-(4-chlorophenyl)-3-hydroxypropanenitrile (2.30 g,
12.7 mmol) and imidazole (3.45 g, 50.7 mmol) in DMF (20 mL) at
0.degree. C. under nitrogen. The reaction mixture was warmed to
room temperature and stirred overnight. The reaction mixture was
partitioned between ether and water. The organic layer was washed
with brine, dried and concentrated. The residue was purified by
column (hexanes:EtOAc, 30:1) to give
3-(tert-butyldimethylsilyloxy)-2-(4-chlorophenyl)propanenitrile
(3.40 g, 91%) as a colorless oil. A solution of EtMgBr in THF (3.0
M, 7.0 mL, 21 mmol) was added dropwise at room temperature to a
stirred solution of this
3-(tert-butyldimethylsilyloxy)-2-(4-chlorophenyl)propanenitrile
(3.1 g, 10 mmol) and Ti(i-PrO)4 (3.4 mL, 11 mmol) in Et.sub.2O (60
mL). After the mixture was stirred at room temperature for 1 hour,
BF.sub.3OEt (2.7 mL, 21 mmol) was added at once. The mixture was
stirred for an additional 1 hour. A solution of 10% NaOH (10 mL)
was added, followed by DCM (300 mL). The resulting precipitate was
filtered and washed with DCM. The combined filtrates were dried and
concentrated. The residue was purified by column chromatography
(30:1 DCM:MeOH) to give
1-(2-(tert-butyldimethylsilyloxy)-1-(4-chlorophenyl)ethyl)cyclopropanamin-
e (2.3 g, 67%) as a colorless oil. LCMS: 326.1 [M+H.sup.+] (APCI+);
Rf: 3.04 min.
Step 2:
Boc2O (1.8 g, 8.5 mmol), triethylamine (1.5 mL, 11 mmol) and DMAP
(86 mg, 0.71 mmol) were added to a stirred solution of
1-(2-(tert-butyldimethylsilyloxy)-1-(4-chlorophenyl)ethyl)cyclopropanamin-
e (2.3 g, 7.1 mmol) in THF (50 mL). The mixture was stirred at room
temperature overnight. The solvent was evaporated, and the residue
partitioned between EtOAc and water. The organic phase was
separated and washed with brine, dried and concentrated. The
residue was purified by column chromatography (hexanes:EtOAc, 6:1)
to give tert-butyl
1-(2-(tert-butyldimethylsilyloxy)-1-(4-chlorophenyl)ethyl)cyclopropylcarb-
amate (2.1 g, 70%.) LCMS: 326.5 [M-Boc+H.sup.+] (APCI+); Rf: 3.07
min.
Step 3:
TBAF (2.8 g, 8.9 mmol) was added to a stirred solution of
tert-butyl
1-(2-(tert-butyldimethylsilyloxy)-1-(4-chlorophenyl)ethyl)cyclopropylcarb-
amate (1.9 g, 4.5 mmol) in THF (80 mL). The mixture was stirred at
room temperature for 2 hours. Saturated NH.sub.4Cl solution was
added to the reaction. The mixture was extracted with ether. The
combined organic layer was washed with brine, dried and
concentrated. The residue was purified by column (hexane:EtOAc,
20:1 to 4:1) to give tert-butyl
1-(1-(4-chlorophenyl)-2-hydroxyethyl)cyclopropylcarbamate (1.1 g,
79%) as a white solid. LCMS: 311.8 [M+H.sup.+] (APCI+); Rf: 3.47
min.
Step 4:
Triethylamine (0.45 mL, 3.2 mmol) was added to a stirred solution
of tert-butyl
1-(1-(4-chlorophenyl)-2-hydroxyethyl)cyclopropylcarbamate (0.200 g,
0.641 mmol) in DCM (3 mL) at -15.degree. C. A solution of
pyridine-sulfur trioxide complex (0.510 g, 3.21 mmol) in DMSO (3
mL) was added to the above solution in one portion. The mixture was
stirred at the same temperature for 10 minutes, and then warmed to
0.degree. C. After stirring at 0.degree. C. for 1 hour, the mixture
was poured into cold brine solution, and extracted with ether. The
combined organic extracts were washed with 10% citric acid and
brine, dried and concentrated. The crude tert-butyl
1-(1-(4-chlorophenyl)-2-oxoethyl)cyclopropylcarbamate was used in
the next step without purification. LCMS: 309.8 [M+H.sup.+]
(APCI+); Rf: 3.62 min.
Step 5:
tert-Butyl 1-(1-(4-chlorophenyl)-2-oxoethyl)cyclopropylcarbamate
(0.64 mmol), 2-methyl-2-butene (1.6 mL, 2.0 M THF solution, 3.2
mmol) and KH.sub.2PO.sub.4 (0.087 g, 0.64 mmol) were dissolved in
t-BuOH (20 mL)-water (6 mL). Sodium chlorite (0.174 g, 1.93 mmol)
was added portionwise at 0.degree. C. The mixture was stirred at
room temperature for 2 hours and then acidified with 10% citric
acid. The reaction was extracted with EtOAc. The combined organic
layers were washed with brine, dried and concentrated to give
2-(1-(tert-butoxycarbonylamino)cyclopropyl)-2-(4-chlorophenyl)acetic
acid (0.19 g, 91%) as a colorless syrup, which was used for amide
coupling without further purification. LCMS: 325.8 [M+H.sup.+]
(APCI+); Rf: 3.31 min.
Step 6:
HBTU (0.097 mmol, 47 mg) was added to a solution of
(S)-5-methyl-4-(piperazin-1-yl)-5,7-dihydrothieno[3,4-d]pyrimidine
dihydrochloride (30 mg, 0.097 mmol) and
2-(1-(tert-butoxycarbonylamino)cyclopropyl)-2-(4-chlorophenyl)acetic
acid (0.097 mmol) in DCM (5 mL) and TEA (5 mL). The mixture was
stirred at room temperature for 6 hours. The solvent was removed,
and the residue was subject to column chromatography, eluted by
DCM/MeOH (50:1) to give tert-butyl
1-(1-(4-chlorophenyl)-2-(4-((S)-5-methyl-5,7-dihydrothieno[3,4-d]pyrimidi-
n-4-yl)piperazin-1-yl)-2-oxoethyl)cyclopropylcarbamate LCMS: 544.0
[M-Boc+H.sup.+] (APCI+); Rf: 3.49 min. The tert-butyl
1-(1-(4-chlorophenyl)-2-(4-((S)-5-methyl-5,7-dihydrothieno[3,4-d]pyrimidi-
n-4-yl)piperazin-1-yl)-2-oxoethyl)cyclopropylcarbamate was
deprotected using procedures described previously to give
2-(1-aminocyclopropyl)-2-(4-chlorophenyl)-1-(4-((S)-5-methyl-5,7-dihydrot-
hieno[3,4-d]pyrimidin-4-yl)piperazin-1-yl)ethanone. Rf: 2.24
min.
LCMS: 444 [M+H.sup.+] (APCI+).
Example 31
##STR00090##
2-(1-aminocyclopropyl)-3-(4-chlorophenyl)-1-(4-((S)-5-methyl-5,7-dihydroth-
ieno[3,4-d]pyrimidin-4-yl)piperazin-1-yl)propan-1-one
LCMS: 458.1 [M+H.sup.+] (APCI+).
Example 32
##STR00091##
3-(1-aminocyclopropyl)-2-(4-chloro-3-fluorophenyl)-1-(4-((S)-5-methyl-5,7--
dihydrothieno[3,4-d]pyrimidin-4-yl)piperazin-1-yl)propan-1-one
LCMS: 476.1 [M+H.sup.+] (APCI+).
Example 33
##STR00092##
4-amino-2-(4-fluorophenyl)-4-methyl-1-(4-((S)-5-methyl-5,7-dihydrothieno[3-
,4-d]pyrimidin-4-yl)piperazin-1-yl)pentan-1-one
LCMS: 444.2 [M+H.sup.+] (APCI+).
Example 34
##STR00093##
4-amino-2-(4-chloro-3-fluorophenyl)-4-methyl-1-(4-((S)-5-methyl-5,7-dihydr-
othieno[3,4-d]pyrimidin-4-yl)piperazin-1-yl)pentan-1-one
LCMS: 478.1 [M+H.sup.+] (APCI+).
Example 35
##STR00094##
4-amino-2-(3,4-difluorophenyl)-4-methyl-1-(4-((S)-5-methyl-5,7-dihydrothie-
no[3,4-d]pyrimidin-4-yl)piperazin-1-yl)pentan-1-one
LCMS: 462.2 [M+H.sup.+] (APCI+).
Example 36
##STR00095##
(R)-2-amino-3-(4-chlorophenyl)-1-(4-((R)-5-methyl-5,7-dihydrothieno[3,4-d-
]pyrimidin-4-yl)piperazin-1-yl)propan-1-one
LCMS: 418.2 [M+H.sup.+] (APCI+).
Example 37
##STR00096##
(R)-2-amino-3-(4-fluorophenyl)-1-(4-((R)-5-methyl-5,7-dihydrothieno[3,4-d-
]pyrimidin-4-yl)piperazin-1-yl)propan-1-one
LCMS: 402.2 [M+H.sup.+] (APCI+).
Example 38
##STR00097##
(R)-2-amino-3-(3,4-difluorophenyl)-1-(4-((R)-5-methyl-5,7-dihydrothieno[3,-
4-d]pyrimidin-4-yl)piperazin-1-yl)propan-1-one
LCMS: 420.2 [M+H.sup.+] (APCI+).
Example 39
##STR00098##
2-(4-chlorophenyl)-3-(isopropylamino)-1-(4-((R)-5-methyl-5,7-dihydrothieno-
[3,4-d]pyrimidin-4-yl)piperazin-1-yl)propan-1-one
LCMS: 460.2 [M+H.sup.+] (APCI+).
Example 40
##STR00099##
2-(4-chlorophenyl)-1-(4-((R)-5-methyl-5,7-dihydrothieno[3,4-d]pyrimidin-4--
yl)piperazin-1-yl)-3-(pyrrolidin-1-yl)propan-1-one
LCMS: 472.2 [M+H.sup.+] (APCI+).
Example 41
##STR00100##
2-(1-aminocyclopropyl)-2-(4-chlorophenyl)-1-(4-((R)-5-methyl-5,7-dihydroth-
ieno[3,4-d]pyrimidin-4-yl)piperazin-1-yl)ethanone
LCMS: 444 [M+H.sup.+] (APCI+).
Example 42
##STR00101##
2-(1-aminocyclopropyl)-3-(4-chlorophenyl)-1-(4-((R)-5-methyl-5,7-dihydroth-
ieno[3,4-d]pyrimidin-4-yl)piperazin-1-yl)propan-1-one
LCMS: 458.1 [M+H.sup.+] (APCI+).
Example 43
##STR00102##
3-(1-aminocyclopropyl)-2-(4-chloro-3-fluorophenyl)-1-(4-((R)-5-methyl-5,7--
dihydrothieno[3,4-d]pyrimidin-4-yl)piperazin-1-yl)propan-1-one
LCMS: 476.1 [M+H.sup.+] (APCI+).
Example 44
##STR00103##
4-amino-2-(4-chlorophenyl)-4-methyl-1-(4-((R)-5-methyl-5,7-dihydrothieno[3-
,4-d]pyrimidin-4-yl)piperazin-1-yl)pentan-1-one
LCMS: 460.2 [M+H.sup.+] (APCI+).
Example 45
##STR00104##
4-amino-2-(4-fluorophenyl)-4-methyl-1-(4-((R)-5-methyl-5,7-dihydrothieno[3-
,4-d]pyrimidin-4-yl)piperazin-1-yl)pentan-1-one
LCMS: 444.1 [M+H.sup.+] (APCI+).
Example 46
##STR00105##
4-amino-2-(4-chloro-3-fluorophenyl)-4-methyl-1-(4-((R)-5-methyl-5,7-dihydr-
othieno[3,4-d]pyrimidin-4-yl)piperazin-1-yl)pentan-1-one
LCMS: 478.1 [M+H.sup.+] (APCI+).
Example 47
##STR00106##
4-amino-2-(3,4-difluorophenyl)-4-methyl-1-(4-((R)-5-methyl-5,7-dihydrothie-
no[3,4-d]pyrimidin-4-yl)piperazin-1-yl)pentan-1-one
LCMS: 462.1 [M+H.sup.+] (APCI+).
Example 48
##STR00107##
(4-(4-chlorophenyl)-1-methylpiperidin-4-yl)(4-(5-methyl-5,7-dihydrothieno[-
3,4-d]pyrimidin-4-yl)piperazin-1-yl)methanone
LCMS: 472.2 [M+H.sup.+] (APCI+).
Example 49
##STR00108##
(S)-(4-(3-chlorophenyl)piperidin-4-yl)(4-(5-methyl-5,7-dihydrothieno[3,4-d-
]pyrimidin-4-yl)piperazin-1-yl)methanone
LCMS: 458.2 [M+H.sup.+] (APCI+).
Example 50
##STR00109##
(S)-(4-(4-chlorophenyl)piperidin-4-yl)(4-(5-methyl-5,7-dihydrothieno[3,4-d-
]pyrimidin-4-yl)piperazin-1-yl)methanone
LCMS: 458.2 [M+H.sup.+] (APCI+).
Example 51
##STR00110##
(R)-(4-(3-chlorophenyl)piperidin-4-yl)(4-(5-methyl-5,7-dihydrothieno[3,4-d-
]pyrimidin-4-yl)piperazin-1-yl)methanone
LCMS: 458.1 [M+H.sup.+] (APCI+).
Example 52
##STR00111##
(R)-2-amino-3-(4-chlorophenyl)-1-((S)-3-methyl-4-((R)-5-methyl-5,7-dihydro-
thieno[3,4-d]pyrimidin-4-yl)piperazin-1-yl)propan-1-one
LCMS: 432.1 [M+H.sup.+] (APCI+).
Example 53
##STR00112##
2-(4-chlorophenyl)-1-((S)-3-methyl-4-((S)-5-methyl-5,7-dihydrothieno[3,4-d-
]pyrimidin-4-yl)piperazin-1-yl)-3-(pyrrolidin-1-yl)propan-1-one
LCMS: 486.1 [M+H.sup.+] (APCI+).
Example 54
##STR00113##
2-(4-chlorophenyl)-1-((S)-3-methyl-4-((R)-5-methyl-5,7-dihydrothieno[3,4-d-
]pyrimidin-4-yl)piperazin-1-yl)-3-(pyrrolidin-1-yl)propan-1-one
LCMS: 486.2 [M+H.sup.+] (APCI+).
Example 55
##STR00114##
2-(4-chlorophenyl)-3-(isopropylamino)-1-((S)-3-methyl-4-((S)-5-methyl-5,7--
dihydrothieno[3,4-d]pyrimidin-4-yl)piperazin-1-yl)propan-1-one
LCMS: 474.2 [M+H.sup.+] (APCI+).
Example 56
##STR00115##
4-amino-2-(4-chlorophenyl)-4-methyl-1-((S)-3-methyl-4-((S)-5-methyl-5,7-di-
hydrothieno[3,4-d]pyrimidin-4-yl)piperazin-1-yl)pentan-1-one
LCMS: 474.1 [M+H.sup.+] (APCI+).
Example 57
##STR00116##
4-amino-2-(4-chloro-3-fluorophenyl)-4-methyl-1-((S)-3-methyl-4-((S)-5-meth-
yl-5,7-dihydrothieno[3,4-d]pyrimidin-4-yl)piperazin-1-yl)pentan-1-one
LCMS: 492.1 [M+H.sup.+] (APCI+).
Example 58
##STR00117##
4-amino-2-(4-chloro-3-fluorophenyl)-4-methyl-1-((S)-3-methyl-4-((R)-5-meth-
yl-5,7-dihydrothieno[3,4-d]pyrimidin-4-yl)piperazin-1-yl)pentan-1-one
LCMS: 450.1 [M+H.sup.+] (APCI+).
Example 59
##STR00118##
2-(4-chlorophenyl)-3-(isopropylamino)-1-((S)-3-methyl-4-((R)-5-methyl-5,7--
dihydrothieno[3,4-d]pyrimidin-4-yl)piperazin-1-yl)propan-1-one
LCMS: 474.1 [M+H.sup.+] (APCI+).
Example 60
##STR00119##
4-amino-2-(4-chlorophenyl)-4-methyl-1-((S)-3-methyl-4-((R)-5-methyl-5,7-di-
hydrothieno[3,4-d]pyrimidin-4-yl)piperazin-1-yl)pentan-1-one
LCMS: 474.1 [M+H.sup.+] (APCI+).
Example 61
##STR00120##
4-amino-2-(4-chloro-3-fluorophenyl)-4-methyl-1-((S)-3-methyl-4-((R)-5-meth-
yl-5,7-dihydrothieno[3,4-d]pyrimidin-4-yl)piperazin-1-yl)pentan-1-one
LCMS: 492.1 [M+H.sup.+] (APCI+).
Example 62
##STR00121##
(R)-3-(4-(benzyloxy)phenyl)-1-((S)-3-methyl-4-((S)-5-methyl-5,7-dihydrothi-
eno[3,4-d]pyrimidin-4-yl)piperazin-1-yl)-2-(methylamino)propan-1-one
LCMS: 486.1 [M+H.sup.+] (APCI+).
Example 63
##STR00122##
(S)-4-amino-2-(4-chlorophenyl)-4-methyl-1-(4-((S)-5-methyl-5,7-dihydrothie-
no[3,4-d]pyrimidin-4-yl)piperazin-1-yl)pentan-1-one
LCMS: 460.1 [M+H.sup.+] (APCI+).
Example 64
##STR00123##
(R)-4-amino-2-(4-chlorophenyl)-4-methyl-1-(4-((S)-5-methyl-5,7-dihydrothie-
no[3,4-d]pyrimidin-4-yl)piperazin-1-yl)pentan-1-one
LCMS: 460.2 [M+H.sup.+] (APCI+).
Example 65
##STR00124##
2-(4-chloro-3-fluorophenyl)-3-(isopropylamino)-1-(4-((S)-5-methyl-5,7-dihy-
drothieno[3,4-d]pyrimidin-4-yl)piperazin-1-yl)propan-1-one
LCMS: 478.1 [M+H.sup.+] (APCI+).
Example 66
##STR00125##
3-(isopropylamino)-1-(4-((S)-5-methyl-5,7-dihydrothieno[3,4-d]pyrimidin-4--
yl)piperazin-1-yl)-2-p-tolylpropan-1-one
LCMS: 440.2 [M+H.sup.+] (APCI+).
Example 67
##STR00126##
(R)-2-amino-3-(4-chlorophenyl)-1-(4-(6,6-dioxido-5,7-dihydrothieno[3,4-d]p-
yrimidin-4-yl)piperazin-1-yl)propan-1-one
Step 1:
m-CPBA (0.10 g, 0.60 mmol) was added to a solution of
(R)-tert-butyl
3-(4-chlorophenyl)-1-(4-(5,7-dihydrothieno[3,4-d]pyrimidin-4-yl)piperazin-
-1-yl)-1-oxopropan-2-ylcarbamate (200 mg, 0.40 mmol) in
CH.sub.2Cl.sub.2 (20 mL). The mixture was stirred at room
temperature for 2 hours. The mixture was washed with saturated
NaHCO.sub.3 solution, and the solvent was removed to afford a
mixture of the sulphoxide and the sulphone which were separated by
column chromatography (20:1 CH.sub.2Cl.sub.2:methanol) to give
(R)-tert-butyl
3-(4-chlorophenyl)-1-(4-(6,6-dioxido-5,7-dihydrothieno[3,4-d]pyrimidin-4--
yl)piperazin-1-yl)-1-oxopropan-2-ylcarbamate (80 mg, 38%) and
(R)-tert-butyl
3-(4-chlorophenyl)-1-(4-(6-oxido-5,7-dihydrothieno[3,4-d]pyrimidin-4-yl)p-
iperazin-1-yl)-1-oxopropan-2-ylcarbamate (80 mg, 39%).
Step 2:
HCl in dioxane (4M, 2 mL) was added to a solution of
3-(4-chlorophenyl)-1-(4-(6,6-dioxido-5,7-dihydrothieno[3,4-d]pyrimidin-4--
yl)piperazin-1-yl)-1-oxopropan-2-ylcarbamate (58 mg, 0.11 mmol) in
DCM (10 mL). The mixture was stirred at room temperature for 4
hours, and the solvent was removed to afford
(R)-2-amino-3-(4-chlorophenyl)-1-(4-(6,6-dioxido-5,7-dihydrothieno[3,4-d]-
pyrimidin-4-yl)piperazin-1-yl)propan-1-one dihydrochloride (47 mg,
100%). LCMS: 436.0 [M+H.sup.+] (APCI+).
Example 68
##STR00127##
(R)-2-amino-3-(4-chlorophenyl)-1-(4-(6-oxido-5,7-dihydrothieno[3,4-d]pyrim-
idin-4-yl)piperazin-1-yl)propan-1-one
m-CPBA (77%, 67 mg, 0.30 mmol) was added to a solution of
(R)-2-amino-3-(4-chlorophenyl)-1-(4-(5,7-dihydrothieno[3,4-d]pyrimidin-4--
yl)piperazin-1-yl)propan-1-one (120 mg, 0.30 mmol) in DCM (10 mL)
and MeOH (1 mL). The mixture was stirred at room temperature for 2
hours. The solvent was removed, and the residue was subject to
column chromatography, eluted by DCM/MeOH (4:1-1:1) to afford
(R)-2-amino-3-(4-chlorophenyl)-1-(4-(6-oxido-5,7-dihydrothieno[3,4-d]pyri-
midin-4-yl)piperazin-1-yl)propan-1-one (21 mg, 17%) as the free
amine. LCMS: 420.2 [M+H.sup.+] (APCI+).
Example 69
##STR00128##
(2R)-2-amino-3-(4-chlorophenyl)-1-(4-(5-methyl-6,6-dioxido-5,7-dihydrothie-
no[3,4-d]pyrimidin-4-yl)piperazin-1-yl)propan-1-one
Step 1:
m-CPBA (0.15 g, 0.67 mmol, 77 wt %) was added to a solution of
tert-butyl
(2R)-3-(4-chlorophenyl)-1-(4-(5-methyl-5,7-dihydrothieno[3,4-d]pyrimidin--
4-yl)piperazin-1-yl)-1-oxopropan-2-ylcarbamate (213 mg, 0.41 mmol)
in CH.sub.2Cl.sub.2 (20 mL). The mixture was stirred at room
temperature for 3 hours. The solvent was removed to afford a
mixture of the sulphoxide and the sulphone which was separated by
column chromatography (20:1 CH.sub.2Cl.sub.2:methanol) to give
(2R)-tert-butyl
3-(4-chlorophenyl)-1-(4-(5-methyl-6,6-dioxido-5,7-dihydrothieno[3,4-d]pyr-
imidin-4-yl)piperazin-1-yl)-1-oxopropan-2-ylcarbamate (100 mg) and
(2R)-tert-butyl
3-(4-chlorophenyl)-1-(4-(5-methyl-6-oxido-5,7-dihydrothieno[3,4-d]pyrimid-
in-4-yl)piperazin-1-yl)-1-oxopropan-2-ylcarbamate (50 mg).
Step 2:
HCl (4M, 1 mL) was added to a solution of (2R)-tert-butyl
3-(4-chlorophenyl)-1-(4-(5-methyl-6,6-dioxido-5,7-dihydrothieno[3,4-d]pyr-
imidin-4-yl)piperazin-1-yl)-1-oxopropan-2-ylcarbamate (0.10 g, 0.18
mmol) in DCM (5 mL) and MeOH (1 mL). The mixture was stirred at
room temperature for 6 hours. The solvent was removed to afford
(2R)-2-amino-3-(4-chlorophenyl)-1-(4-(5-methyl-6,6-dioxido-5,7-dihydrothi-
eno[3,4-d]pyrimidin-4-yl)piperazin-1-yl)propan-1-one as the
di-hydrochloride salt. LCMS: 450.1 [M+H.sup.+] (APCI+).
Example 70
##STR00129##
(2R)-2-amino-3-(4-chlorophenyl)-1-(4-(5-methyl-6-oxido-5,7-dihydrothieno[3-
,4-d]pyrimidin-4-yl)piperazin-1-yl)propan-1-one
HCl (4M, 1 mL) was added to a solution of
3-(4-chlorophenyl)-1-(4-(5-methyl-6-oxido-5,7-dihydrothieno[3,4-d]pyrimid-
in-4-yl)piperazin-1-yl)-1-oxopropan-2-ylcarbamate (0.050 g, 0.091
mmol) in DCM (4 mL) and MeOH (1 mL). The mixture was stirred at
room temperature for 6 hours. The solvent was removed to afford
(2R)-2-amino-3-(4-chlorophenyl)-1-(4-(5-methyl-6-oxido-5,7-dihydrothieno[-
3,4-d]pyrimidin-4-yl)piperazin-1-yl)propan-1-one as the
di-hydrochloride salt (0.40 g). LCMS: 450.1 [M+H.sup.+]
(APCI+).
Example 71
##STR00130##
(2R)-2-amino-3-(4-chlorophenyl)-1-(4-(5-ethyl-6,6-dioxido-5,7-dihydrothie-
no[3,4-d]pyrimidin-4-yl)piperazin-1-yl)propan-1-one
LCMS: 464.1 [M+H.sup.+] (APCI+).
Example 72
##STR00131##
(2R)-2-amino-3-(4-chloro-3-fluorophenyl)-1-(4-(5-ethyl-6,6-dioxido-5,7-dih-
ydrothieno[3,4-d]pyrimidin-4-yl)piperazin-1-yl)propan-1-one
Step 1:
m-CPBA (0.1 g, 0.45 mmol) was added to a solution of tert-butyl
(2R)-3-(4-chloro-3-fluorophenyl)-1-(4-(5-ethyl-5,7-dihydrothieno[3,4-d]py-
rimidin-4-yl)piperazin-1-yl)-1-oxopropan-2-ylcarbamate (50 mg, 0.09
mmol) in DCM (10 mL). The mixture was stirred at room temperature
for 2 hours. The solvent was removed, and the residue was subject
to column chromatography, eluted by ethyl acetate to give
tert-butyl
(2R)-3-(4-chloro-3-fluorophenyl)-1-(4-(5-ethyl-6,6-dioxido-5,7-dihydrothi-
eno[3,4-d]pyrimidin-4-yl)piperazin-1-yl)-1-oxopropan-2-ylcarbamate
(5 mg). LCMS: 582.0 [M+H.sup.+] (APCI+).
Step 2:
HCl in dioxane (4M, 2 mL) was added to a solution of tert-butyl
(2R)-3-(4-chloro-3-fluorophenyl)-1-(4-(5-ethyl-6,6-dioxido-5,7-dihydrothi-
eno[3,4-d]pyrimidin-4-yl)piperazin-1-yl)-1-oxopropan-2-ylcarbamate
(0.005 g, 0.009 mmol) in DCM (2 mL) and MeOH (1 mL). The mixture
was stirred at room temperature for 5 hours. The solvent was
removed to afford
(2R)-2-amino-3-(4-chloro-3-fluorophenyl)-1-(4-(5-ethyl-6,6-dioxido-5,7-di-
hydrothieno[3,4-d]pyrimidin-4-yl)piperazin-1-yl)propan-1-one as the
HCl salt (4 mg, 97%). LCMS: 482.1 [M+H.sup.+] (APCI+).
Example 73
##STR00132##
(4-(4-chlorophenyl)piperidin-4-yl)(4-(5-methyl-5,7-dihydrothieno[3,4-d]pyr-
imidin-4-yl)piperazin-1-yl)methanone
HBTU (0.03066 g, 0.08084 mmol) was added to a solution of
5-methyl-4-(piperazin-1-yl)-5,7-dihydrothieno[3,4-d]pyrimidine
dihydrochloride (0.025 g, 0.08084 mmol),
1-(tert-butoxycarbonyl)-4-(4-chlorophenyl)piperidine-4-carboxylic
acid (0.02747 g, 0.08084 mmol), and DIEA (0.05632 mL, 0.3234 mmol)
in DMF (2 mL). The reaction mixture was shaken for 4 hours, after
which it was diluted with ethyl acetate and water. The mixture was
extracted with ethyl acetate, and the combined extracts were washed
with water, saturated NaHCO.sub.3, dried (Na.sub.2SO.sub.4),
filtered, and concentrated. The crude was flashed on Biotage 12M
(4:1 DCM:EA flushed to elute DIEA, then 1:3 DCM:EA eluted prod) to
give the Boc intermediate. The Boc intermediate was then dissolved
in dioxane (1 mL), and 4M HCl/dioxane (0.6063 mL, 2.425 mmol) was
added, causing slow precipitation. The reaction mixture was stirred
at room temperature overnight (16 hours), after which it was
concentrated to dryness. The solids were dissolved in minimal MeOH,
and the product was triturated by addition of ether. The solids
were collected by filtration thru a medium frit funnel with
nitrogen pressure, rinsed with ether, and dried in vacuo to give
(4-(4-chlorophenyl)piperidin-4-yl)(4-(5-methyl-5,7-dihydrothieno[-
3,4-d]pyrimidin-4-yl)piperazin-1-yl)methanone dihydrochloride
(0.030 g, 69.90% yield) as a pale yellow powder. HPLC .about.94%
pure. LC/MS (APCI+) m/z 458.
Example 74
##STR00133##
2-(4-chlorophenyl)-1-(4-((S)-5-methyl-5,7-dihydrothieno[3,4-d]pyrimidin-4--
yl)piperazin-1-yl)-3-(2-methylaziridin-1-yl)propan-1-one
HBTU (37 mg, 0.097 mmol) was added to a solution of the
(S)-5-methyl-4-(piperazin-1-yl)-5,7-dihydrothieno[3,4-d]pyrimidine
dihydrochloride (30 mg, 0.097 mmol) and
2-(4-chlorophenyl)-3-(2-methylaziridin-1-yl)propanoic acid (47 mg,
0.097 mmol) in DCM (5 mL) and TEA (1 mL). The mixture was stirred
at room temperature for 1 hour. The solvent was removed, and the
residue was subject to column chromatography, eluting with
EA-DCM/MeOH (20:1-10:1). The product was treated with HCl (4M, 2
mL) afforded
2-(4-chlorophenyl)-1-(4-((S)-5-methyl-5,7-dihydrothieno[3,4-d]pyrimidin-4-
-yl)piperazin-1-yl)-3-(2-methylaziridin-1-yl)propan-1-one as the
HCl salt (1 mg, 2%). LC/MS (APCI+) m/z 458.1.
The foregoing description is considered as illustrative only of the
principles of the invention. Further, since numerous modifications
and changes will be readily apparent to those skilled in the art,
it is not desired to limit the invention to the exact construction
and process shown as described above. Accordingly, all suitable
modifications and equivalents may be considered to fall within the
scope of the invention as defined by the claims that follow.
The words "comprise," "comprising," "include," "including," and
"includes" when used in this specification and in the following
claims are intended to specify the presence of stated features,
integers, components, or steps, but they do not preclude the
presence or addition of one or more other features, integers,
components, steps, or groups.
* * * * *